

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

H&Q LIFE SCIENCES INVESTORS

Form 497

August 22, 2006

H&Q LIFE SCIENCES INVESTORS

4,484,838 SHARES

ISSUABLE UPON EXERCISE OF NON-TRANSFERABLE RIGHTS
TO SUBSCRIBE FOR SUCH SHARES

NEW YORK STOCK EXCHANGE SYMBOL: HQL

H&Q Life Sciences Investors is issuing non-transferable rights ("Rights") to its Shareholders of record as of the close of business on August 18, 2006 (the "Record Date"). These Rights will allow you to subscribe for one (1) Share of the Trust for every three (3) Rights held (the "Offer"). You will receive one Right for each whole Share that you hold of record as of the Record Date, rounded down to the nearest number of Rights evenly divisible by three. The Rights will not be listed for trading on the New York Stock Exchange ("NYSE") or any other exchange. You may also purchase Shares not acquired by other Shareholders subject to certain limitations and subject to allotment as described in this Prospectus.

THE SUBSCRIPTION PRICE PER SHARE WILL BE 95% OF THE VOLUME WEIGHTED AVERAGE SHARE PRICE OF A SHARE ON THE NYSE ON SEPTEMBER 22, 2006 (THE "PRICING DATE") AND THE FOUR PRECEDING BUSINESS DAYS.

RIGHTS MAY BE EXERCISED AT ANY TIME UNTIL 5:00 P.M. EASTERN TIME, ON SEPTEMBER 21, 2006, UNLESS THE OFFER IS EXTENDED AS DISCUSSED IN THIS PROSPECTUS. As the Offer expires before September 22, 2006, Shareholders who exercise their Rights will not know the Subscription Price at the time they exercise their Rights. For additional information regarding the Offer, please call The Altman Group (the "Information Agent") at (800)-870-0126.

The Trust is a diversified, closed-end management investment company whose shares of beneficial interest are listed and traded on the NYSE under the symbol "HQL." The Trust's investment objective is to seek long-term capital appreciation by investing primarily in equity and related securities (including securities subject to legal or contractual restrictions as to resale) of U.S. and foreign companies principally engaged in the development, production or distribution of products or services related to scientific advances in life sciences (including biotechnology, pharmaceuticals, diagnostics, managed health-care and medical equipment, hospitals, healthcare information technology and services, devices, supplies and other healthcare-related subsectors), agriculture and environmental management ("Life Sciences Companies"). The Trust emphasizes investment in securities of emerging growth Life Sciences Companies, which may offer limited products or services or which are at the research and development stage with no marketable or approved products or technologies. The Trust may also invest up to 40% of its net assets in securities subject to legal or contractual restrictions as to resale ("Restricted Securities"). The Trust's investments in Restricted Securities may include "start-up", early and later stage financings of privately held companies (sometimes referred to as "venture capital" investments), private placements by public companies, and interests in joint ventures and limited partnership. See "Risk Factors--Investment in Emerging Growth Companies" and "Risk Factors--Liquidity of Portfolio." The Trust may also invest in securities of large, well-known companies with existing products in the life sciences industries. The Trust may not be able to achieve its investment objective. FOR A DISCUSSION OF THE RISKS ASSOCIATED WITH AN INVESTMENT IN THE TRUST, SEE "RISK FACTORS AND SPECIAL CONSIDERATIONS."

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

The Fund adopted a managed distribution policy in May 1999 pursuant to an exemptive order obtained from the Securities and Exchange Commission ("SEC" or "Commission"). In accordance with the policy, since March 2000, the Fund has made regular quarterly distributions at a rate equal to 2.0% of the Fund's net asset value. The Fund's Board may terminate the managed distribution policy at any time; any such change or termination may have an adverse effect on the market price for the Fund's shares.

To the extent that the Fund's taxable income in any fiscal year exceeds the aggregate amount distributed based on a fixed percentage of its net asset value, the Fund would make an additional distribution in the amount of that excess near the end of the calendar year. To the extent that the aggregate amount distributed by the Fund based on a fixed percentage of its net asset value exceeds its current and accumulated earnings and profits, the amount of that excess would constitute a return of capital or net realized capital gains for tax purposes.

The actual sources of the Fund's quarterly distributions may be net investment income, net realized capital gains, return of capital or a combination of the foregoing and may be subject to retroactive recharacterization at the end of the Fund's fiscal year based on tax regulations. The actual amounts attributable to each of these sources will be reported to shareholders in January of each year on Form 1099-DIV.

This Prospectus sets forth concisely the information about the Trust you should know before investing, including information about risks. You should read this Prospectus and retain it for future reference. A Statement of Additional Information dated August 17, 2006 (the "SAI") containing additional information about the Trust has been filed with the SEC and is incorporated by reference in its entirety into this Prospectus. All inquiries regarding the Fund, including request for a copy of the SAI, the table of contents of which appears on page 52 of this Prospectus, and the Fund's annual and semi-annual reports may be obtained without charge by contacting the Information Agent at (800)870-0126. The Commission maintains a website (<http://www.sec.gov>) that contains material incorporated by reference in this Prospectus and SAI and other information regarding the Trust. The Fund's annual and semi-annual reports are also available on the Fund's website at www.hqcm.com.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THESE SECURITIES OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS.
ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

	ESTIMATED SUBSCRIPTION PRICE (1)	ESTIMATED SALES LOAD
Per Share.....	\$13.91	NONE
Total Maximum.....	\$62,384,097	NONE

(FOOTNOTES SET FORTH ON NEXT PAGE)

August 17, 2006

(CONTINUED FROM PREVIOUS PAGE)

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

- (1) Estimated on the basis of the volume weighted average share price of a Share on the NYSE on August 14, 2006 and the four preceding business days. The Trust may increase the number of Shares subject to subscription by up to 25% of the Shares offered hereby, or up to an additional 1,121,210 Shares, for an aggregate total of 5,606,048 Shares. If the Trust increases the number of Shares subject to subscription by 25%, the total maximum Estimated Subscription Price will be approximately \$77,980,128 and the total maximum Estimated Proceeds to the Trust will be approximately \$77,980,128. No sales load will be charged by the Trust in connection with this Offer. However, Shareholders that choose to exercise their Rights through broker-dealers, banks and nominees may incur a servicing fee charged by such broker-dealer, bank or nominee.
- (2) Before deduction of expenses related to the Offer incurred by the Trust, estimated at approximately \$462,000.

The Trust announced the Offer after the close of trading on the NYSE on March 15, 2006. The NAV at the close of business on March 15, 2006 and August 14, 2006 was \$17.15 and \$14.06, respectively, and the last reported sales price of a Share on the NYSE on those dates was \$17.31 and \$14.73, respectively.

The Trust may increase the number of Shares subject to subscription by up to 25%, or up to an additional 1,121,210 Shares, for an aggregate total of 5,606,048 Shares.

As a result of the terms of the Offer, Shareholders who do not fully exercise their Rights, including the Over-Subscription Privilege described in the section of this Prospectus entitled "The Offer--Over-Subscription Privilege," will, upon the completion of the Offer, own a smaller proportional interest in the Trust than they owned before the Offer. The Offer will result in either a dilution or accretion of NAV for all Shareholders, whether or not they exercise some or all of their Rights, because the Subscription Price per Share may be less than or greater than the then-current NAV. The amount of dilution or accretion might be significant. See "The Offer."

The Trust's investment adviser is Hambrecht & Quist Capital Management, LLC (the "Investment Adviser"). The employees of the Trust's Investment Adviser and the Trustees and officers of the Trust may purchase Shares through the Primary Subscription and the Over-Subscription Privilege on the same terms as other Shareholders.

Information about the Trust can be reviewed and copied at the Securities and Exchange Commission's Public Reference Room in Washington, DC. Call (202) 551-8090 for information on the operation of the Public Reference Room. This information is also available at the Commission's Internet site at <http://www.sec.gov>, and copies may be obtained upon payment of a duplicating fee by writing the Public Reference Section of the Securities and Exchange Commission, 100 F Street, NE, Washington, DC 20549.

PROSPECTUS SUMMARY

YOU SHOULD CONSIDER THE MATTERS DISCUSSED IN THIS SUMMARY BEFORE INVESTING IN THE TRUST THROUGH THE OFFER. THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO MORE DETAILED INFORMATION APPEARING ELSEWHERE IN THIS PROSPECTUS.

THE OFFER

The Offer

H&Q Life Sciences Investors (the "Trust") is issuing to its shareholders of record ("Shareholders") as of the close of business on August 18, 2006 (the "Record Date") non-transferable rights ("Rights") to subscribe for an aggregate of 4,484,838 shares of beneficial interest ("Shares") of the Trust (the "Offer"). You will receive one Right for each whole Share you held as of the Record Date, rounded down to the nearest number of Rights evenly divisible by three. You may subscribe for one Share for every three Rights you hold (the "Primary Subscription"). Any Shareholder on the Record Date who is issued fewer than three Rights will not be entitled to subscribe for a share in the Offer.

Subscription Price

The subscription price per Share (the "Subscription Price") will be 95% OF THE VOLUME WEIGHTED AVERAGE SHARE PRICE OF A SHARE ON THE NYSE ON SEPTEMBER 22, 2006 (THE "PRICING DATE") AND THE FOUR PRECEDING BUSINESS DAYS.

AS THE EXPIRATION DATE IS BEFORE THE PRICING DATE, SHAREHOLDERS WHO CHOOSE TO EXERCISE THEIR RIGHTS WILL NOT KNOW THE SUBSCRIPTION PRICE AT THE TIME THEY EXERCISE THEIR RIGHTS.

Subscription Period

Rights may be exercised at any time during the subscription period (the "Subscription Period"), which starts on September 5, 2006 and ends at 5:00 p.m., Eastern Time, on September 21, 2006 (the "Expiration Date").

Over-Subscription
Privilege

The Trust may, at its discretion, issue up to an additional 25% of the Shares in the Offer to honor over-subscription requests if there are not enough Shares available from the Primary Subscription to honor all over-subscription requests (the "Over-Subscription Privilege"). If there are enough Shares left after the Primary Subscription, all over-subscriptions will be honored in full. If there are not enough Shares available to honor all over-subscriptions (after giving effect to any increase in the number of Shares to be offered), the available Shares will be allocated pro rata among those Shareholders who over-subscribe based on the number of Rights originally issued to them by the Trust. The number of Shares issued to Shareholders who subscribe pursuant to the Over-Subscription Privilege will generally be in proportion to the number of Shares owned by them in the Fund on the Record Date. The allocation process may involve a series of allocations to assure that the total number of Shares available for over-subscriptions is distributed on a pro rata basis.

Fractional Shares

Fractional Shares will not be issued upon the exercise of Rights. Therefore, shares will be issued for Rights submitted in multiples of three only.

Purpose of the Offer

The Trust's Investment Adviser believes that increasing the Trust's assets for investment through the Offer will benefit the Trust and its Shareholders by allowing the Trust to take further advantage of available investment opportunities in securities of companies in the life sciences industries ("Life Sciences Companies"). While there can be no assurance that any benefits will be realized, increasing the Trust's investment assets through the Offer is intended to:

- allow the Trust to make greater or additional investments at a time when the Trust's investment adviser believes that securities of selected Life Sciences Companies, including specialty and generic pharmaceuticals companies, medical technology companies, life sciences information services and other innovative life sciences product and biotechnology companies, are positioned for price appreciation due to (i) demographic changes, (ii) recent developments in the pharmaceutical, biotechnology and medical technology industries relating to products that have or will extend or improve the quality of patients' lives, and (iii) the recent passage of a Medicare reform bill that may spur dramatic growth in prescription volume;
- increase the Trust's average investment size, giving the Trust additional negotiating leverage and pricing influence over venture capital, private investments in public entities (PIPEs) and other private equity investments and investments in the public markets; and
- provide the Trust with the ability to make additional investments without realizing capital gains on current investments or otherwise selling current investments at an unfavorable time.

In addition, if the Offer is fully subscribed, the Offer may possibly reduce operating costs per Share. The Offer allows you the opportunity to purchase additional Shares of the Trust at a price that will be below market value at the Expiration Date. See "The Offer--Purpose of the Offer."

Use of Proceeds

The Trust expects to invest the net proceeds of the Offer primarily in securities of Life Sciences Companies, particularly investments in specialty and generic pharmaceuticals companies, health services management, medical devices, and other innovative life sciences product and biotechnology companies. Any investments will be made in accordance with the Trust's investment objective and policies. Investment of the proceeds is expected to take up to six months from their receipt by the Trust, depending on market conditions and the availability of appropriate securities. See "Use of Proceeds."

Notice of NAV Decline

The Trust will suspend the Offer until it amends this Prospectus if, after the effective date of this Prospectus, the Trust's NAV declines more than 10% from its NAV as of that date. If that occurs, the Trust will notify you of the decline and permit you

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

to cancel your exercise of your Rights. Shareholders will have their payment for additional shares returned to them if they opt to cancel the exercise of their Rights.

2

How to Obtain Subscription Information - Contact your broker, bank or trust company.
- Contact The Altman Group (the "Information Agent") toll-free at (800) 870-0126.

How to Subscribe You may subscribe in one of two ways:
- Deliver a completed Exercise Form and payment to Computershare Trust Company, N.A., (the "Subscription Agent") by the Expiration Date.
- If your Shares are held in a brokerage, bank or trust account, have your broker, bank or trust company deliver an Exercise Form and payment or a Notice of Guaranteed Delivery to the Subscription Agent by the Expiration Date.

Tax Consequences For Federal income tax purposes, neither the receipt nor the exercise of the Rights will result in taxable income to Shareholders. You will not realize a taxable loss if your Rights expire without being exercised. See "The Offer--Certain Federal Income Tax Consequences of the Offer."

IMPORTANT DATES TO REMEMBER

Record Date..... August 18, 2006
Subscription..... September 5--September 21, 2006*
Deadline for delivery of Exercise Form together with payment of Estimated Subscription Price or for delivery of Notice of Guaranteed Delivery..... September 21, 2006*
Expiration Date..... September 21, 2006*
Pricing Date..... September 22, 2006*
Deadline for payment of final Subscription Price pursuant

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

to Notice of Guaranteed Delivery..... September 26, 2006*
Confirmation to Registered Shareholders**..... October 2, 2006*
For Registered Shareholders** Purchases--deadline for
payment of unpaid balance if final Subscription Price is
higher than Estimated Subscription Price..... October 12, 2006*

* Unless the Offer is extended.

** Registered Shareholders are those Shareholders who are the record owners of Trust Shares (that is, their names appear directly on the records of the Trust's transfer agent) and whose Shares are not held through a broker-dealer or other nominee or intermediary.

3

THE TRUST

The Trust

The Trust is a diversified, closed-end management investment company. The Trust was organized as a Massachusetts business trust on February 20, 1992 and commenced operations on May 8, 1992. As of August 14, 2006, the Trust had 13,454,515 Shares outstanding. Shares of the Trust are traded on the NYSE under the symbol "HQL." As of August 14, 2006, the Trust's NAV was \$14.06 and the Trust's last reported share price of a Share on the NYSE was \$14.73.

Distributions

The Trust intends to make quarterly distributions to its Shareholders equal to 2.0% of the Trust's net asset value. Net realized capital gains in excess of the total distributed under this policy are generally included in the December distribution. The Trust's quarterly distribution policy may be changed by the Board of Trustees without Shareholder approval.

The current distribution policy is to declare distributions in stock. Stock distributions will automatically be paid in newly-issued full Shares of the Trust plus cash in lieu of any fraction of a Share, unless otherwise instructed by the Shareholder. If a Shareholder elects to receive a distribution in cash, rather than in Shares, the Shareholder's relative ownership in the Trust will be reduced.

The first regular quarterly distribution to be paid on Shares acquired upon exercise of Rights will be the first quarterly distribution the record date for which occurs after the issuance of the Shares. The Shares issued in the Offer will not be entitled to the distribution declared to Shareholders of record on September 8, 2006 which is payable

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

in September 2006. SEE "Dividends and Distributions."

General Investment Guidelines

The Trust's investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences Companies. Under normal market conditions, the Trust expects to invest at least 80% of its net assets in securities of Life Sciences Companies. This policy may not be changed without 60 days' prior notice to Shareholders. The Trust will not have less than 25% of its net assets invested in Life Sciences Companies. A company will be deemed to be a Life Sciences Company if, at the time the Trust makes an investment therein, 50% or more of such company's sales, earnings or assets arise from or are related to healthcare, agriculture or environmental management, as the case may be. The Trust may also invest in securities of companies that do not satisfy the above criteria but that are expected by the Investment Adviser to have 25% or more of sales, earnings or assets arising from or dedicated to healthcare, agriculture or environmental management, but investments in such securities will not count toward achieving the percentages mentioned above. The Investment Adviser determines, in its discretion, whether a company is a Life Sciences Company.

The Trust may invest up to 25% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of U.S. issuers traded in foreign markets ("Foreign Securities"). The Trust may buy and sell currencies for the purpose of settlement of transactions in Foreign Securities.

4

Venture Capital Investments

The Trust emphasizes investment in securities of emerging growth Life Sciences Companies. These investments are often venture capital investments. The Trust may invest up to 40% of its net assets in securities subject to legal or contractual restrictions as to resale ("Restricted Securities"), including venture capital investments. The Trust's investments in Restricted Securities may include "start-up," early and later stage financings of privately-held companies and private placements in public companies. See "Investment Objective and Policies."

Investment Adviser

Hambrecht & Quist Capital Management LLC serves as Investment Adviser to the Trust. The Investment Adviser also serves as investment adviser to H&Q Healthcare Investors ("HQH"), a closed-end management investment company that invests in companies in the healthcare industries. See "Management of the Trust--Investment Adviser." The majority of the Trust's Board of Trustees is unaffiliated with the

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Investment Adviser; nevertheless, the Trust may be subject to certain potential conflicts of interest. See "Portfolio Transactions and Brokerage."

Portfolio Management

Currently Daniel R. Omstead, Ph.D., Christopher F. Brinzey, M.B.A., Frank T. Gentile, Ph.D. and Jason C. Akus, M.D./M.B.A. are members of the team that makes investments on behalf of the Trust. These members also perform other duties, including making investment decisions on behalf of HQH. See "Management of the Trust--Investment Adviser."

Compensation of Investment Adviser

Starting July 1, 2006, for the services provided by the Investment Adviser under the Investment Advisory Agreement between the Investment Adviser and the Trust ("Advisory Agreement"), the Trust pays a fee, computed and payable monthly, equal, when annualized, to (i) 2.5% of the average net assets for the month of its venture capital and other Restricted Securities (as defined) up to 25% of net assets and (ii) for the month, for all other assets, 0.98% of the average net assets up to \$250 million, 0.88% of the average net assets for the next \$250 million, 0.80% of the average net assets for the next \$500 million and 0.70% of the average net assets thereafter. The aggregate monthly fee may not exceed a rate when annualized of 1.375% (approximately 0.11% per month). Prior to July 1, 2006, the Trust paid a fee computed and payable monthly, equal, when annualized, to (i) 2.5% of the average net assets for the month of its venture capital and other Restricted Securities (as defined) up to 25% of net assets and (ii) for the month, for all other assets, 1.0% of the average net assets up to \$250 million, 0.90% of the average net assets for the next \$250 million, 0.80% of the average net assets for the next \$500 million and 0.70% of the average net assets thereafter. The aggregate monthly fee could not exceed a rate when annualized of 1.375% (approximately 0.11% per month). Because the advisory fee is based on the average net assets of the Trust, and since the Offer is expected to result in an increase in net assets, the Investment Adviser will benefit from the Offer by an increase in the dollar amount of the fee. Shareholders may also benefit from the Offer because it may also marginally reduce the total expense ratio, even for non-participating shareholders.

RISK FACTORS AND SPECIAL CONSIDERATIONS

THIS PROSPECTUS CONTAINS CERTAIN STATEMENTS THAT MAY BE DEEMED TO BE "FORWARD-LOOKING STATEMENTS." ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS AS A RESULT OF UNCERTAINTIES SET FORTH BELOW AND ELSEWHERE IN THE PROSPECTUS. SEE "RISK FACTORS," STARTING ON PAGE 31, FOR A MORE COMPLETE DESCRIPTION OF RISKS THAT MAY BE ASSOCIATED WITH AN INVESTMENT IN THE TRUST.

Dilution--Net Asset Value
and Non-
Participation in the Offer

Shareholders who do not fully exercise their Rights including the Over-Subscription Privilege described in the section of this Prospectus entitled "The Offer-Over-Subscription Privilege," will, at the completion of the Offer, own a smaller proportional interest in the Trust than if they exercised their Rights. As a result of the Offer shareholders may experience dilution in NAV per Share if the Subscription Price is below the then current NAV per Share. If the Subscription Price per Share is below the then current NAV per Share, shareholders will experience an immediate dilution of the aggregate NAV of their Shares if they do not participate in the Offer and will experience a reduction in the NAV per Share whether or not they participate in the Offer. The Trust cannot state precisely the extent of this dilution (if any) if shareholders do not exercise their Rights because the Trust does not know what the NAV per Share will be at the time of the Offer or what proportion of the Rights will be exercised. Assuming, for example, that all Rights are exercised, the Estimated Subscription Price is \$13.91 and the Trust's NAV per Share is \$14.06, the Trust's NAV per Share (after payment of estimated offering expenses) would be reduced by approximately \$0.06 per share. See "RISK FACTORS--DILUTION OF NET ASSET VALUE AND EFFECT OF NON-PARTICIPATION IN THE OFFER."

Share Price Volatility

Volatility in the market price of Shares may increase during the rights offering period. The Offer may result in some Shareholders selling their Shares, which would exert downward price pressure on the price of Shares, while others wishing to participate in the Offer may buy Shares, having the opposite effect.

Under-Subscription

It is possible that the Offer will not be fully subscribed. Under-subscription of the Offer could have an impact on the net proceeds of the Offer and the ratios described herein.

Market Risk

As with any investment company that invests in equity securities, the Trust is subject to market risk--the possibility that the prices of equity securities will decline over short or extended periods of time. As a result, the value of an investment in the Trust's Shares will fluctuate with the market. You could lose money over short or long periods of time.

Political and economic news can influence market-wide trends and can cause disruptions in the U.S. or world financial markets. Other factors may be ignored by the market as a whole but may cause movements in the price of one company's stock or the stock of companies in one or more industries. All of these factors may have a greater impact on initial public offerings and emerging company shares.

Selection Risk

Different types of equity securities tend to shift into and out of favor with investors, depending on market and economic conditions. The performance of funds that invest in equity securities of Life Sciences Companies may at times be better or worse than the performance of funds that focus on other types of securities or that have a broader investment style.

Concentration in the Life Sciences Industries

Under normal market conditions, the Trust expects to invest at least 80% of its net assets in securities of Life Sciences Companies. The Trust will not have less than 25% of its net assets invested in Life Sciences Companies. As a result, the Trust's portfolio may be more sensitive to, and possibly more adversely affected by, regulatory, economic or political factors or trends relating to the life sciences industries than a portfolio of companies representing a larger number of industries. As a result of its concentration policy, the Trust's investments may be subject to greater risk and market fluctuation than a fund that has securities representing a broader range of investments.

Life Sciences Companies have in the past been characterized by limited product focus, rapidly changing technology and extensive government regulation. In particular, technological advances can render an existing product, which may account for a disproportionate share of a company's revenue, obsolete. Obtaining governmental approval from agencies such as the Food and Drug Administration (FDA) for new products can be lengthy, expensive and uncertain as to outcome. These factors may result in abrupt advances and declines in the securities prices of particular companies and, in some cases, may have a broad effect on the prices of securities of companies in particular life sciences industries.

Intense competition exists within and among certain life sciences industries, including competition to obtain and sustain proprietary technology protection, including patents, trademarks and other intellectual property rights, upon which Life Sciences Companies can be highly dependent for maintenance of profit margins and market exclusivity. The complex nature of the technologies involved can lead to patent disputes, including litigation that could result in a company losing an exclusive right to a patent.

Cost containment measures implemented by the federal government, state governments and the private sector have adversely affected certain sectors of the life sciences industries. The implementation of any such further cost containment measures may have an adverse effect on some companies in the life sciences industries.

Product development efforts by Life Sciences Companies may

not result in commercial products. Even after a product is commercially released, governmental agencies may require additional clinical trials or change the labeling requirements for products, if additional product side effects are identified, which could have a material adverse effect on the market price of the securities of those Life Sciences Companies. Certain Life Sciences Companies in which the Trust may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing and sale of pharmaceutical, medical device or other products. There can be no assurance that a product liability claim would not have a material adverse effect on the business, financial condition or securities prices of a company in which the Trust has invested.

7

All of these factors may cause the value of the Trust's Shares to fluctuate significantly over relatively short periods of time.

Investment in Emerging Growth Companies

The Trust emphasizes investment in equity securities of emerging Life Sciences Companies. While these securities offer the opportunity for significant capital gains, investments also involve a degree of risk that can result in substantial losses. There can be no assurance that in the future securities of start-up or emerging growth companies will yield returns commensurate with their associated risks.

Liquidity of Portfolio

The Trust may invest substantially all of its net assets in securities of emerging growth Life Sciences Companies, including venture capital and other private equity investments. Venture capital and other private equity investments are limited to 40% of the Trust's net assets. Some of these securities are traded in the over-the-counter market or on stock exchanges where the low trading volume of a particular security may result in abrupt and erratic price movements. An investment in such securities may have limited liquidity, and the Trust may find it necessary to sell at a discount from recent prices or to sell over extended periods of time when disposing of such Securities. Restricted Securities in which the Trust may invest cannot be sold except in a public offering registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to an exemption from the Securities Act or in compliance with applicable Securities and Exchange Commission (the "Commission") regulations.

Valuation of Restricted Securities including Venture Capital Investments

Some of the Trust's investments generally have no established trading market or are subject to restrictions on resale. Because of the type of investments that the Trust

makes and the nature of its business, the valuation process requires an analysis of various factors. The Trust's fair value methodology includes the examination of, among other things, (i) the existence of any contractual restrictions on the disposition of the securities; (ii) information obtained from the issue which may include an analysis of the company's financial statements, the company's products or intended markets, or the company's technologies; and (iii) the price of a security negotiated at arm's-length in an issuer's subsequent completed round of financing.

As there is typically no readily available market value for the venture capital investments and some of the Restricted Securities in the Trust's portfolio, venture capital investments and such Restricted Securities in the Trust's Portfolio are valued at fair value as determined in good faith by the Board of Trustees pursuant to a valuation policy and a consistently applied valuation process. Because of the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Trust's investments determined in good faith by the Board of Trustees, or in accordance with valuation procedures approved by the Board of Trustees, may differ significantly from the values that would have been used had a ready market existed for the investments, and the differences could be material. There is no single standard for determining fair value in good faith. As a result, determining fair value requires that judgment be applied to the specific facts and circumstances of each portfolio investment subject to fair value determinations, while employing a consistently applied valuation process for the types of investments the Trust makes.

Foreign Securities

The Trust may invest up to 25% of its net assets in Foreign Securities. Foreign Securities may be less liquid and have prices that are more volatile than securities of comparable U.S. companies. An investment in Foreign Securities may also involve currency risk.

Key Personnel

There may be only a limited number of securities professionals who have comparable experience to that of the Trust's existing portfolio management team in the area of Life Sciences Companies. If one or more of the team members dies, resigns, retires or is otherwise unable to act on behalf of the Investment Adviser, there can be no assurance that a suitable replacement could be found immediately.

Concentration of Investments

The Trust may from time to time concentrate its investments in a few issuers and take large positions in those issuers. As a result, the Trust may be subject to a greater risk of

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

loss than an investment company that diversifies its investments more broadly. Taking larger positions is also likely to increase the volatility of the Trust's net asset value reflecting fluctuation in the value of its large holdings.

Discount to NAV

Market price risk is a risk separate and distinct from the risk that the Trust's net asset value will decrease. Although the Trust's Shares have recently traded on the NYSE at a market price above their net asset value (a premium), the Trust's Shares have traded in the market below (a discount), at and above net asset value since the commencement of the Trust's operations. There can be no assurance that the Trust's shares will trade at a premium in the future or that any such premium is sustainable. The Trust's Shares have traded at discounts of as much as 35.95% since the Trust commenced operations. The Trust cannot predict whether the Shares will trade in the future at, above or below their net asset value. See "Share Price and NAV under Financial Highlights and Investment Performance" for quarterly discount and/or premium information.

Declaration of Trust

The Trust's Declaration of Trust ("Declaration of Trust"), dated February 20, 1992, as amended, presently has provisions that could have the effect of limiting the ability of other entities or persons to (1) acquire control of the Trust, (2) cause it to engage in certain transactions, or (3) modify its structure. These provisions may be considered "anti-takeover" provisions.

9

Repurchase of Shares

You may dispose of your Shares on the NYSE or other markets on which the Shares may trade, but because the Trust is a closed-end investment company, you do not have the right to redeem your Shares. At least once a year the Trustees consider whether the Trust should repurchase its Shares in the open market or make a tender offer. Any repurchases will comply with the provisions of the Investment Company Act of 1940, as amended ("Investment Company Act"), and Massachusetts law that apply to open market transactions. There is no assurance that any action undertaken to repurchase Shares will result in the Shares trading at a price which approximates net asset value. Repurchases of Shares by the Trust would also decrease its total assets and may increase its expenses as a percentage of average net assets as a result. The Trust's net income will be reduced by the amount of any interest owed on any borrowings made to finance any Share repurchase transactions. The Trust has no current plans to repurchase its Shares.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Related Party Transactions The majority of the Board is unaffiliated with the Investment Adviser; nevertheless, the Trust may be subject to certain potential conflicts of interest. Although the Trust has no obligation to do so, it may place brokerage orders with brokers who provide supplemental investment research and market and statistical information about the life sciences industries to the Investment Adviser. In addition, other investment companies advised by the Investment Adviser may concurrently invest with the Trust in both Restricted Securities and publicly held securities. The Investment Adviser may also provide managerial assistance to issuers of securities in which the Trust invests. The Trust also may invest, subject to applicable law, in companies in which the principals of the Investment Adviser or Trustees of the Trust have invested or for which they serve as directors or executive officers.

10

TRUST EXPENSES

FEES AND EXPENSES

ANNUAL EXPENSES (AS A PERCENTAGE OF AVERAGE NET ASSETS ATTRIBUTABLE TO SHARES)	
Management Fee.....	1.30%
Other Expenses (1).....	0.36%

Total Annual Expenses (2).....	1.66%
	====

(1) "Other Expenses" have been estimated for the current fiscal year.

(2) The estimated 1.66% expense ratio assumes that the Offer is fully subscribed, yielding estimated proceeds (net of offering expenses) of approximately \$61,922,097 (assuming a Subscription Price of \$13.91 per Share) and that, as a result, based on the Trust's net assets attributable to Shareholders on August 14, 2006 of \$189,222,947, the net assets attributable to Shareholders would be \$251,145,044.

HYPOTHETICAL EXAMPLE

The following hypothetical example demonstrates the projected dollar amount of total cumulative expenses that would be incurred over various periods with respect to a hypothetical investment in Shares of the Trust. These amounts are based upon payment by the Trust of investment advisory fees and other expenses at the levels set forth in the table above.

You would directly or indirectly pay the following expenses on a \$1,000 investment in the Trust, assuming (i) all dividends and other distributions are reinvested at NAV, (ii) the market price at the time of investment was equal to the net asset value per share, (iii) the percentage amounts listed under Annual Expenses above remain the same in the years shown, and (iv) a 5% annual return:

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

1 YEAR	3 YEARS	5 YEARS	10 YEARS
\$17	\$52	\$90	\$197

See also Note (2) above for assumptions made in calculating the expenses in this hypothetical example. See "Financial Highlights" for the Trust's actual ratio of expenses to average net assets for the fiscal year ended September 30, 2005.

The purpose of the table above is to assist you in understanding the various costs and expenses that you will bear directly or indirectly as an investor in the Trust. For more information regarding the management fees paid by the Trust, refer to the section of this Prospectus entitled "Management of the Trust--Investment Adviser."

The above table and the assumption in the hypothetical example of a 5% annual return are required by regulations of the Commission applicable to all investment companies. The assumed 5% annual return is not a prediction of, and does not represent, the projected or actual performance of the Trust's Shares. For more complete descriptions of certain of the Trust's costs and expenses, see "Management of the Trust--Investment Adviser."

THIS HYPOTHETICAL EXAMPLE SHOULD NOT BE CONSIDERED A REPRESENTATION OF PAST OR FUTURE EXPENSES, AND THE TRUST'S ACTUAL EXPENSES MAY BE GREATER OR LESS THAN THOSE SHOWN.

11

FINANCIAL HIGHLIGHTS AND INVESTMENT PERFORMANCE

FINANCIAL HIGHLIGHTS

The financial highlights table is intended to help you understand the Trust's financial performance. Information is shown for the six month period ended March 31, 2006 and the Trust's last ten fiscal years. Certain information reflects financial results from a single Trust Share. In the table, "total investment return at market value" represents the rate that an investor would have earned on an investment in the Fund. The information for the fiscal years ended September 30, 2005 and September 30, 2004 was audited by Deloitte & Touche LLP, an independent registered public accounting firm. Financial highlights information included for the fiscal years ended September 30, 2003, 2002, and 2001 was audited by PricewaterhouseCoopers LLP, whose report dated November 25, 2003 expressed an unqualified opinion on those financial statements and financial highlights. Financial highlights information for the fiscal years ended September 30, 2000, 1999, 1998, 1997 and 1996 was audited by Arthur Andersen LLP, whose report dated November 3, 2000 expressed an unqualified opinion on those financial statements and financial highlights. The report of Deloitte & Touche LLP, together with the financial statements of the Trust, are included in the Trust's September 30, 2005 Annual Report, and are included elsewhere in this Prospectus.

FOR THE
SIX-MONTHS
ENDED
MARCH 31,

FOR THE YEAR ENDED SEP

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

	2006 (UNAUDITED)	2005	2004	2003
Net asset value per share:				
Beginning of period.....	\$ 18.19	\$ 15.90	\$ 16.68	\$ 15.14
Net investment loss(2).....	\$ 0.01 (3)	\$ (0.21)	\$ (0.26)	\$ (0.21)
Net realized and unrealized gain (loss) on investments.....	\$ 0.56	3.79	0.86	3.55
Total increase (decrease) from investment operations.....	\$ 0.57	\$ 3.58	\$ 0.60	\$ 3.34
Capital gain distributions to shareholders.....	\$ (1.41)	\$ (1.29)	\$ (1.38)	\$ (1.80)
Net asset value per share:				
End of period.....	\$ 17.35	\$ 18.19	\$ 15.90	\$ 16.68
Per share market value:				
End of period.....	\$ 17.11	\$ 16.85	\$ 16.20	\$ 15.28
Total investment return at market value.....	10.73%	12.77%	15.52%	47.65%
RATIOS AND SUPPLEMENTAL DATA:				
Net assets at end of period.....	\$230,090,053	\$229,291,326	\$191,837,984	\$190,352,471
Ratio of operating expenses to average net assets.....	1.67%*	1.74%	1.73%	1.74%
Ratio of net investment loss to average net assets.....	0.07%* (3)	(1.29)%	(1.56)%	(1.38)%
Portfolio turnover rate.....	27.97%	73.79%	34.93%	32.36%
Number of shares outstanding at end of period.....	13,262,472	12,605,204	12,066,409	11,412,475

(1) In 2002, the Fund adopted the provisions of the AICPA Audit and Accounting Guide for Investment Companies and began accreting discounts and amortizing premiums on all debt securities. The effect of this change for the year ended September 30, 2002 was a decrease in net investment loss per share of \$.006, an increase in net realized and unrealized loss on investments per share of \$.006, and a decrease in the ratio of net investment loss to average net assets from (1.28%) to (1.25%). Per share data and ratios for the periods prior to October 1, 2001 have not been restated to reflect this change in presentation.

(2) Net investment loss per share has been computed using average shares outstanding.

(3) Includes a special dividend from an issuer in the amount of \$0.10 per share. Excluding the special dividend, the ratio of net investment income/(loss) to average net assets would have been (1.14%) annualized.

* Annualized.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

	FOR THE YEAR ENDED SEPTEMBER 30			
	2000	1999	1998	19
Net asset value per share:				
Beginning of year.....	\$ 17.804	\$ 13.713	\$ 18.825	\$
Net investment loss(2).....	\$ (0.300)	\$ (0.205)	\$ (0.239)	\$
Net realized and unrealized gain (loss) on investments.....	24.756	4.576	(4.133)	
Total increase (decrease) from investment operations.....	\$ 24.456	\$ 4.371	\$ (4.372)	\$
Capital gain distributions to shareholders.....	\$ (2.895)	\$ (0.280)	\$ (0.740)	\$
Net asset value per share:				
End of year.....	\$ 39.365	\$ 17.804	\$ 13.713	\$
Per share market value:				
End of year.....	\$ 31.313	\$ 14.125	\$ 10.875	\$
Total investment return at market value.....	155.36%	39.9%	23.89%	
RATIOS AND SUPPLEMENTAL DATA:				
Net assets at end of year.....	\$318,271,356	\$131,562,804	\$100,030,321	\$131,9
Ratio of operating expenses to average net assets.....	1.51%	1.60%	1.62%	
Ratio of net investment loss to average net assets.....	(1.06)%	(1.30)%	(1.50)%	
Portfolio turnover rate.....	12.70%	23.49%	18.21%	
Number of shares outstanding at end of year.....	8,085,152	7,389,487	7,294,722	7,0

13

PORTFOLIO CHARACTERISTICS

A substantial portion of the Trust's investment portfolio consists of venture capital and private equity investments. As of June 30, 2006, 20.80% of the Trust's assets were invested in Restricted Securities of 26 Life Sciences Companies, two of which companies are publicly-traded. The Trust continues to value these publicly traded securities at or below current market prices as they remain restricted as to resale.

From inception, the Trust has made 237 venture capital investments in 85 private companies and 18 private placements in public companies.

The following sets forth certain information with respect to the composition of the Trust's investment portfolio as of June 30, 2006.

H&Q LIFE SCIENCES INVESTORS

PORTFOLIO--AS OF JUNE 30, 2006

EDGAR REPRESENTATION OF DATA POINTS USED IN PRINTED GRAPHIC

RESTRICTED UNRESTRICTED TOTAL

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

BIOPHARMACEUTICALS	0.13%	25.49%	25.62%
DRUG DELIVERY	0.00%	2.56%	2.56%
DRUG DISCOVERY TECHNOLOGIES	3.54%	5.27%	8.81%
EMERGING BIOPHARMACEUTICALS	5.01%	18.91%	23.92%
GENERIC PHARMACEUTICALS	0.00%	4.33%	4.33%
HEALTHCARE SERVICES	4.09%	4.42%	8.51%
MEDICAL DEVICES AND DIAGNOSTICS	7.15%	14.51%	21.66%
SHORT-TERM INVESTMENTS	0.00%	4.59%	4.59%

The following table sets forth the Trust's ten largest holdings as a percentage of net assets as of June 30, 2006.

THE TRUST'S TEN LARGEST HOLDINGS BY ISSUER
(AS OF JUNE 30, 2006)

	% OF NET ASSETS

Conor Medsystems, Inc.....	4.96%
Gilead Sciences, Inc.....	4.49%
Concentric Medical, Inc.....	3.45%
Cubist Pharmaceuticals, Inc.....	3.17%
Genzyme Corporation.....	2.63%
IDEXX Laboratories, Inc.....	2.21%
CardioNet, Inc.....	1.98%
PHT Corporation.....	1.74%
Lexicon Genetics, Inc.....	1.72%
Align Technology, Inc.....	1.72%

14

SHARE PRICE AND NAV

The Trust's Shares are publicly-held and have been listed and are trading on the NYSE under the symbol "HQL". The following table sets forth for the quarters indicated the high and low closing prices per Share on the NYSE, the corresponding NAV, the percentage premium or discount at such closing prices, and the number of Shares traded. The NAV as of the close of business on August 14, 2006 was \$14.06 and the last reported sales price of a Share that day was \$14.73.

QUARTER ENDED	MARKET PRICE (1) HIGH	CORRES- PONDING NET ASSET VALUE (2)	PREMIUM/ (DISCOUNT) (2)	MARKET PRICE (1) LOW	CORRES- PONDING NET ASSET VALUE (2)	PREMIUM/ (DISCOUNT) (2)
-----	-----	-----	-----	-----	-----	-----
Fiscal 2004						
Dec. 31.....	\$16.48	\$17.20	(4.20)%	\$15.51	\$16.85	(8.00)%
Mar. 31.....	18.37	18.21	0.90	15.84	16.96	(6.60)
June 30.....	18.24	18.94	(3.70)	15.38	16.84	(8.70)
Sept. 30.....	16.20	15.90	1.90	13.79	15.02	(8.20)
Fiscal 2005						
Dec. 31.....	16.93	16.22	4.40	15.56	15.80	(1.50)
Mar. 31.....	16.69	16.15	3.30	14.36	15.57	(7.80)

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

June 30.....	16.10	16.30	(1.20)	14.24	15.17	(6.10)
Sept. 30.....	17.51	18.04	(2.90)	15.88	16.64	(4.60)
Fiscal 2006						
Dec. 31.....	17.42	17.29	0.80	15.43	15.68	(1.60)
Mar. 31.....	17.77	16.98	4.70	15.62	16.23	(3.80)
June 30.....	17.22	17.15	0.41	14.67	14.42	1.73

 (1) Source: Factset

(2) Based on the Trust's computations, on the day that the high or low market price was recorded.

Shares of the Trust have frequently traded at a discount to NAV but have occasionally traded at a premium to NAV. There can be no assurance that Shares will trade at premium to NAV in the future. Certain features of and steps taken by the Trust may have tended to reduce the discount from net asset value at which its Shares might otherwise have traded, although the Trust is not able to determine what effect, if any, these various features and steps may have had. The Trust's current 2% distribution policy (see "Dividends and Distributions"), begun in May 1999, may have contributed to this effect. The Trust's Declaration of Trust also requires that the Board annually consider and vote upon the conversion of the Trust to an open-end company. This trend may also have resulted in whole or in part from other factors, such as the Trust's investment performance and the performance of the life sciences industry generally.

INVESTMENT PERFORMANCE

The table below presents average annual total returns of the Trust's Shares on two separate bases. The first column presents the Trust's market value return, which is the average annual rate of return, based on the Trust's market value, on an amount invested in the Trust from the beginning to the end of the stated period and assumes reinvestment of net investment income dividends and capital gains distributions. This figure reflects the actual experience of a Shareholder, before commission costs, who bought and sold Shares of the Trust at the beginning and ending dates. The second column features the NAV return, which presents the same information, but values the Trust at NAV rather than market value.

The record of the NASDAQ Biotech Index ("NBI") has been included so that the Trust's results may be compared with an unmanaged capitalization-weighted index comprised of approximately 150

15

small and large biotech companies. The record of the S&P 500 has been included so that the Trust's results may be compared with an unmanaged, base-weighted aggregate methodology index including 500 leading companies in leading industries in the United States, focused on the large-cap segment of the market.

The figures for each index assume reinvestment of dividends. It is not possible to invest directly in any index.

H&Q LIFE SCIENCES INVESTORS ANNUALIZED RETURNS (FOR PERIODS ENDED JUNE 30, 2006)

			NASDAQ	
			BIOTECH INDEX	S&
HQL STOCK*	HQL NAV*		("NBI")**	IN

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

1 YEAR.....	10.55%	1.76%	7.60%
3 YEARS.....	11.54%	6.00%	3.39%
5 YEARS.....	4.02%	(1.19)%	(6.03)%
10 YEARS.....	11.46%	8.40%	9.69%

* Source: Based on the Trust's computations

** Source: Factset, Annualized Compounded Return, dividends reinvested on ex-date

THE ABOVE RESULTS REPRESENT PAST PERFORMANCE AND SHOULD NOT BE CONSIDERED AN INDICATION OF FUTURE PERFORMANCE. The information is provided for purposes of presenting an historical perspective of the Trust. The investment return and net asset and market prices will fluctuate, so that Shares may be worth more or less than their original cost when sold.

THE OFFER

TERMS OF THE OFFER

The Trust is issuing to its Shareholders non-transferable Rights to subscribe for an aggregate of 4,484,838 Shares. The Trust may increase the number of Shares subject to subscription by up to 25% of the Shares, for an aggregate total of 5,606,048 Shares. Shareholders will receive one non-transferable Right for each Share held as of the Record Date, rounded down to the nearest number of Rights evenly divisible by three. The Rights entitle a Shareholder to acquire, at the Subscription Price, one Share for every three Rights held. If you exercise all of the Rights issued to you, you may subscribe for Shares which were not otherwise subscribed for by others in the Primary Subscription.

Rights may be exercised at any time during the Subscription Period, which commences on September 5, 2006 and ends at 5:00 p.m., Eastern Time, on September 21, 2006, unless extended by the Trust (such date, as it may be extended, is referred to in this Prospectus as the "Expiration Date").

Fractional Shares will not be issued upon the exercise of Rights. Therefore, shares will be issued for Rights submitted in multiples of three only.

The Rights are non-transferable. Therefore, only the underlying Shares will be listed for trading on the NYSE or any other exchange.

For purposes of determining the number of Shares a Shareholder may acquire pursuant to the Offer, broker-dealers whose Shares are held of record by Cede & Co., Inc. ("Cede"), nominee for the Depository Trust Company, or by any other depository or nominee, will be deemed to be the holders of the Rights that are issued to Cede or such other depository or nominee on their behalf. Shares acquired pursuant to the Over-Subscription Privilege are subject to allotment, which is more fully discussed under "The Offer--Over-Subscription Privilege."

The Subscription Price will be BE 95% OF THE VOLUME WEIGHTED AVERAGE SHARE PRICE OF A SHARE ON THE NYSE ON SEPTEMBER 22, 2006 (THE "PRICING DATE") AND THE FOUR PRECEDING BUSINESS DAYS. As the Expiration Date is before the Pricing Date, Shareholders who choose to exercise their Rights will not know the Subscription Price at the time they exercise their Rights.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

The Rights will be evidenced by Exercise Forms which will be mailed to Shareholders. You may exercise your Rights by completing an Exercise Form and delivering it, together with payment by means of (i) a check or money order or (ii) a Notice of Guaranteed Delivery to the Subscription Agent during the Subscription Period. The methods by which Rights may be exercised and Shares paid for are set forth below in "Exercise of Rights" and "Payment for Shares."

PURPOSE OF THE OFFER

The Board of Trustees of the Trust (the "Board") has determined that it is in the best interests of the Trust and its Shareholders to increase the assets of the Trust available for investment through the Offer, so that the Trust will be in a better position to more fully take advantage of available investment opportunities in Life Sciences Companies, including investments in specialty and generic pharmaceuticals companies, medical technology, life sciences information services and other innovative life sciences products and biotechnology companies. The Board was informed by the Investment Adviser that high quality venture capital investment opportunities are available and that Shareholders could potentially realize significant benefits from increased investment in both venture capital and publicly-traded Life Sciences Companies. The Board also reviewed data suggesting that increased asset size could favorably affect the Trust's expense ratio since the additional assets raised in the Offer were expected to allow the Trust to spread fixed costs over a larger number of Shares. The Board unanimously approved the Offer and concluded that increasing the assets of the Trust through the Offer would be beneficial to the Trust and its Shareholders. However, there can be no assurance that the anticipated benefits discussed herein will occur as a result of increasing the assets of the Trust through the Offer.

In determining that the initiation of the Offer and the proposed terms of the Offer were in the best interest of Shareholders, the Board considered a variety of factors, including those set forth below:

RECENT DEVELOPMENTS IN CERTAIN LIFE SCIENCES SECTORS. Demographic changes continue to create new medical opportunities. The Managed Care Institute has estimated that by the year 2010 over 13% of the population will be 65 or older vs. 12% in 2002. This population consumes three to four times the healthcare goods and services as the rest of the population. This will drive an increase in all types of medical products, from drugs to orthopedic procedures. Furthermore, Medicare enrollment is expected to increase significantly in the coming years. This trend will dramatically increase the demand for new healthcare services and technologies.

In addition, recent developments in the pharmaceutical, biotechnology, and medical technology industries have produced a series of blockbuster products that are expected to improve the quality of patients' lives. Hundreds of therapeutic products to treat a variety of diseases or conditions have completed human clinical trials and are awaiting FDA marketing approval; there are approximately 1,000 products in late stage human clinical trials, and thousands of products are in earlier stage trials and pre-clinical development. The last five years has seen the commercialization of products that have advanced the treatment of cancer, rheumatoid arthritis, erectile dysfunction, psoriasis, multiple sclerosis and depression. In the next five years, the Investment Adviser anticipates approval of other novel products which are expected to have a significant impact in treating sleep disorders, obesity, cardiovascular disease, additional indications in cancer, and chronic and acute pain.

The Investment Adviser also believes that the recent Medicare drug bill will alter the healthcare landscape. Under this bill, it is estimated that at least 10 million people will have gained coverage of a

prescription drug benefit. The Investment Adviser believes that there will be a dramatic growth in prescription volume resulting from passage of the Medicare bill.

Based on these trends and events, the Investment Adviser continues to believe, and has advised the Board of Trustees, that there are outstanding opportunities for investment in life sciences and biotechnology related companies. In addition to the companies and products in which investments have already been made the Investment Adviser, sees great promise from several developing trends. In particular, the Investment Adviser sees tremendous potential in the areas of 1) generic pharmaceuticals, 2) specialty pharmaceuticals, 3) disease management, 4) novel medical devices, 5) novel drugs derived from known and novel targets and 6) products which will benefit from impending changes in the regulatory landscape. A major benefit to our shareholders from the proposed rights offering will be our ability to incrementally invest in additional companies on the forefront of these developing trends.

Completion of the Offer will allow the Fund to continue to invest in and/or own stock in the companies in which it has already invested and still take advantage of these developing trends. Without completing the proposed Offer, the Fund may well have to choose between maintaining some of its existing investments and investing in companies which will take advantage of the developing trends.

INCREASED INVESTMENT SIZE. The Investment Adviser believes that larger investments by the Trust provide additional negotiating leverage and pricing influence over venture capital, private investments in public entities (PIPEs), and other private equity investments and investments in the public markets. With an increased asset base through the Offer, the Trust may be able to make investments of the size necessary to achieve more favorable investment terms.

ADDITIONAL INVESTMENTS. In order to take advantage of new investment opportunities in the life sciences industries without the Offer, the Trust might be required to sell a portion of its existing investment which would result in transaction costs and may result in a realization of significant capital gains or otherwise take place at a time when the investment sold may not have fully achieved the Trust's investment objective for it. The Offer provides the Trust with the ability to both capitalize on new investment opportunities and maintain its investment in existing assets.

OPPORTUNITY TO PURCHASE BELOW MARKET PRICE. The Offer affords existing Shareholders the opportunity to purchase additional Shares at a price that will be below market value at the Expiration Date. However, Shareholders who do not fully exercise their Rights will own, upon completion of the Offer, a smaller proportional interest in the Trust than they owned before the Offer. The Board of Trustees took this into account in adopting the Subscription Price formula applicable to the Offer and selecting the ratio of Rights offered relative to the number of Shares held on the Record Date. See "Risk Factors."

REDUCTION IN OPERATING COSTS PER SHARE. The Board was advised by the Investment Adviser that the Trust could potentially achieve additional economies of scale as a result of an increase in the Trust's total assets. The Investment Adviser believes that the increase in assets from the Offer could reduce the Trust's expenses as a percentage of average net assets per Share because fixed costs would be spread over a greater number of Shares.

The Board voted unanimously to approve the terms of the Offer. One of the Trust's Trustees who voted to authorize the Offer is affiliated with the Investment Adviser and, therefore, could benefit indirectly from the Offer. The

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

other seven Trustees are not "interested persons" of the Trust within the meaning of the Investment Company Act. The Investment Adviser may also benefit from the Offer because its fee is based on the net assets of the Trust. See "Management of the Trust--Investment Adviser." It is not possible to state precisely the amount of additional compensation the Investment Adviser might receive as a result of the Offer because it is not known how many Shares will be subscribed for and because the proceeds of the Offer will be invested in additional portfolio securities, which will fluctuate in value. However, if the Offer is fully subscribed, it would add (net of offering

18

expenses) approximately \$61,922,097 to the net assets of the Fund. This amount, assuming no fluctuation due to changes in the market, would add \$792,603 to the Investment Adviser's annual compensation based upon an advisory fee of 1.28%. The Fund's assets could increase further if the Shares subject to the Over-Subscription Privilege considered by the Board were to be issued.

The Board considered the possibility of a decline in the market price of Shares of the Fund. The Board was advised by the Investment Adviser that, if market conditions were to become less favorable, the Investment Adviser may desire to reevaluate the Offer. The Investment Adviser indicated to the Board that, should the Fund begin to trade at a significant discount to NAV, it would re-examine the Offer and may consider recommending cancellation of the Offer or a change in the terms of the Offer.

The Fund will suspend the Offer until it amends this Prospectus if, after the effective date of this Prospectus, the Fund's NAV declines more than 10% from its NAV as of that date. A shareholder who exercises Rights pursuant to the Primary Subscription is hereinafter referred to as an "Exercising Shareholder". In such event, the Fund will notify Shareholders and permit Exercising Shareholders to cancel exercise of their Rights. Exercising Shareholders will have their payment for additional Shares returned to them if they opt to cancel the exercise of their Rights.

The Trust may, in the future, choose to make additional rights offerings from time to time for a number of shares and on terms that may or may not be similar to this Offer. Any such future rights offerings will be made in accordance with the then applicable requirements of the Investment Company Act and the Securities Act.

There can be no assurance that the Trust or its Shareholders will achieve any of the foregoing objectives or benefits through the Offer.

OVER-SUBSCRIPTION PRIVILEGE

If some Shareholders do not exercise all of the Rights initially issued to them in the Primary Subscription, such Shares which have not been subscribed for will be offered, by means of the Over-Subscription Privilege, to Shareholders who have exercised all the Rights initially issued to them and who wish to acquire more than the number of Shares for which the Rights issued to them are exercisable. Shareholders who exercise all the Rights initially issued to them will be asked to indicate, on the Exercise Form which they submit with respect to the exercise of the Rights, how many Shares they are willing to acquire pursuant to the Over-Subscription Privilege. The Trust may, at its discretion, issue up to an additional 25% of the Shares in the Offer to honor over-subscription requests if sufficient Shares are not available from the Primary Subscription to honor all over-subscriptions. If sufficient Shares remain, all over-subscriptions will be honored in full. If sufficient Shares are not available to honor all over-subscriptions (after giving effect to any increase in the number of Shares to be offered), the available Shares will be allocated among those who over-subscribe based on the number of Rights

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

originally issued to them by the Trust, so that the number of Shares issued to Shareholders who subscribe pursuant to the Over-Subscription Privilege will generally be in proportion to the number of Shares owned by them in the Trust on the Record Date. The allocation process may involve a series of allocations to assure that the total number of Shares available for over-subscriptions is distributed on a pro-rata basis. The Over-Subscription Privilege may result in additional dilution of interest and voting rights to Shareholders, and additional reduction in the Trust's NAV per share.

The Trustees and officers of the Trust and employees of the Investment Adviser may purchase Shares in the Offer and pursuant to the Over-Subscription Privilege. Any such purchases will be made on the same terms applicable to other Shareholders.

THE SUBSCRIPTION PRICE

The Subscription Price per Share will be 95% OF THE VOLUME WEIGHTED AVERAGE SHARE PRICE OF A SHARE ON THE NYSE ON SEPTEMBER 22, 2006 (THE "PRICING DATE") AND THE FOUR PRECEDING BUSINESS DAYS.

19

The Trust announced the Offer after the close of trading on the NYSE on March 15, 2006. The NAV at the close of business on March 15, 2006 and August 14, 2006 was \$17.15 and \$14.06, respectively, and the last reported share price of a Share on the NYSE on those dates was \$17.25 and \$14.73, respectively. Since the Expiration Date occurs before the Pricing Date, Shareholders who decide to acquire Shares on the Primary Subscription or pursuant to the Over-Subscription Privilege will not know the purchase price for such Shares when they make such decision. Information about the Trust's NAV may be obtained by calling (800) 451-2597.

EXPIRATION OF THE OFFER

Rights will expire at 5:00 p.m., Eastern Time, on the Expiration Date and thereafter may not be exercised, unless the Offer is extended.

Any extension, termination, or amendment will be followed as promptly as practical by announcement thereof, such announcement in the case of an extension to be issued no later than 9:00 a.m., Eastern time, on the next business day following the previously scheduled Expiration Date. The Trust will not, unless otherwise obligated by law, have any obligation to publish, advertise, or otherwise communicate any such announcement other than by making a release to the Dow Jones News Service or such other means of announcement as the Trust deems appropriate.

The Fund may elect to terminate the Offer, if in the judgment of the Fund's Board of Trustees, market circumstances significantly change. In such event, the Fund's Board of Trustees would likely determine that the risks associated with proceeding with the offer would be greater to the Fund and the shareholders than the risks associated with early termination, which risks could include negative public perception of the Fund and a negative impact on the Fund's performance.

SUBSCRIPTION AGENT

The Subscription Agent is Computershare Trust Company, N.A. which will receive, for its administrative, processing, invoicing and other services as Subscription Agent, a fee estimated to be \$25,000, which includes reimbursement for all out-of-pocket expenses related to the Offer. SIGNED EXERCISE FORMS SHOULD BE SENT TO COMPUTERSHARE TRUST COMPANY, N.A., by one of the methods described below:

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

SUBSCRIPTION CERTIFICATE DELIVERY METHOD	ADDRESS
By First Class Mail.....	Computershare Attn: HQL Rights Offering P.O. Box 859208 Braintree, MA 02185
By Overnight Courier or Express Mail.....	Computershare Attn: HQL Rights Offering 161 Bay State Drive Braintree, MA 02184
By Broker-Dealer or other Nominee.....	Shareholders whose Shares are held in a brokerage, bank or trust account may contact their broker or other nominee and instruct them to submit an Exercise Form or a Notice of Guaranteed Delivery and Payment on their behalf.

DELIVERY TO AN ADDRESS OTHER THAN AS SET FORTH ABOVE DOES NOT CONSTITUTE A VALID DELIVERY.

20

INFORMATION AGENT

Any questions or requests for assistance may be directed to the Information Agent at its telephone number and address listed below:

The Altman Group, Inc.
1200 Wall Street West, 3rd Floor
Lyndhurst, New Jersey 07071
Toll Free: (800)-870-0126

You may also call the Trust at (617) 772-8500 or contact your bank, broker or other nominee for information with respect to the Offer.

The Information Agent will receive a fee estimated to be approximately \$6,800, which includes reimbursement for all out-of-pocket expenses related to its services as Information Agent.

EXERCISE OF RIGHTS

Rights may be exercised by completing and signing the reverse side of the Exercise Form which accompanies this Prospectus and mailing it in the envelope provided, or otherwise delivering the completed and signed Exercise Form to the Subscription Agent, together with payment for the Shares as described below under "Payment for Shares." Completed Exercise Forms and related payments must be received by the Subscription Agent before 5:00 p.m., Eastern time, on or before the Expiration Date (unless payment is effected by means of a Notice of Guaranteed Delivery as described below under "Payment for Shares") at the offices of the Subscription Agent at the address set forth above. Rights may also be exercised through an Exercising Shareholder's broker, who may charge such Exercising Shareholder a servicing fee.

Shareholders for whom there is not a current address ("stop mail" accounts) will not be mailed this Prospectus or other subscription materials. Shareholders

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

whose record addresses on the Record Date are outside of the United States will not be mailed Exercise Forms.

EXERCISING SHAREHOLDERS WHO ARE RECORD OWNERS. Exercising Shareholders may choose between either option set forth under "Payment for Shares" below. If time is of the essence, option (2) will permit delivery of the Exercise Form and payment after the Expiration Date.

INVESTORS WHOSE SHARES ARE HELD BY A BROKER-DEALER OR OTHER NOMINEE. Exercising Shareholders whose Shares are held by a Nominee such as a broker-dealer, bank or trust company must contact the Nominee to exercise their Rights. In that case, the Nominee will complete the Exercise Form on behalf of the Exercising Shareholder and arrange for proper payment by one of the methods set forth under "Payment for Shares" below.

NOMINEES. Nominees who hold Shares for the account of others should notify the respective beneficial owners of such Shares as soon as possible to ascertain such beneficial owners' intentions and to obtain instructions with respect to exercising the Rights. If the beneficial owner so instructs, the Nominee should complete the Exercise Form and submit it to the Subscription Agent with the proper payment described under "Payment for Shares" below.

All questions as to the validity, form, eligibility (including times of receipt and matters pertaining to beneficial ownership) and the acceptance of subscription forms and the Subscription Price will be determined by the Trust, which determinations will be final and binding. No alternative, conditional or contingent subscriptions will be accepted. The Trust reserves the absolute right to reject any or all subscriptions not properly submitted or the acceptance of which would, in the opinion of the Trust's counsel, be unlawful. The Trust also reserves the right to waive any irregularities or conditions, and the Trust's interpretations of the terms and conditions of the Offer shall be final and binding. Any

21

irregularities in connection with subscriptions must be cured within such time as the Trust shall determine unless waived. Neither the Trust nor the Subscription Agent shall be under any duty to give notification of defects in such subscriptions or incur any liability for failure to give such notification. Subscriptions will not be deemed to have been made until such irregularities have been cured or waived.

PAYMENT FOR SHARES

You may exercise your Rights and pay for Shares subscribed for pursuant to the Primary Subscription and Over-Subscription Privilege in one of the following ways:

- (1) DELIVER EXERCISE FORM AND PAYMENT TO THE SUBSCRIPTION AGENT BY THE EXPIRATION DATE:

Exercising Shareholders may deliver to the Subscription Agent at any of the offices set forth above on page 20 (i) a completed and executed Exercise Form indicating the number of Rights they have been issued and the number of Shares they are acquiring pursuant to the Primary Subscription, as well as the number of any additional Shares they would like to subscribe for under the Over-Subscription Privilege and (ii) payment for all such ordered Shares based on the Estimated Subscription Price of \$13.91 per Share, both no later than 5:00 p.m., Eastern Time, on the Expiration Date.

The Subscription Agent will deposit all checks received by it for the purchase of Shares into a segregated interest bearing account of the Trust (the

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

interest from which will belong to the Subscription Agent) pending proration and distribution of Shares.

A PAYMENT PURSUANT TO THIS METHOD (1) MUST BE IN U.S. DOLLARS BY MONEY ORDER OR CHECK DRAWN ON A BANK LOCATED IN THE U.S., (2) MUST BE PAYABLE TO "H&Q LIFE SCIENCES INVESTORS" AND (3) MUST ACCOMPANY AN EXECUTED EXERCISE FORM FOR SUCH SUBSCRIPTION TO BE ACCEPTED. THIRD (OR MULTIPLE) PARTY CHECKS WILL NOT BE ACCEPTED.

(2) CONTACT YOUR BROKER, BANK OR TRUST COMPANY TO DELIVER NOTICE OF GUARANTEED DELIVERY TO THE SUBSCRIPTION AGENT BY THE EXPIRATION DATE:

Exercising Shareholders may request a NYSE or National Association of Securities Dealers, Inc. member, bank or trust company to execute a Notice of Guaranteed Delivery (or equivalent electronic information) and deliver it, by facsimile or otherwise, to the Subscription Agent by 5:00 p.m., Eastern time, on the Expiration Date indicating (i) the number of Rights they wish to exercise, the number of Primary Subscription Shares they wish to acquire, and the number of Over-Subscription Privilege Shares for which they wish to subscribe and (ii) guaranteeing delivery of payment and a completed Exercise Form from such Exercising Shareholder by September 21, 2006. You must arrange for payment to the nominee, who will in turn submit your Exercise Form and payment on your behalf by September 26, 2006. The Subscription Agent will not honor a Notice of Guaranteed Delivery unless the completed Exercise Form is received by the Subscription Agent by the close of business on September 21, 2006 and full payment for the Shares is received by it by the close of business on September 26, 2006.

On October 2, 2006 (the "Confirmation Date"), the Subscription Agent will send a confirmation to each Exercising Shareholder (or, if the Shares are held by a depository or other nominee, to such depository or other nominee), showing (i) the number of Shares acquired pursuant to the Primary Subscription, (ii) the number of Shares, if any, acquired pursuant to the Over-Subscription Privilege, (iii) the per Share and total purchase price for the Shares, and (iv) any additional amount payable by such Exercising Shareholder to the Trust or any excess to be refunded by the Trust to such Exercising Shareholder in each case based upon the final Subscription Price. Any additional payment required from an Exercising Shareholder must be received by the Subscription Agent by, October 12, 2006 (the "Final Payment Date"). Any excess payment to be refunded by the Trust to an Exercising Shareholder

22

will be mailed by the Subscription Agent to the holder as promptly as practicable after the Final Payment Date. In the case of any Shareholder who exercises his or her right to acquire Shares pursuant to the Over-Subscription Privilege, any excess payment which would otherwise be refunded to the Shareholder will be applied by the Trust toward payment for additional Shares acquired pursuant to exercise of the Over-Subscription Privilege. Any additional payment required from a Shareholder must be received by the Subscription Agent by the close of business on October 12, 2006. Any excess payment to be refunded by the Trust to a Shareholder will be mailed by the Subscription Agent to such Shareholder as promptly as possible within ten (10) business days after the Confirmation Date. All payments by a Shareholder must be made in United States dollars by money order or check drawn on a bank located in the United States of America and payable to H&Q LIFE SCIENCES INVESTORS.

Issuance and delivery of certificates for the Shares purchased are subject to actual collection of checks and actual payment pursuant to any Notice of Guaranteed Delivery.

If an Exercising Shareholder does not make payment of any additional amounts

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

due by October 12, 2006 the Trust reserves the right to take any or all of the following actions: (i) apply any payment received by it toward the purchase of the greatest whole number of Shares which could be acquired by such Exercising Shareholder upon exercise of the Primary Subscription and/or Over-Subscription Privilege based on the amount of such payment; (ii) allocate the Shares subject to subscription rights to one or more other Shareholders; (iii) sell all or a portion of the Shares deliverable upon exercise of subscription rights on the open market and apply the proceeds thereof to the amount owed; and/or (iv) exercise any and all other rights or remedies to which it may be entitled, including, without limitation, the right to set-off against payments actually received by it with respect to such subscribed Shares.

AN EXERCISING SHAREHOLDER WILL NOT HAVE THE RIGHT TO CANCEL THE EXERCISE OF RIGHTS OR RESCIND A PURCHASE AFTER THE SUBSCRIPTION AGENT HAS RECEIVED PAYMENTS, EITHER BY MEANS OF A NOTICE OF GUARANTEED DELIVERY OR A CHECK OR MONEY ORDER, EXCEPT AS DESCRIBED UNDER "THE OFFER-NOTICE OF NAV DECLINE."

The risk of delivery of subscription forms and payments to the Subscription Agent will be borne by the Exercising Shareholder and not the Trust, the Subscription Agent or the Information Agent. If the mail is used to exercise Rights, it is recommended that such Exercise Forms and payment be sent by registered mail, properly insured, with return receipt requested, and that a sufficient number of days be allowed to ensure delivery to the Trust and clearance of payment before 5:00 p.m., Eastern time, on the Expiration Date. Because uncertified personal checks may take at least five business days to clear and may, at the discretion of the Trust, not be accepted if not cleared before the Expiration Date, you are strongly encouraged to pay, or arrange for payment, by means of certified or bank cashier's check.

NOTICE OF NAV DECLINE

The Trust will suspend the Offer until it amends this Prospectus if, after the effective date of this Prospectus, the Trust's NAV declines more than 10% from its NAV as of that date. In such event, the Trust will notify you of any such decline and thereby permit you to cancel your exercise of your Rights. Shareholders will have their payment for additional Shares returned to them if they opt to cancel the exercise of their Rights.

DELIVERY OF SHARES

Shareholders whose Shares are held of record by Cede or by any other depository or Nominee on their behalf or their broker-dealers' behalf will have any Shares that they acquire pursuant to the Offer credited to the account of Cede or such other depository or nominee. With respect to all other Shareholders, Shares will be issued after the expiration of the Offer, and clearance of checks, which can take up to 17 business days.

23

EMPLOYEE PLAN CONSIDERATIONS

Shareholders that are employee benefit plans subject to the Employee Retirement Income Security Act of 1974, as amended ("ERISA") (including corporate savings and 401(k) plans), and plans that are subject to Code Section 4975, such as profit sharing/retirement plans for self-employed individuals and Individual Retirement Accounts (collectively, "Retirement Plans") should be aware that additional contributions of cash to Retirement Plans (other than rollover contributions or trustee-to-trustee transfers from other Retirement Plans) to exercise Rights would be treated as Retirement Plan contributions and therefore, when taken together with contributions previously made, may be treated as excess or nondeductible contributions and may be subject to excise taxes. In the case of Retirement Plans qualified under Section 401(a)

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

of the Internal Revenue Code of 1986, as amended (the "Code"), additional cash contributions could cause violations of the maximum contribution limitations of Section 415 of the Code or other qualification rules. Retirement Plans in which contributions are so limited should consider whether there is an additional source of funds available within the Retirement Plan, such as a reallocation from another investment option or other liquidation of assets, with which to exercise the Rights. Because the rules governing Retirement Plans are extensive and complex, Retirement Plans contemplating the exercise of Rights should consult with their counsel before such exercise.

Retirement Plans and other tax exempt entities should also be aware that if they borrow to finance their exercise of Rights, they may become subject to the tax on unrelated business taxable income under Section 511 of the Code. If any portion of an Individual Retirement Account ("IRA") is used as security for a loan, the portion so used will be treated as a distribution to the IRA depositor.

ERISA contains fiduciary responsibility requirements, and ERISA and the Code contain prohibited transactions rules that may affect the exercise of Rights. Due to the complexity of these rules and the penalties for noncompliance, Retirement Plans should consult with their counsel regarding the consequences of their exercise of Rights under ERISA and the Code.

CERTAIN FEDERAL INCOME TAX CONSEQUENCES OF THE OFFER

The following discussion summarizes the principal federal income tax consequences of the Offer to Shareholders and Exercising Shareholders. It is based upon the Code, U.S. Treasury regulations, Internal Revenue Service rulings and policies and judicial decisions in effect on the date of this Prospectus. This discussion does not address all federal income tax aspects of the Offer that may be relevant to a particular Shareholder because of his individual circumstances or to Shareholders subject to special treatment under the Code (such as insurance companies, financial institutions, tax-exempt entities, dealers in securities, foreign corporations, and persons who are not citizens or residents of the U.S.), and it does not address any state, local or foreign tax consequences. Accordingly, each Shareholder should consult his or her own tax advisor as to the specific tax consequences of the Offer to him or her. Each Shareholder should also review the discussion of certain tax considerations affecting the Trust and Shareholders set forth under "Taxation" below.

For federal income tax purposes, neither the receipt nor the exercise of the Rights by Shareholders will result in taxable income to those Shareholders, and no loss will be realized if the Rights expire without exercise.

The Shareholder's basis in the Right will be zero unless either (i) the fair market value of the Right on the date of distribution is 15% or more of the fair market value on such date of the Shares with respect to which the Right was distributed, or (ii) the Shareholder elects, on its federal income tax return for the taxable year in which the Right is received, to allocate part of the basis of such Shares to the Right. If either of clauses (i) and (ii) is applicable, then if the Right is exercised, the Exercising Shareholder will allocate its basis in the Shares with respect to which the Right was distributed between such Shares and the Right in proportion to the fair market values of each on the date of distribution.

The holding period of a Right received by a Shareholder includes the holding period of the Shares with regard to which the Right is issued. If the Shareholder exercises a Right, the holding period of the Shares acquired begins on the date the Right is exercised.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

In the event a Shareholder allows rights to expire without exercising them, the Rights will be deemed to have a zero basis and, therefore, the Shareholder will not recognize any loss upon the expiration of the Rights. In addition, the tax basis of the Shares with respect to which the expired Rights were distributed will remain unchanged compared to their basis prior to the Offer.

The Shareholder's basis for determining gain or loss upon the sale of a Share acquired upon the exercise of a right will be equal to the sum of the Shareholder's basis in the Right, if any, and the Subscription Price. Gain or loss recognized by a Shareholder upon the sale of a Share acquired through the Offer will be capital gain or loss (assuming the Share was held as a capital asset at the time of sale) and will be long-term capital gain or loss if the Share was held for more than a year.

The foregoing is only a summary of the applicable federal income tax laws presently in effect and does not include any state or local tax consequences of the Offer. Moreover, the foregoing does not address the many factors that may determine whether an investor will be liable for the federal alternative minimum tax. You should consult your own tax advisor concerning the tax consequences of this transaction.

SPECIAL CONSIDERATIONS

Shareholders who do not fully exercise their Rights should expect that they will, at the completion of the Offer, own a smaller proportional interest in the Trust than would otherwise be the case if they exercised their Rights. The Trust cannot determine the extent of this dilution at this time because it does not know what proportion of the Trust's Shares will be purchased as a result of the Offer.

Shareholders who do not fully exercise their Rights may experience dilution in their holdings because they will indirectly bear the expenses of the Offer. Further, Shareholders that do not submit subscription requests pursuant to the Over-Subscription Privilege may also experience dilution in their holdings, if the Trust offers additional Shares for subscription. The Trust cannot state precisely the amount of any potential decrease in NAV because it does not know at this time how many Shares will be subscribed for or what the NAV or market price per Share will be at the Pricing Date. As of August 14, 2006, the Trust's Shares traded at a 4.77% premium to NAV. If the Trust's Shares trade at a similar premium to NAV as of the Pricing Date, the Trust estimates that such dilution would be minimal. See "Risk Factors--Dilution of NAV and Effect of Non-Participation in the Offer." Except as described in this Prospectus, you will have no right to rescind your subscription requests after receipt of your payment for Shares by the Subscription Agent.

OTHER RIGHTS OFFERINGS

The Trust made a rights offering in November 1993 at a price that was lower than its then-current NAV, and may have similar rights offerings in the future. Any such future rights offerings would be separately registered with the Commission and made by means of separate prospectuses.

RESTRICTION ON FOREIGN SHAREHOLDERS

Shareholders on the Record Date whose record addresses are outside the United States will receive written notice of the Offer; however, Exercise Forms will not be mailed to such Shareholders. The Rights to which those Exercise Forms relate will be held by the Subscription Agent for such foreign Shareholders' accounts until instructions are received in writing with payment to exercise the Rights. If no such instructions are received by the Expiration Date, such Rights will expire. See "Subscription Agent."

USE OF PROCEEDS

Assuming all Shares offered hereby are sold at an estimated Subscription Price (the "Estimated Subscription Price") of \$13.91 per Share, the net proceeds of the Offer will be approximately \$61,922,097, after deducting expenses payable by the Trust estimated at approximately \$462,000. The net proceeds of the Offer will be invested in accordance with the Trust's investment objective and policies. See "Investment Objective and Policies." Various factors affect investments in emerging growth companies that are different from factors affecting investments in large well-known companies, including the additional research required to investigate a large number of small companies and the volatility and illiquidity of securities of those companies. Accordingly, initial investment of the proceeds in publicly-traded securities may take place during a period of up to six months following completion of the Offer, depending on market conditions and the availability of appropriate securities. Restricted Securities may be purchased as appropriate opportunities arise, which could take up to one year or longer, and the Trust may choose to be more fully invested in publicly-traded securities during such period. Pending investment in the securities described above, the proceeds will be held in obligations of the U.S. Government, its agencies or instrumentalities ("U.S. Government Securities"), highly rated money market instruments or mutual funds that invest in such instruments. As a result of this short-term investment of the proceeds, a lower return may be realized.

INVESTMENT OBJECTIVE AND POLICIES

GENERAL

The Trust's investment objective is to seek long-term capital appreciation by investing primarily in Life Sciences Companies. The Trust's investment objective is a fundamental policy and may not be changed without the affirmative vote of the holders of a majority of the outstanding Shares (as such term is defined in Section 2(a)(42) of the Investment Company Act). For a more detailed description of the Trust's investment objective and policies see "Additional Information about Investments, Investment Techniques and Risks" and "Investment Restrictions" in the SAI. For a description of the risks that may be associated with an investment in the Trust, see the section of this Prospectus entitled "Risk Factors."

In an effort to achieve its investment objective, the Trust will invest primarily in securities of U.S. and foreign companies that are believed by the Investment Adviser to have significant potential for above-average, long-term growth in revenues and earnings. The Investment Adviser expects that such companies generally will possess most of the following characteristics: strong market position for their services or products, experienced business management, recognized technological expertise and the ability either to generate funds internally to finance growth or to secure outside sources of capital. The Investment Adviser will typically attempt to invest in securities that sell at price-earnings ratios or at multiples of underlying asset or potential values which, relative to other comparable securities or to the company's growth expectations, the Investment Adviser believes, do not fully reflect the company's potential.

The Trust emphasizes investment in securities of emerging growth Life Sciences Companies which may offer limited products or services or which are at the research and development stage with no marketable or approved products or technologies. The Trust may also invest up to 40% of its net assets in Restricted Securities. The Trust may invest in securities of large, well-known companies with existing products in the life sciences industries that are believed by the Investment Adviser to be undervalued in relation to their

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

long-term growth potential or asset value.

The Trust may invest up to 25% of its net assets in Foreign Securities. The Trust may buy and sell currencies for the purpose of settlement of transactions in Foreign Securities.

Under normal market conditions, the Trust will invest at least 80% of its total assets in securities of Life Sciences Companies. The Trust expects to invest primarily in securities of Life Sciences Companies in the healthcare industry (which includes the biotechnology sector) and is required, except

26

for temporary defensive purposes, to invest at least 25% of its net assets in such companies. For purposes of satisfying the foregoing requirements, a company will be deemed to be a Life Sciences Company if, at the time the Trust makes an investment therein, 50% or more of such company's sales, earnings efforts or assets arise from or are related to healthcare, agriculture or environmental management, as the case may be. The Trust may also invest in companies that do not satisfy the above criteria but that are expected by the Investment Adviser to have 25% or more of sales, earnings efforts or assets arising from or dedicated to healthcare, agriculture or environmental management, but investments in such securities will not count toward achieving the percentages mentioned above. Determinations as to whether a company is a Life Sciences Company will be made by the Investment Adviser in its discretion.

The equity and related securities in which the Trust may invest consist of common stock of Life Sciences Companies and, to a lesser extent, of preferred stock, convertible debt, limited partnership interests and warrants or other rights to acquire common or preferred stocks of such companies. The Trust's investments in venture capital opportunities, which are considered Restricted Securities, will be made primarily in convertible preferred stock. The Trust may also purchase non-convertible debt securities in connection with its venture capital investments, and otherwise when the Investment Adviser believes that such investments would be consistent with the Trust's investment objective. While these debt investments typically will not be rated, the Investment Adviser believes that, in light of the risk characteristics associated with investments in emerging growth companies (see "Risk Factors"), if such investments were to be compared with investments rated by S&P or Moody's, they may be rated as low as "C" in the rating categories established by S&P and Moody's. Such securities are commonly referred to as "junk bonds" and are considered, on balance, as predominantly speculative.

Investments will not be made in any company with the objective of exercising control over that company's management. The Trust nevertheless may, provide managerial assistance to any such company as is normally the case with venture capital funds. The Trust may also make investments contemporaneously with other venture capital groups that may provide issuers with significant managerial assistance.

SHORT SALES, WHEN-ISSUED, DELAYED DELIVERY TRANSACTIONS AND REPURCHASE AGREEMENTS

The Trust may, to a limited degree, engage in short sales, when-issued and delayed delivery transactions, enter into repurchase agreements and lend its portfolio securities. Short sales are transactions in which the Trust sells a security it does not own in anticipation of an expected decline in the price of that security. In such a transaction, the Trust must borrow the security to make the delivery to the buyer. The price at which the Trust purchases the security to cover its borrowing (together with the transaction and carrying costs associated with the short sale) may be more or less than the sale price of the security. The Trust may also make short sales "against the box", which are the

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

short sales of a security the Trust owns or has the right to acquire at no additional cost. A short sale "against the box" may be used to defer recognition for federal income tax purposes of any net gain or loss on securities. "When-issued" securities are securities whose terms are available and for which a market exists, but which are not available for immediate delivery. "Delayed delivery" transactions are those in which the Trust purchases a security but settlement of the transaction is to occur after the customary settlement date. Purchases of when-issued or delayed delivery securities are made at a fixed price for delivery at a later date. The value of the security at the settlement date may be more or less than the purchase price. Short sales (other than "against the box") and when-issued and delayed delivery transactions are subject to certain asset coverage requirements. The Trust will cover its positions in such instruments consistent with Commission guidelines. For example, the Trust may maintain with its custodian a segregated account consisting of cash, U.S. Government Securities or high quality liquid debt obligations having a value at least equal to the Trust's obligations under such instruments.

The Trust may invest in repurchase agreements with respect to 10% of its net assets. Repurchase agreements allow the Trust to acquire a security subject to the obligation of the seller to repurchase

27

and the Trust to resell such security at a fixed time and price reflecting the Trust's costs and interest. It is the Trust's present intention to enter into repurchase agreements for a relatively short period (usually not more than one week) only with commercial banks and registered broker-dealers and only with respect to U.S. Government Securities and money market instruments. The Trust intends to take possession of collateral to secure a seller's repurchase obligation, and the Investment Adviser will monitor repurchase transactions to ensure that the value of the underlying securities will at all times be at least equal to the total amount of the repurchase obligation, including an interest factor. If the seller defaults, the Trust could realize a loss on the sale of the underlying security to the extent that the proceeds of sale, including accrued interest, are less than the resale price provided in the agreement, including interest. The Trust may also choose to lend its portfolio securities, subject to the limitation that all such loans will not exceed 20% of the Trust's net assets. Loans must be collateralized, on each business day, by an amount of cash, bank letters of credit or U.S. Government Securities equal to the value of the loaned securities.

PUT OR CALL OPTIONS

The Trust may purchase and sell (or write) put or call options on any security in which it is permitted to invest or on any index of securities or other index the change in value of which has a high degree of correlation with the changes in value of the Trust's portfolio securities, and may purchase and sell (or write) on a covered basis financial futures contracts and options on such futures.

The Trust may also enter into forward foreign currency exchange contracts and may purchase and sell (or write) exchange-traded or OTC options on currencies, foreign currency futures contracts and options on foreign currency futures contracts to protect against a decline in the U.S. dollar equivalent value of its foreign currency portfolio securities or the payments thereon that may result from an adverse change in foreign currency exchange rates. Although the Trust believes that use of such strategies may benefit the Trust, if the Investment Adviser's judgment about the general direction of securities market movements, foreign exchange rates or interest rates is incorrect, the Trust's overall performance could be poorer than if it had not pursued those strategies. The use of these strategies entails certain risks. Under normal market conditions, the Trust does not intend to engage in the practices described in

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

this section to any significant extent.

CASH, U.S. GOVERNMENT SECURITIES, MONEY MARKET INSTRUMENTS OR MONEY MARKET MUTUAL FUNDS

When, in the opinion of the Investment Adviser, adverse market conditions or industry expectations support such action, the Trust may, for temporary defensive purposes, invest up to 100% of its net assets in cash, U.S. Government Securities, money market instruments or money market mutual funds. Money market instruments in which the Trust may invest include certificates of deposit and bankers' acceptances issued by domestic branches of federally-insured U.S. banks and savings and loan associations and commercial paper and high and upper medium grade corporate debt securities rated, as of the date of purchase, among the following rating categories of the indicated rating service: bonds--Moody's Aaa, Aa or A; S&P AAA, AA or A; notes--Moody's MIG-1, MIG-2 or MIG-3; S&P SP-1 + to SP-2; commercial paper--Moody's P-1; S&P A-1. The Trust also may invest in shares of money market mutual funds that invest in money market instruments and U.S. Government Securities. Money market mutual funds are investment companies and the Trust's investments in those companies are subject to certain limitations. See "Investment Restrictions". As a shareholder in money market mutual funds, the Trust will bear its ratable share of such companies' expenses, including investment adviser or management fees, and will remain subject to the payment of fees to the Investment Adviser to the extent that the Trust assumes a temporary defensive position for the purpose of avoiding losses, it will not participate in the capital appreciation, if any, of securities in which the Trust would normally invest.

The Trust also has adopted certain other investment restrictions in an effort to achieve its investment objective. See "Investment Restrictions".

28

RECENT DEVELOPMENTS IN THE LIFE SCIENCES SECTOR

Demographic changes continue to create new medical opportunities. It is estimated that by the year 2010 over 13% of the population will be 65 or older vs. 12% in 2002. This population consumes three to four times the healthcare goods and services as the rest of the population. This will drive an increase in all types of medical products, from drugs to orthopedic procedures. Furthermore, Medicare enrollment is expected to increase significantly in the coming years. This trend will dramatically increase the demand for new healthcare services and technologies.

In addition, hundreds of recent developments in the pharmaceutical, biotechnology, and medical technology industries have produced a series of blockbuster products that have or will extend or improve the quality of patients' lives. Therapeutic products to treat a variety of diseases or conditions have completed human clinical trials and are awaiting FDA marketing approval; there are over 1,000 late stage clinical trials ongoing for new and old drugs, and thousands of products are in earlier stage trials and pre-clinical development. The last five years has seen the commercialization of products that have made incredible advances in treating cancer, rheumatoid arthritis, erectile dysfunction, psoriasis, multiple sclerosis and depression. In the next five years, the Investment Adviser anticipates approval of other novel products which will have a comparable impact in treating sleep disorders, obesity, cardiovascular disease, additional indications in cancer, and chronic and acute pain.

The Investment Adviser also believes that the recent Medicare drug bill will dramatically alter the healthcare landscape. Under this bill, it is estimated that at least 10 million people will gain new coverage of a prescription drug benefit. The Investment Adviser believes that there will be a dramatic growth in

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

prescription volume resulting from passage of the Medicare bill. Based on these trends and events, the Investment Adviser continues to believe there are outstanding opportunities for investment in healthcare and biotechnology related companies. HQL continues to be invested in a number of very promising companies and the Investment Adviser looks forward to continued price appreciation in these companies.

In addition to the companies and products in which investments have already been made, the Investment Adviser sees great promise from several developing trends. In particular, the Investment Adviser sees tremendous potential in the areas of 1) generic pharmaceuticals, 2) specialty pharmaceuticals, 3) disease management, 4) novel medical devices, 5) novel drugs derived from known and novel targets and 6) products which will benefit from impending changes in the regulatory landscape. A major benefit to our shareholders from the proposed rights offering will be our ability to incrementally invest in additional companies on the forefront of these developing trends.

Investments in the healthcare industry are likely to continue to be a principal component of the Trust's portfolio. The healthcare industry constitutes a large segment of the US economy. The U.S. Department of Health and Human Services ("HHS") reports that national health care expenditures in 2004 represented 1.9 trillion dollars, 16% of the U.S. gross national product.. Healthcare Spending is likely to increase significantly as Americans over 65 years of age increase in proportion of the rest of society and as the obesity epidemic in the United States becomes even more common. It is estimated that by the year 2010 over 13% of the population will be 65 or older compared to 12% in 2002. Additionally, the U.S. Centers for Disease Control (CDC) has reported that 42 states have obesity rates greater than or equal to 20% in 2004.

To better describe the potential opportunities in various sub-sectors, the following information describes examples of trends in key sub-sectors.

- i. **GENERIC PHARMACEUTICALS.** The global generic drug industry is about \$356 billion in size and, according to numbers from the Generic Pharmaceuticals Association ("GPhA"), this number could reach \$60 billion by 2008. This growth has been driven by a number of factors, the most important of which has been the utilization of generic drugs as a low cost alternative. One

29

recently published statistic by the Managed Care Institute showed that a 1% increase in generic drug utilization could reduce annual drug spending by 1%. With healthcare drug costs as the fastest growing segment of healthcare, and more specifically branded pharmaceuticals, the increased utilization of generics has, and will be, a rational choice.

While cost savings have motivated the success of generics to this point, other growth drivers motivate us to increase the Trust's exposure to the generic drug space going forward. The Investment Adviser is seeing a more aggressive approach by the generic drug manufacturers to file for generic alternatives. This has led to an increase in the number of new Abbreviated New Drug Application ("ANDAs"). We are also seeing a shift in the FDA approach towards the generic drug companies as exemplified by a median approval time that has dropped nearly nine months in the last eight years. Finally, the Investment Adviser is expecting multiple blockbuster drugs to go off patent over the next few years with branded product sales of close to \$60 billion. While these numbers are subject to a number of factors including patent disputes, the genericization of these products would double the size of the generic market, making it the fastest growing pharmaceutical sector in healthcare.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

- ii. SPECIALTY PHARMACEUTICALS. The specialty pharmaceutical sector is evolving into a sector that the Investment Adviser anticipates will be a high growth area of the healthcare industry and a key component to the Trust's portfolio. Early in the evolution of this sector, specialty pharmaceuticals were used to describe companies built around drug delivery systems or companies built around older, under-promoted, acquired products. The business models of these companies were low margin businesses surviving on single digit royalty streams and products where pricing pressures existed. Today these companies are migrating to higher value proprietary models. Drug delivery companies are taking existing, validated molecules and using their delivery systems, including oral, transdermal, and sustained release systems, to supersede intravenous, injectable or multiple dose a day dosage regimes. The companies pursuing this life cycle extension strategy are improving therapy not only through greater patient compliance with prescription directions, but also through improved administration of consistently efficacious quantities of the drug. Companies pursuing the acquisitive business model are looking to in-license later staged products, develop their R&D budget, expand their sales forces and compete with biotech and pharmaceuticals in niche markets. These companies are characterized by low risk R&D strategies, using validated molecular targets.
- iii. DISEASE MANAGEMENT. As healthcare costs spiraled in the 1980's, the healthcare industry turned to managed care companies as a way of minimizing the excess administrative burden of the cost plus model. As managed care evolved and expanded, it began to rely on information technology to help manage the increasingly complex relationships and growing number of "transactions" between patient, provider, and payor. Companies in these sectors performed well. However, today managed care requires new tools. People are living longer and want to live better. Demographic changes and an aging population use substantially more healthcare services than do younger individuals. The Managed Care Institute expects Medicare enrollment to increase in the coming years. The Investment Adviser believes this trend will increase the demand for new healthcare services and technologies focused on maximizing the benefit of every healthcare dollar spent. Creative disease management programs to manage high risk populations could be implemented by large employers and other healthcare providers. New devices and healthcare services that improve overall wellness, and quality of life will become popular with the graying of America. Other services of healthcare with a focus on cutting unnecessary costs will be focused on the better management of information, particularly such areas as claims processing, patient management direct costs and quality

30

control, and ultimately automation of patient records. The Investment Adviser expects that these areas will provide opportunities for investment.

- iv. NOVEL MEDICAL DEVICES. Medical technology includes all products used in healthcare other than pharmaceuticals. Products range from crutches to spine implants to drug-eluting stents and other medical technology accounts for 15% of all dollars spent in healthcare--more money than is spent on all 400 pharmaceuticals and biotechnology products combined. Currently there are approximately 170 publicly traded medical technology companies. Of these companies, approximately 200 are currently valued at under \$200M in market capitalization. Medical technology company valuations are directly correlated with the underlying company fundamentals; and thus stock performance is a function of operational performance. The Investment Adviser believes

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

that medical technology companies which achieve good earnings performance will produce returns that are less susceptible to fluctuations in general market conditions relative to big pharmaceuticals, healthcare services, and biotechnology companies. The Investment Adviser expects that Medical Technology Companies will be well represented in the Trust.

- v. NOVEL DRUGS FROM KNOWN OR NOVEL TARGETS. The Adviser believes that the use of genomic approaches will continue to allow us to identify and clinically validate new molecular targets. Most existing drugs interact with one or more of under 200 target molecules in the body. The genomic era of the last five to ten years has identified thousands of new potential targets through which new and novel medicines should be able to beneficially intervene in disease processes, particularly in cancer. The recent approvals of Avastin and Velcade are examples of approved drugs that address novel targets. In addition, the Investment Adviser sees tremendous potential in the use of immuno-stimulation to help manage cancer. The Investment Adviser anticipates continued development of monoclonal antibodies for oncology indications. In the area of target selection, the Investment Adviser sees increased use of structural biology, pathways analysis, imaging technology, and biomarker development. This area presents a significant potential opportunity for investments by the Trust.
- vi. REGULATORY CHANGES. In the recent past, the FDA has made a number of changes to its requirements for drug development that the Investment Adviser believes create new opportunities for investment by the Trust. For example, the FDA has recently developed the special protocol assessment (SPA) development route for biologics. This approach allows sponsoring companies to obtain a binding A PRIORI agreement with the FDA on the approvability of a drug based on the success of a defined clinical trial. The Investment Adviser thinks this approach adds clarity to the likelihood of success of certain products. The Investment Adviser further thinks that its expertise in evaluating these trial designs gives it (and therefore the Trust) a competitive advantage in selecting companies for investment. The Investment Adviser also anticipates the FDA will soon define a path to approval of generic biologics as there is currently no viable path. Once an approved approach is defined, the Investment Adviser believes a number of companies will seek approval of generic biologics. The Investment Adviser expects that this area will provide additional opportunities for investments.

RISK FACTORS

An investment in the Shares of the Trust involves a high degree of risk. Prospective investors should consider carefully the following risk factors in addition to the other information set forth in this Prospectus.

Because the Trust intends to invest substantially all of its assets in equity securities of Life Sciences Companies, an investor should be aware of certain special considerations and risk factors relating to

investments in such companies. No assurance can be given that Life Sciences Companies will grow, that a sufficient number of appropriate investments will be available or that the Trust's particular investment choices will be successful. Investors should also be aware of considerations and risks relating to the Trust's investment practices. An investment in the Trust should not itself be considered a balanced investment program and is intended to provide diversification only as part of a more complete investment program. The Trust is

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

intended for long-term investors not seeking current income.

DILUTION OF NET ASSET VALUE AND EFFECT OF NON-PARTICIPATION IN THE OFFER

As a result of the terms of the Offer, shareholders who do not fully exercise their Rights, including the Over-Subscription Privilege, will, at the completion of the Offer, own a smaller proportional interest in the Trust than they owned prior to the Offer. In addition, an immediate dilution of the NAV per Share may be experienced by all shareholders as a result of the Offer whether or not they exercise any or all of their Rights, if the Subscription Price of each Share is less than the then current NAV per Share and the number of Shares outstanding after the Offer increases in greater proportion than the increase in the net assets of the Trust. Because it is not known at this time how many Shares will be subscribed for or what the Subscription Price will be, it is not possible to state precisely the amount of dilution you may experience. For example, if the assumed Subscription Price is \$13.91, representing a market price of 95% of NAV, assuming that all Rights are exercised in the Primary Subscription and all Shares are issued pursuant to the Over-Subscription Privilege, the Trust's NAV would be reduced by approximately \$0.06 per Share or approximately 0.41% of NAV. The example assumes a NAV of \$14.06 per Share, based on the Trust's NAV after the close of trading on Monday, August 14, 2006. Since May 8, 1992 (commencement of operations), Shares of the Trust have traded at various times at, above and below the NAV.

If the Subscription Price is greater than the then current NAV per Share and the number of Shares outstanding after the Offer increases proportionately less than the increase in net assets of the Trust, all shareholders may experience an immediate accretion of the aggregate NAV per share, whether or not they exercise any of all of their Rights.

If you do not participate in the Over-Subscription Privilege, your percentage ownership may also be diluted. Although it is not possible to state precisely the amount of such a decrease or increase in value, because it is not known at this time how many Shares will be subscribed for or what the Subscription Price will be, such dilution or accretion might be substantial.

MARKET RISK

As with any investment company that invests in equity securities, the Trust is subject to market risk--the possibility that the prices of equity securities will decline over short or extended periods of time. As a result, the value of an investment in the Trust's Shares will fluctuate with the market. You could lose money over short or long periods of time.

Political and economic news can influence market-wide trends and can cause disruptions in the U.S. or world financial markets. Other factors may be ignored by the market as a whole but may cause movements in the price of one company's stock or the stock of companies in one or more industries. All of these factors may have a greater impact on initial public offerings and emerging company shares.

SELECTION RISK

Different types of equity securities tend to shift into and out of favor with investors, depending on market and economic conditions. The performance of funds that invest in Life Sciences Companies may at times be better or worse than the performance of funds that focus on other types of securities or that have a broader investment style.

CONCENTRATION ON LIFE SCIENCES COMPANIES

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Under normal market conditions, the Trust expects to invest primarily in securities of Life Sciences Companies representing a small number of industries and to invest at least 25% of its net assets in securities of Life Sciences Companies in the healthcare industry. The Trust's portfolio may therefore be more sensitive to, and possibly more adversely affected by, regulatory, economic or political factors or trends relating to the healthcare, agriculture and environmental management industries than a portfolio of companies representing a larger number of industries. This risk is in addition to the risks normally associated with any strategy seeking capital appreciation by investing in a portfolio of equity securities.

Life sciences Companies are characterized by limited product focus, rapidly changing technology and extensive government regulation. In particular, technological advances can render an existing product, which may account for a disproportionate share of a company's revenue, obsolete. Obtaining governmental approval from agencies such as the FDA and the U.S. Department of Agriculture for new products can be lengthy, expensive and uncertain as to outcome. Such delays in product development may result in the need to seek additional capital, potentially diluting the interests of existing investors such as the Trust. In addition, governmental agencies may, for a variety of reasons, restrict the release of certain innovative technologies of commercial significance, such as genetically altered material. These various factors may result in abrupt advances and declines in the securities prices of particular companies and, in some cases, may have a broad effect on the prices of securities of companies in particular life sciences industries.

While a concentration of investments in any life sciences industry or in Life Sciences Companies generally may increase the risk and volatility of an investment company's portfolio, the Trust will endeavor to reduce risk by having a portfolio of investments that is diversified within its stated objective and policies. Such volatility is not limited to the biotechnology sector, and companies in other sectors may be subject to similar abrupt movements in the market prices of their securities. No assurance can be given that future declines in the market prices of securities of companies in the industries in which the Trust may invest will not occur, or that such declines will not adversely affect the net asset value of the Trust or the price of the Shares.

With respect to healthcare, cost containment measures already implemented by the federal government, state governments and the private sector have adversely affected certain sectors of these industries. There is increasing discussion at all levels of government as to how to extend health insurance coverage to the millions of people in the United States who are currently uninsured, while also restraining the growth of total healthcare expenditures. The implementation of any of the measures under discussion may create increased demand for healthcare products and services but also may have an adverse effect on some companies in the healthcare industries. No assurance can be given that healthcare reform legislation will be enacted or, if enacted, as to its ultimate form. Increased emphasis on managed care in the United States may put pressure on the price and usage of products sold by Life Sciences Companies in which the Trust may invest and may adversely affect the sales and revenues of Life Sciences Companies.

Product development efforts by Life Sciences Companies may not result in commercial products for many reasons, including, but not limited to, failure to achieve acceptable clinical trial results, limited effectiveness in treating the specified condition or illness, harmful side effects, failure to obtain regulatory approval, and high manufacturing costs. Even after a product is commercially released, governmental agencies may require additional clinical trials or change the labeling requirements for products if additional product side effects are identified, which could have a material adverse effect on the market price of the securities of those Life Sciences Companies.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Certain Life Sciences Companies in which the Trust may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing and sale of pharmaceutical, medical devices or other products. There can be no assurance that a product liability

33

claim would not have a material adverse effect on the business, financial condition or securities prices of a company in which the Trust has invested.

All of these factors may cause the value of the Trust's Shares to fluctuate significantly over relatively short periods of time.

INVESTMENT IN EMERGING GROWTH COMPANIES

The Trust emphasizes investment in equity securities of emerging growth Life Sciences Companies. While these securities offer the opportunity for significant capital gains, such investments also involve a degree of risk that can result in substantial losses. Some of the Life Sciences Companies in which the Trust may invest are expected to be companies that are in a "start-up" stage of development, have little or no operating history, operate at a loss or with substantial variations in operating results from period to period, have limited products, markets, financial resources or management depth, or have the need for substantial additional "follow-on" capital to support expansion or to achieve or maintain a competitive position. Such additional investments may dilute the interests of prior investors, such as the Trust. Some of these Life Sciences Companies may be emerging companies at the research and development stage with no marketable or approved products or technology. There can be no assurance that securities of start-up or emerging growth companies will, in the future, yield returns commensurate with their associated risks.

LIQUIDITY OF PORTFOLIO INVESTMENTS

The Trust may invest substantially all of its net assets in securities of emerging Life Sciences Companies that are traded in the over-the-counter markets or on stock exchanges where the low trading volume of a particular security may result in abrupt and erratic price movements. An investment in such securities may have limited liquidity, and the Trust may find it necessary to sell at a discount from recent prices or to sell over extended periods of time when disposing of such securities. In addition, the Trust may invest up to 40% of its net assets in Restricted Securities, which by their terms are illiquid because they are subject to legal or contractual restrictions on resale. The Trust cannot sell Restricted Securities except in a public offering registered under the Securities Act or pursuant to an exemption from registration under the Securities Act, including a transaction in compliance with Rule 144 under the Securities Act. Rule 144 permits only limited sales under specified conditions unless the Trust has held the securities for at least two years and is unaffiliated with the issuer. Restricted Securities are expected to include venture capital investments that may take many years from the date of initial investment to reach a state of maturity when public disposition or other value realization events can be considered or expected. Adverse conditions in the securities markets at certain times may preclude a public offering of an issuer's unregistered securities. The lack of an active secondary market and resale restrictions may result in the inability of the Trust to sell a security at an attractive price and may substantially delay the sale of a security that the Trust seeks to sell. Companies whose securities are not publicly-traded are also not subject to the same disclosure and other legal requirements as are applicable to companies with publicly-traded securities. Restricted Securities eligible for resale to qualified institutional buyers pursuant to Rule 144A under the Securities Act are subject to the 40% limitation described above.

VALUATION OF RESTRICTED SECURITIES INCLUDING VENTURE CAPITAL INVESTMENTS

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Some of the Trust's investments generally have no established trading market or are subject to restrictions on resale. Because of the type of investments that the Trust makes and the nature of its business, the valuation process requires an analysis of various factors. The Trust's fair value methodology includes the examination of, among other things, (i) the existence of any contractual restrictions on the disposition of the securities; (ii) information obtained from the issue, which may include an analysis of the company's financial statements, the company's products or intended markets,

34

or the company's technologies; and (iii) the price of a security negotiated at arm's-length in an issuer's completed subsequent round of financing.

Since there is typically no readily available market value for the venture capital investments and some of the Restricted Securities in the Trust's portfolio, venture capital investments and such Restricted Securities in the Trust's portfolio are valued at fair value as determined in good faith by the Board of Trustees pursuant to a valuation policy and a consistently applied valuation process. Because of the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Trust's investments determined in good faith by the Board of Trustees, or in accordance with valuation procedures approved by the Board of Trustees, may differ significantly from the values that would have been used had a ready market existed for the investments, and the differences could be material. There is no single standard for determining fair value in good faith. As a result, determining fair value requires that judgment be applied to the specific facts and circumstances of each portfolio investment subject to fair value determination while employing a consistently applied valuation process for the types of investments the Trust makes.

FOREIGN SECURITIES

The Trust may invest up to 25% of its net assets in Foreign Securities. Foreign Securities may be less liquid and have prices that are more volatile than securities of comparable U.S. companies. Foreign stock exchanges and brokers are generally subject to less governmental supervision and regulation than U.S. exchanges and brokers, and commissions on foreign stock exchanges are generally higher than negotiated commissions in the United States. Sometimes there are delays in the settlement of transactions effected in foreign markets. Certain countries restrict foreign investments in their securities markets. These restrictions may limit or prohibit investment in certain countries or in certain industries or market sectors, or may increase the cost of investing in securities of particular companies.

Foreign companies are not generally subject to uniform accounting, auditing and financial reporting standards or to other regulatory requirements comparable to those applicable to U.S. companies. There may be less available information concerning non-U.S. issuers of securities held by the Trust than is available concerning U.S. companies. In some foreign countries, nationalization, expropriation, confiscatory taxation or establishment of exchange controls are possible. Income earned in a foreign nation may be subject to taxation (including withholding taxes on interest and dividends), or other taxes may be imposed on investments in Foreign Securities. Other risks associated with investments in Foreign Securities include difficulties in pursuing legal remedies and obtaining judgments in foreign courts, political or social instability and diplomatic developments that could adversely affect the Trust's investments in companies located in foreign countries. An investment in Foreign Securities may also involve a degree of currency risk.

JUNK BONDS AND UNRATED DEBT SECURITIES

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

The Trust may invest up to 10% of its net assets, in the aggregate, in non-convertible debt securities of Life Sciences Companies. These securities and other investments in such companies will not normally be rated, but the Investment Adviser believes that such securities may be comparable to securities rated as low as "C" in the rating categories established by S&P and Moody's. These securities, which are commonly referred to as "junk bonds", are regarded, on balance, as predominantly speculative in terms of the capacity of the issuer to pay interest or repay principal in accordance with the terms of the obligation and accordingly involve more credit risk than securities rated in the higher rating categories. Such debt securities are dependent upon favorable business, financial or economic conditions, may be subordinated to senior debt and can be regarded as having extremely poor prospects of ever attaining any real investment standing.

The market prices of such securities tend to reflect individual corporate developments to a greater extent than do securities rated in the higher rating categories, which react primarily to fluctuations in the general level of interest rates. Junk bonds also tend to be more sensitive to economic conditions than higher rated securities. Adverse publicity and investor perceptions, whether or not based on fundamental analysis, regarding junk bonds may depress the price for such securities. These and other factors adversely affecting the market prices of such securities will adversely affect the Trust's net asset value. Although some risk is inherent in all securities ownership, holders of debt securities have a claim on the assets of the issuer prior to the holders of equity securities. Therefore, an investment in debt securities generally entails less risk than an investment in equity securities of the same issuer.

35

Junk bonds are frequently issued by corporations in the growth stage of their development. They may also be issued in connection with a corporate reorganization or a corporate takeover. Companies that issue such securities often are highly leveraged and may not have available to them more traditional methods of financing. Therefore, the risk associated with acquiring the securities of such issuers generally is greater than is the case with higher rated securities. For example, during an economic downturn such issuers may not have sufficient revenues to meet their interest payment obligations. The issuer's ability to service its debt obligations may also be adversely affected by specific corporate developments, the issuer's inability to meet specific projected business forecasts or the unavailability of additional financing. The risk of loss from default by the issuer is significantly greater for the holders of such securities because such securities are often unsecured and subordinated to other creditors of the issuer.

The Trust may have difficulty disposing of junk bonds and unrated debt securities because they may not have an active secondary market. The lack of an active secondary market may have an adverse effect on market prices and the Trust's ability to dispose of particular issues and may also make it more difficult for the Trust to obtain accurate market quotations for purposes of valuing these securities.

SUBSTANTIAL COMPETITION

Intense competition exists within and among certain life sciences industries, including competition to obtain and sustain proprietary technology protection. Life Sciences Companies can be highly dependent on the strength of patents for maintenance of profit margins and market exclusivity. The complex nature of the technologies involved can lead to patent disputes, including litigation that could result in a company losing an exclusive right to a patent. Competitors of Life Sciences Companies, particularly of the emerging growth Life Sciences Companies that the Trust emphasizes, may have substantially greater

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

financial resources, more extensive development, manufacturing, marketing and service capabilities, and a larger number of qualified managerial and technical personnel. Such competitors may succeed in developing technologies and products that are more effective or less costly than any that may be developed by Life Sciences Companies in which the Trust invests and may also prove to be more successful in production and marketing. Competition may increase further as a result of potential advances in the life sciences and greater availability of capital for investment in these fields.

PRODUCT LIABILITY EXPOSURE

Certain Life Sciences Companies in which the Trust may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing and sale of pharmaceutical and medical device products. There can be no assurance that a product liability claim would not have a material adverse effect on the business, financial condition or securities prices of a company in which the Trust has invested.

KEY PERSONNEL

Investment decisions on behalf of the Trust are made by a team of individuals. Some members of the group have experience in financial analysis of public and private companies. Others have deep scientific backgrounds and considerable operating experience in biotechnology and/or pharmaceutical companies. One member has a medical degree. The Investment Adviser believes that the investment process benefits from a considered evaluation of potential investments by a group containing a variety of specialized backgrounds. The team currently in place is composed of members with a variety of specialized backgrounds. The Investment Adviser believes that no single individual in the group is individually critical but believes that the overall capability is key. There may be only a limited number of professionals who have, in total, comparable relevant experience to that of the current group. If one

36

or more team members dies, resigns, retires or is otherwise unable to act on behalf of the Investment Adviser, there can be no assurance that a suitable replacement could be found immediately.

DIVERSIFIED STATUS

The Trust operates as a "diversified" management investment company, as defined in the Investment Company Act. Under this definition, at least 75% of the value of the Trust's total assets must, at the time of investment, consist of cash and cash items (including receivables), U.S. Government Securities, securities of other investment companies, and other securities limited in respect of any one issuer to an amount not greater in value than 5% of the value of the Trust's total assets and to not more than 10% of the voting securities of a single issuer. This limit does not apply, however, to 25% of the Trust's assets, which may be invested in a single issuer. Notwithstanding its diversified status, the Trust may, from time to time, concentrate its investments in a few issuers and take large positions in those issuers, consistent with being a "diversified" investment company. As a result, the Trust may be subject to a greater risk of loss than an investment company that diversifies its investments more broadly. Taking larger positions is also likely to increase the volatility of the Trust's net asset value reflecting fluctuation in the value of its large holdings.

DISCOUNT TO NAV

The Shares are listed on the New York Stock Exchange under the symbol "HQL." The shares of closed-end investment companies frequently trade at a discount to

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

NAV, but may trade at a premium. This is characteristic of shares of a closed-end fund and is a risk separate and distinct from the risk of a decline in the NAV as a result of a fund's investment activities. Because of this factor and the nature of the Trust's investment objective and policies, the Trust is designed primarily for long-term investors and should not be considered a vehicle for trading purposes. Since its initial public offering in May 1992, Shares have traded at various times at both a discount and a premium to NAV but, generally shares have traded at a discount. The risk that the Shares may trade at a discount to NAV may be greater for investors expecting to sell their Shares in a relatively short period of time. The Trust cannot predict whether the Shares will trade in the future at, above or below NAV.

CERTAIN PROVISIONS OF THE DECLARATION OF TRUST

The Trust's Declaration of Trust has provisions that could have the effect of limiting the ability of other entities or persons to (1) acquire control of the Trust, (2) cause it to engage in certain transactions or (3) modify its structure. The Board is divided into three classes, each having a term of three years. Each year the term of office of one class will expire: Daniel R. Omstead, Ph.D, Lucinda H. Stebbins, CPA and Henri Termeer will continue until 2009, Robert P. Mack, M.D., Eric Oddleifson and Oleg M. Pohotsky will continue in office until 2008, Lawrence S. Lewin and Uwe E. Reinhardt, Ph.D. will continue in office until 2007. This provision could delay for up to two years the replacement of a majority of the Board. A Trustee may be removed from office by Shareholders only by a vote of two-thirds of the outstanding Shares of the Trust. Subject to the requirements of the Investment Company Act, vacancies on the Board of Trustees may be filled by the remaining Trustees for the balance of the term of the class.

When a Principal Shareholder (as defined below) is a party to the transaction, the affirmative vote or consent of the holders of 75% of the Trust's Shares outstanding and entitled to vote will be required to authorize any of the following types of transactions:

- (i) the merger or consolidation of the Trust with or into any Principal Shareholder;
- (ii) the issuance of any securities of the Trust to any Principal Shareholder for cash (except pursuant to any cash dividend reinvestment program available to all Shareholders and approved by the Trustees);
- (iii) the sale, lease or exchange of all or a substantial part of the assets of the Trust to or with any Principal Shareholder (except assets having an aggregate fair market value of less than \$1,000,000, aggregating for the purpose of such computation all assets sold, leased or exchanged in any series of similar transactions within a 12-month period); or
- (iv) the sale or lease to the Trust, in exchange for securities of the Trust, of any assets of any Principal Shareholder (except assets having an aggregate fair market value of less than \$1,000,000, aggregating for the purpose of such computation all assets sold, leased or exchanged in any series of similar transactions within a 12-month period).

However, such 75% vote or consent will not be required with respect to the foregoing transactions where the Board approves by resolution a memorandum of understanding with the Principal Shareholder with respect to, and substantially consistent with, such transaction. For this purpose, a "Principal Shareholder" is any corporation, person or other entity which is the beneficial owner, directly or indirectly, of more than five percent (5%) of the outstanding Shares or any "affiliate" or "associate" (as those terms are defined in Rule 12b-2 of

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

the General Rules and Regulations under the Securities Exchange Act of 1934 as in effect on April 21, 1987) of a Principal Shareholder. In addition to the Shares which a corporation, person or other entity beneficially owns directly, (a) any corporation, person or other entity shall be deemed to be the beneficial owner of any Shares (i) which it has the right to acquire pursuant to any agreement or upon exercise of the conversion rights or warrants, or otherwise (but excluding share options granted by the Trust) or (ii) which are beneficially owned, directly or indirectly (including Shares deemed owned through application of clause (i) above), by any other corporation, person or entity with which it or its affiliate or associate has any agreement, arrangement or understanding for the purpose of acquiring, holding, voting or disposing of Shares, or which is its affiliate or associate, and (b) the outstanding Shares shall include Shares deemed owned through application of clauses (i) and (ii) above but shall not include any other Shares which may be issuable pursuant to any agreement, or upon exercise of conversion rights or warrant, or otherwise.

These provisions could have the effect of depriving Shareholders of an opportunity to sell their Shares at a premium over prevailing market price by discouraging a third party from seeking to obtain control of the Trust in a tender offer or similar transaction. The Board has determined that the 75% voting requirements described above, which are greater than the minimum requirements under state law or the Investment Company Act, are in the best interests of the Shareholders.

REPURCHASE OF SHARES

You may dispose of your Shares on the NYSE or other markets on which the Shares may trade, but because the Trust is a closed-end investment company, you do not have the right to redeem your Shares. The Trustees, however, intend to consider, from time to time, but not less frequently than annually, the desirability of open market purchases or tender offers. Any Share repurchases will be made in accordance with the applicable provisions of the Investment Company Act and Massachusetts law in open market transactions. Shares repurchased by the Trust will be held in its treasury. Although the Trust has no present intention of doing so, it reserves the right to incur debt to finance such repurchases or tender offers, provided that it will not repurchase securities during the periods when it has outstanding borrowings in excess of 5% of its net assets. Interest on any borrowings to finance Share repurchase transactions will increase the Trust's expenses and will reduce the Trust's net income. There can be no assurance that Share repurchases, if any, will cause the Shares to trade at a price equal to or in excess of their net asset value. Nevertheless, the possibility that a portion of the Trust's outstanding Shares may be the subject of repurchases may reduce the spread between market price and net asset value that might otherwise exist. The Trust may not repurchase Shares except (i) on a securities exchange and after notification to Shareholders of its intent to purchase Shares within the six months preceding the purchase, (ii) pursuant to a tender offer to all Shareholders, or (iii) as otherwise

38

permitted by the Commission. Any related interest charges will be paid by the Trust and borne pro rata by the Shareholders indirectly through their interest in the Trust.

If the Trust repurchases its Shares for a price below their NAV, the NAV of those Shares that remain outstanding would be enhanced, but this does not necessarily mean that the market price of those outstanding Shares would be affected, either positively or negatively. There is no assurance that any action undertaken to repurchase Shares will result in the Shares trading at a price which approximates net asset value. Repurchases of Shares by the Trust would also decrease its total assets and accordingly may increase its expenses as a

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

percentage of average net assets. Further, interest on any borrowings to finance any such share repurchase transactions would reduce the Trust's net income. The Trust has no current plans to repurchase its Shares.

RELATED PARTY TRANSACTIONS

The majority of the Board is unaffiliated with the Investment Adviser; nevertheless, the Trust may be subject to certain potential conflicts of interest. Although the Trust has no obligation to do so, it may place brokerage orders with brokers who provide supplemental investment research and market and statistical information about the life sciences industries. In addition, other investment companies advised by the Investment Adviser may concurrently invest with the Trust in both Restricted Securities and publicly traded securities under certain conditions. The Investment Adviser may also provide managerial assistance to issuers of securities in which the Trust invests.

The Trust also may invest, subject to applicable law, in companies in which the principals of the Investment Adviser or Trustees of the Trust have invested, or for which they serve as directors or executive officers. The Investment Company Act prohibits the Trust from engaging in certain transactions involving its "affiliates," including, among others, the Trust's Trustees, officers and employees, the Investment Adviser and any "affiliates" of such affiliates except pursuant to an exemptive order or the provisions of certain rules under the Investment Company Act. In the view of the staff of the Commission, other investment companies advised by the Investment Adviser may, in some instances, be viewed to be affiliates of the Trust. Such legal restrictions and delays and costs involved in obtaining necessary regulatory approvals may preclude or discourage the Trust from making certain investments and no assurance can be given that any exemptive order sought by the Trust will be granted.

INVESTMENT TECHNIQUES

In addition to the investment practices described above, the Trust may utilize the following investment practices:

WHEN-ISSUED AND DELAYED DELIVERY TRANSACTIONS

The Trust may purchase securities on a "when issued" basis or a "delayed delivery" basis. A "when issued" basis refers to a transaction involving securities that have been authorized but have not yet been issued. A delayed delivery transaction is one in which a contract to purchase or sell a security is agreed upon at a fixed price in the future at a date beyond the customary settlement period. When-issued and delayed delivery transactions involve the risk that the value of the securities involved may change before they are delivered to the Trust. In addition, the counterparty could fail to perform its part of the contract by failing to buy from or sell to the Trust as previously agreed.

REPURCHASE AGREEMENTS

A repurchase agreement allows the Trust to buy a security on an agreement with the seller in which the seller agrees to buy back the security, with interest, at a later date. It is the Trust's present intention to enter into repurchase agreements for a relatively short period (usually not more than one

week) only with commercial banks and registered broker-dealers and only with respect to U.S. Government Securities and money market instruments. A repurchase agreement involves the risk that the seller could be unable or unwilling to honor its commitment to repurchase the securities, in which case the Trust would suffer a loss.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

LOANS OF PORTFOLIO SECURITIES

In an attempt to make productive use of its assets, the Trust may lend its portfolio securities on a short-term basis, subject to the limitation that the Trust will not lend a security if, as a result of such loan, all securities then subject to loans would exceed 20% of the Trust's net assets. In the event that the Trust invests the cash collateral from such loans of portfolio securities, the Trust may realize additional gains or losses. Lending portfolio securities involves the risk that the borrower could fail to return the securities borrowed, in which case the Trust could suffer a loss.

HEDGING

In order to hedge against changes in the value of its portfolio securities, the Trust may from time to time engage in certain hedging strategies. The Trust will engage in hedging activities from time to time in the Investment Adviser's discretion, and may not necessarily be engaging in such activities when movements in the securities markets, foreign exchange rates, or interest rates that could affect the value of the assets of the Trust occur. The risks of hedging include the possibility that interest rates, securities prices and currency exchange rates may not move in the direction that the portfolio managers anticipated. In addition, the skills involved in employing hedging strategies differ from the skills involved in selecting portfolio securities, and the derivative instruments used in hedging strategies may imperfectly correlate with the underlying security, interest rate or currency being hedged. Hedging strategies can also expose the Trust to the risk of its inability to close-out a hedged position and adverse price movements may result in a loss substantially greater than the Trust's initial investment in the hedging instrument (potential loss in some hedging strategies is unlimited).

FUTURES CONTRACTS

The Trust may enter into contracts for the purchase or sale for future delivery (a "futures contract") of baskets of securities, financial indices, financial instruments or foreign currencies. The Trust would purchase or sell futures contracts to attempt to protect the value of its securities from market-wide price movements and fluctuations in interest or foreign exchange rates without actually buying or selling securities or foreign currency. Similar to the risks of hedging, the risks of futures contracts include the possibility that interest rates, securities prices and currency exchange rates may not move in the direction anticipated. The skills involved in selecting futures contracts differ from the skills involved in selecting portfolio securities. In addition, the futures contract may imperfectly correlate with the underlying security, interest rate or currency underlying the contract, and there can be no assurance that a liquid market will exist at a time when the Trust seeks to close out a futures position.

FOREIGN CURRENCY TRANSACTIONS

The Trust may enter into forward foreign currency exchange contracts and may purchase and sell foreign currency futures contracts to protect against a decline in the U.S. dollar equivalent value of its foreign currency portfolio securities or the payments thereon that may result from an adverse change in foreign currency exchange rates. Foreign currency exchange rates may fluctuate significantly over short periods of time and may also be affected by political developments, including intervention by U.S. or foreign governments.

Under normal market conditions, the Trust currently does not intend to engage in the foregoing practices or investments with the exception of investments in money market instruments.

MANAGEMENT OF THE TRUST

BOARD OF TRUSTEES

Under the Trust's Declaration of Trust and the laws of the Commonwealth of Massachusetts, the Trust's business and affairs are managed under the direction of its Board. Investment decisions for the Trust are made by the Investment Adviser, subject to any direction it may receive from the Board, which periodically reviews the Trust's investment performance. The Statement of Additional Information includes additional information about the members of the Board and is available, without charge, upon request, by calling the Information Agent at (800) 870-0126.

INVESTMENT ADVISER

The Investment Adviser is a limited liability company organized under the laws of the State of Delaware and registered as an investment adviser under the Investment Advisers Act of 1940, as amended. The Investment Adviser is located at 30 Rowes Wharf, Fourth Floor, Boston, MA 02110-3328.

At inception, Hambrecht & Quist Capital Management Incorporated ("HQCM, Inc.") was the Trust's investment adviser. HQCM, Inc. was formed as a wholly-owned subsidiary of Hambrecht & Quist Group. HQCM, Inc. remained the Investment Adviser as The Chase Manhattan Corporation ("Chase") first acquired Hambrecht & Quist Group and then merged with J.P. Morgan Incorporated to form J.P. Morgan Chase & Co. In 2002, the management of HQCM, Inc. formed the Investment Adviser as an independent entity to effect a buyout of HQCM, Inc. In this transaction, the Investment Adviser acquired certain of the assets of HQCM, Inc., and substantially all of the management and staff of HQCM, Inc. became employees of the Investment Adviser. The Investment Adviser is owned by Daniel R. Omstead, Mary Omstead and the Alan G. Carr Irrevocable Trust. Mr. Carr, a former portfolio manager, president and trustee of the Trust, passed away in October 2003. Dr. Omstead is currently the President and Chief Executive Officer of the Investment Adviser. Mary Omstead is Dr. Omstead's wife. Under the terms of the Investment Adviser's current Amended and Restated Limited Liability Company Agreement, the Investment Adviser will purchase the Alan G. Carr Irrevocable Family Trust's interest in the Investment Adviser.

The Investment Adviser also provides investment advisory services to another closed-end investment company, H&Q Healthcare Investors ("HQH"), which invests in companies in the health care industries. As of June 30, 2006, the Investment Adviser managed approximately \$571 million in assets for the Trust and HQH.

The Investment Advisory Agreement between the Investment Adviser and the Trust (the "Advisory Agreement") provides that, subject to the supervision and direction of the Board, the Investment Adviser is responsible for the actual management of the Trust's portfolio. The Investment Adviser is also obligated to supervise or perform certain administrative and management services for the Trust and is obligated to provide the office space, facilities, equipment and personnel necessary to perform its duties under the Advisory Agreement. The responsibility for making decisions to buy, sell or hold a particular security rests with the Investment Adviser. However, the Investment Adviser may consider investment analysis from various sources, including broker-dealers with which the Trust does business.

Subject to the supervision and direction of the Board of Trustees of the Trust, the Investment Adviser manages the Trust's portfolio in accordance with the Trust's investment objective and policies as stated in the Trust's Prospectus; makes investment decisions for the Trust; places purchase and sale orders for portfolio transactions for the Trust; supplies the Trust with office

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

facilities (which may be in the Investment Adviser's own offices), statistical and research data, data processing services, clerical, internal executive and administrative services, and stationery and office supplies; supplies or directs and supervises a third party administrator or custodian in the provision to the Trust of accounting and

41

bookkeeping services, the calculation of the net asset value of shares of the Trust, internal auditing services, and other clerical services in connection therewith, and prepares or supervises and directs a third party administrator or custodian in the preparation of reports to shareholders of the Trust, tax returns and reports to and filings with the Commission and state Blue Sky authorities. The Investment Adviser also provides investment research and supervision of the Trust's investments and conducts a continual program of investment, evaluation and, if appropriate, sale and reinvestment of the Trust's assets. In addition, the Investment Adviser furnishes the Trust with whatever statistical information the Trust may reasonably request with respect to the securities that the Trust may hold or contemplate purchasing.

Starting July 1, 2006, for the services provided by the Investment Adviser under the Advisory Agreement, the Trust pays a fee, computed and payable monthly, equal when annualized to (i) 2.5% of the average net assets for the month of its venture capital and other Restricted Securities (as defined) up to 25% of net assets and (ii) for the month, for all other assets, 0.98% of the average net assets up to \$250 million, 0.88% of the average net assets for the next \$250 million, 0.80% of the average net assets for the next \$500 million and 0.70% of the average net assets thereafter. The aggregate monthly fee may not exceed a rate when annualized of 1.375% (approximately 0.11% per month). Prior to July 1, 2006, the Trust paid a fee computed and payable monthly, equal, when annualized, to (i) 2.5% of the average net assets for the month of its venture capital and other Restricted Securities (as defined) up to 25% of net assets and (ii) for the month, for all other assets, 1.0% of the average net assets up to \$250 million, 0.90% of the average net assets for the next \$250 million, 0.80% of the average net assets for the next \$500 million and 0.70% of the average net assets thereafter. The aggregate monthly fee could not exceed a rate when annualized of 1.375% (approximately 0.11% per month). Because the advisory fee is based on the average net assets of the Trust and since the Offer is expected to result in an increase in net assets, the Investment Adviser should benefit from the Offer by an increase in the dollar amount of the fee. The investment advisory fee paid by the Trust exceeds that paid by most registered investment companies to their investment advisers. The Trust believes that the fee is commensurate with the nature and quality of the services required for identifying, evaluating and monitoring the Trust's Restricted Securities investments. A discussion regarding the basis for the Board of Trustee approval of the Investment Advisory Agreement is available in the September 30, 2005 annual report to shareholders.

Under the Advisory Agreement, the Investment Adviser has agreed to bear all expenses in connection with the performance of its services under the Advisory Agreement, including compensation of and office space for officers and employees of the Trust connected with investment and economic research, trading and investment management of the Trust, as well as the fees of all Trustees of the Trust who are "affiliated persons" of the Investment Adviser, as that term is defined in the Investment Company Act, or any of its "affiliated persons." Under the Advisory Agreement, the Trust must pay (or, if Trust expenses are paid by the Investment Adviser, shall reimburse the Investment Adviser for) all other expenses incurred in the organization and operation of the Trust including, among other things, expenses for legal and auditing services, costs of printing proxy statements, prospectuses, share certificates and shareholder reports, charges of the custodian, any sub-custodian and transfer agent, expenses in connection with the Dividend Reinvestment Plan, the Commission, and National

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Association of Securities Dealers, Inc. fees, fees and expenses of the Trustees who are not "affiliated persons" of the Investment Adviser or any of its "affiliated persons," accounting and valuation costs, administrator's fees, membership fees in trade associations, fidelity bond coverage for the Trust's officers and employees, errors and omissions insurance coverage for Trustees and officers, interest, brokerage costs, taxes, stock exchange listing fees and expenses, expenses of qualifying the Trust's Shares for sale in various states, expenses associated with personnel performing exclusively shareholder servicing functions, certain other organization expenses, litigation and other extraordinary or non-recurring expenses, and other expenses properly payable by the Trust. The Trust may enter into arrangements to have third parties assume any expenses for which it is responsible.

42

PORTFOLIO MANAGEMENT

At the current time a team of analysts, including Daniel R. Omstead, Ph.D., Christopher F. Brinzey, M.B.A., Frank T. Gentile, Ph.D., and Jason C. Akus, M.D./M.B.A. are members of the team that makes investments on behalf of the Trust. These members also perform other duties including making investments on behalf of H&Q. Each of the members of the team listed below has been on the Trust's portfolio management team, which is responsible for the day-to-day management of the Trust's portfolio, since joining the Investment Adviser. Each team member's business experience for at least the last five years is included below.

Daniel R. Omstead, Ph.D., is President and Chief Executive Officer of the Investment Adviser. He is also President of the Trust and H&Q. Before joining the Investment Adviser, Dr. Omstead was President and CEO of Reprogenesis, Inc., a private development stage biotech company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies to form Curis, Inc. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development at Cytotherapeutics, Inc., a public biotech company that developed CNS therapies. Before entering the biotech industry, Dr. Omstead was employed for 14 years in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson & Johnson and at Merck Sharpe & Dohme Research Laboratories, a division of Merck & Company, Inc. While at Johnson & Johnson, Dr. Omstead participated in the development of Orthoclone OKT3-TM-, Eprex-TM-/Procrit-TM- and other biological products. While at Merck, he worked on the development of Recombivax-TM-, Mefoxin-TM-, Heartguard-TM- and other traditional drug products. Dr. Omstead holds Doctoral and Master's Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.

Christopher F. Brinzey is Senior Vice President, Research of the Investment Adviser. Mr. Brinzey joined the Investment Adviser in February of 2001 and is responsible for investment research and venture investment due diligence in the following areas: specialty pharmaceuticals and life sciences information technology and services. Before joining the Investment Adviser, Mr. Brinzey was a senior analyst for Advest Incorporated's life sciences research team where he covered and helped to finance a number of companies in the life sciences information technology and eHealth sector. Other prior work experience includes project management and consulting for SunGard Financial Systems, a subsidiary of SunGard Data Systems, a global IT solutions and eProcessing company. Mr. Brinzey received a B.A. in psychology from Hobart College and an MBA from Northeastern University.

Frank T. Gentile, Ph.D., is Senior Vice President, Research of the Investment Adviser. Dr. Gentile joined the Investment Adviser in

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

September 2002. His emphasis is on the analysis of private and public companies in the fields of Functional Genomics and Proteomics, as well as Cell and Gene Therapy. Previously Dr. Gentile was Vice President, Technology Program Management at Millennium Pharmaceuticals. At Millennium, Dr. Gentile was responsible for management of all technology platform development programs. Before joining Millennium, Dr. Gentile was Vice President of Product Development at Curis, Inc., a biotechnology company in Cambridge developing products in the area of Regenerative Medicine. From 1997 to 2000, he was Director and then Vice President, Program Management at Reprogenesis, Inc. From 1990-1997 he was employed at CytoTherapeutics, Inc., where he held several scientific and management positions. Dr. Gentile received a B.E. degree in Chemical Engineering from The Cooper Union and a Ph.D. in Chemical Engineering from MIT. Before working in industry, he was a post-doctoral fellow at the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland. He is also an Adjunct Associate Professor of Biotechnology at Brown University. He has written over 120 peer reviewed publications and holds 30 U.S. patents in the area of biotechnology.

Jason C. Akus, M.D./M.B.A., is Vice President, Research and is responsible for investment research and due diligence in the biotechnology, medical device, and diagnostic areas. Dr. Akus joined

43

the Investment Adviser in July of 2001 after graduating from Tufts with an M.D. and M.B.A. Dr. Akus also graduated from Tufts with a B.S. in Mathematics. During medical school, Dr. Akus consulted for a variety of life sciences information technology companies. See "Investment Adviser and Investment Advisory Agreement" in the Statement of Additional Information for further information about compensation of these persons, management of client assets by these persons and ownership of Trust Shares by these persons.

CODE OF ETHICS

The Board approved a Code of Ethics under Rule 17j-1 of the Investment Company Act that covers the Trust and the Investment Adviser. The Code of Ethics establishes procedures for personal investing and restricts certain transactions. Employees subject to the Code of Ethics may invest in securities for their personal investment accounts, including, in certain cases, securities that may be purchased or held by the Trust. See "Code of Ethics" in the Statement of Additional Information.

DESCRIPTION OF THE TRUST

The Trust is a diversified, closed-end management investment company. The Trust was organized as a Massachusetts business trust on February 20, 1992 pursuant to a Declaration of Trust governed by Massachusetts law and commenced operations on May 8, 1992. The Declaration of Trust is referred to in this Prospectus as the "Declaration of Trust" unless the context requires otherwise. The Trust's principal offices are located at 30 Rowes Wharf, Fourth Floor, Boston, MA 02110-3328.

The Trust's capitalization consists of an unlimited number of shares of beneficial interest, \$.01 par value. Each Share represents an equal proportionate beneficial interest in the Trust and, when issued and outstanding, will be fully paid and non-assessable by the Trust. Upon any liquidation of the Trust, Shareholders will be entitled to share pro rata in the net assets of the Trust available for distribution after paying or adequately providing for the payment of all liabilities. The Trust will send annual and semi-annual financial statements to Shareholders and may also issue more abbreviated interim reports to update Shareholders on a quarterly basis. The Trust will hold annual meetings of its Shareholders in accordance with the provisions of the Trust's By-laws and

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

the rules of the NYSE.

Shareholders are entitled to one vote for each whole Share held and a proportionate fractional vote for each fractional Share held. The Trust's Shares do not have cumulative voting rights, which means that the holders of more than 50% of the Shares of the Trust voting for the election of Trustees can elect all of the Trustees, and, in such event, the holders of the remaining Shares will not be able to elect any Trustees. The Trust has a staggered Board, whereby one class of Trustees is elected each year.

There were 13,454,515 Shares outstanding as of the Record Date. Assuming that all Rights are exercised pursuant to the Primary Subscription, an additional 4,484,838 Shares will be issued. The Trust may, at its discretion, issue up to an additional 25% of the Shares in the Offer to honor over-subscription requests if sufficient Shares are not available from the Primary Subscription to honor all over-subscriptions.

For information regarding risk factors pertaining to the Trust, see "Risk Factors."

As of August 7, 2006, to the best of the Trust's knowledge, and based solely on Schedule 13D/G filings made with the Commission, there was no person who controlled the Trust.

PORTFOLIO TRANSACTIONS AND BROKERAGE

Subject to policies established by the Board, the Investment Adviser is primarily responsible for the execution of the Trust's portfolio transactions and the allocation of brokerage. In executing such transactions, the Investment Adviser will seek to obtain the best price and execution for the Trust, taking into account such factors as price, size of order, difficulty of execution, operational facilities of

44

the firm involved, the firm's risk in positioning a block of securities, and research, market and statistical information provided by such firm. While the Investment Adviser generally seeks reasonably competitive commission rates, the Trust will not necessarily pay the lowest commission available.

The Trust intends to purchase and hold securities for capital appreciation and it is not anticipated that frequent portfolio changes will be made for short-term trading purposes or to take advantage of short-term swings in the market. However, changes may be made in the portfolio consistent with the investment objective and policies of the Trust whenever changes are believed by the Investment Adviser to be in the best interest of the Trust and its Shareholders. Risk factors, particularly those relating to a specific security investment or to the market and economic conditions, may also affect the rate at which the Trust buys and sells its portfolio holdings. The Trust has no fixed policy with respect to portfolio turnover rate. The Trust may engage in short-term trading or portfolio securities, including initial public offerings, which may result in increasing the Trust's portfolio turnover rate. The portfolio turnover rate is calculated by dividing the lesser of purchases or sales of long-term portfolio securities by the average monthly value of the Trust's long-term portfolio securities. A high rate of portfolio turnover (100% or more) could produce higher trading costs and taxable distributions, which would detract from the Trust's performance. The Trust's portfolio turnover rate for the fiscal years ended September 30, 2005 and September 30, 2004 was 73.79% and 34.93%, respectively.

NET ASSET VALUE

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

The NAV of the Trust's Shares is calculated at the close of regular trading on the NYSE (generally 4:00 p.m., Eastern Time) every day that the NYSE is open. The Trust makes this information available daily by telephone (800) 451-2597, via its web site (www.hqcm.com) and through electronic distribution for media publication, including major internet-based financial services web sites and portals (bloomberg.com, yahoo.com, cbsmarketwatch.com, etc.). Currently, The Wall Street Journal, The New York Times and Barron's publish NAVs for closed-end investment companies at least weekly.

NAV is calculated by dividing the value of the securities held by the Trust plus any cash or other assets minus all liabilities, including accrued expenses, by the total number of Shares outstanding at such time. Securities for which market quotations are readily available are valued at market price.

Portfolio securities that are traded on one or more U.S. national securities exchanges or in the over-the-counter market that are National Market System securities are valued at the last sale price or, lacking any sales, at the mean between last bid and asked prices. Other over-the-counter securities are valued at the most recent bid prices as obtained from one or more dealers that make markets in the securities. Redeemable securities issued by a registered open-end investment company are valued at net asset value per share. Other securities are valued at the mean between the closing bid and asked prices. Short-term investments that mature in 60 days or less are valued at amortized cost, unless the Board determines that such valuation does not constitute fair value.

Bonds, other than convertible bonds, are valued using a third-party pricing system. Convertible bonds are valued using this pricing system only on days when there is no sale reported. Temporary cash investments with maturity of 60 days or less are valued at amortized cost. Puts and calls generally are valued at the close of regular trading on the securities or commodities exchange on which they are primarily traded. Options on securities generally are valued at their last bid price in the case of exchange-traded options or, in the case of OTC-traded options, the average of the last bid price as obtained from two or more dealers unless there is only one dealer, in which case that dealer's price is used. Forward foreign currency contracts are valued on the basis of the value of the underlying currencies at the prevailing currency exchange rate. The prevailing currency exchange rate shall be determined within one hour of when the most recently available exchange rate information has been received based on information obtained from a bank or banks.

45

Securities that are primarily traded on foreign securities exchanges generally are valued at the last sale price on the exchange on which they are primarily traded. Foreign securities that are primarily traded on the foreign over-the-counter market are generally valued at the last sale quotation, if market quotations are available, or the last reported bid price if there is no active trading in a particular security on a given day. However, if intervening events result in market volatility that significantly affects the value of any such foreign securities after the close of trading on the relevant foreign market, but before the Trust values its Shares on any particular day on which the Trust is required to value its Shares, the Trust is required to determine the value of such securities at "fair value," as determined in good faith by or under the direction of the Board of Trustees.

Quotations of foreign securities in foreign currencies are converted, at current exchange rates, to their U.S. dollar equivalents to determine their current value. In addition, to the extent that the Trust values its foreign securities (other than ADR's and ADS's) as of the close of trading on various exchanges and over-the-counter markets throughout the world, the calculation of the Trust's net asset value may not take place contemporaneously with the valuation of foreign securities held by the Trust.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

The value of any security or other asset for which market quotations are not readily available shall be determined in a manner that most fairly reflects the security's (or asset's) "fair value". Each such determination is based on a consideration of all relevant factors, which are likely to vary from one pricing context to another. Examples of such factors may include, but are not limited to: (1) the type of the security; (2) the size of the holding (including percent of outstanding securities of issuer held by the Trust); (3) the initial cost of the security; (4) the existence of any contractual restrictions on the security's disposition and the time to freedom from such restrictions; (5) the price and extent of public trading in similar securities of the issuer or of comparable companies; (6) quotations or prices from broker-dealers and/or pricing services; (7) information obtained from the issuer, analysts, and/or the appropriate stock exchange (for exchange-traded securities); (8) an analysis of the company's financial statements; (9) an evaluation of the forces that influence the issuer and the market(s) in which the security is purchased and sold (e.g., the existence of pending merger activity, public offerings or tender offers that might affect the value of the security); and (10) the price of securities in a subsequent round of financing of an issuer in an arm's-length transaction, if the round includes a new third party investor.

Sometimes a "significant valuation event" may cause the market value of a security to differ from the fair market value of that security. A "significant valuation event" is an event that causes or is likely to cause a market quotation to be unavailable or unreliable, and may include: situations relating to a single issue in a market sector; significant fluctuations in U.S. or foreign markets; market disruptions or closings caused by human error, equipment failures, natural disasters, armed conflicts, acts of God, governmental actions or other developments, as well as the same or similar events which may affect specific issues or the securities markets even though not tied directly to the securities markets. A significant valuation event occurring after the close of trading but before the time of valuation may mean that the closing price for the security does not constitute a readily available market quotation. If a significant valuation event has occurred, the security will be valued at fair value as determined in good faith by the Board in accordance with the procedures herein described. Such valuations and procedures will be reviewed periodically by the Board.

The fair value of investments for which no market exists cannot be precisely determined. With respect to securities of a company in its early stage of development, valuation will typically be based upon the original cost to the Trust. This methodology will typically be used until significant developments affecting the portfolio company provide a basis for a change in valuation. The status of portfolio companies is monitored for progress against plan, advancement of the stage of product development, and other factors. When revenues and earnings are present they are monitored. Valuation changes are event driven. When an appropriate event occurs (e.g., the completion of a third party transaction or a significant change in business model) valuation is changed accordingly. In addition, the Trust will typically base changes in valuation on actual transactions or on actual firm offers by

46

sophisticated independent investors unaffiliated with the Adviser. Legal or contractual restrictions on the sale of portfolio securities by the Trust will be considered in the valuation of such securities.

Other assets, which include cash, prepaid and accrued items, accounts receivable and income on investments and from the sale of portfolio securities, are carried in accordance with generally accepted accounting principles, as are all liabilities. Liabilities primarily include accrued expenses, sums owed for securities purchased and dividends payable.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

DIVIDENDS AND DISTRIBUTIONS

The Trust expects to distribute to Shareholders annually dividends of all or a portion of its investment company taxable income, if any. For federal income tax purposes, the Trust is required to distribute substantially all of its investment company taxable income for each year. Net capital gain (i.e., the excess of net long-term capital gain over net short-term capital loss), if any, may be distributed or may be retained at the discretion of the Board. "Investment company taxable income," as used herein, includes all interest and other ordinary income earned by the Trust on its portfolio holdings and net short-term capital gains in excess of net long-term capital losses, less the Trust's expenses. See "Taxation--Distributions."

Various factors will affect the level of the Trust's income, including the asset mix, the performance of the companies represented in the Trust's portfolio, and the Trust's use of hedging and fluctuations in the rate of exchange between foreign currencies and the U.S. dollar to the extent the Trust has invested in Foreign Securities. Notices will be provided in accordance with Section 19(a) of the Investment Company Act.

QUARTERLY DISTRIBUTION POLICY

In May 1999, the Trust's Board of Trustees adopted a managed distribution policy with respect to the Trust's Shares. Under the managed distribution policy, the Trust intends to make quarterly distributions to its Shareholders equal to 2.0% of the Trust's net asset value. The current distribution policy is to declare distributions in stock. Distributions will automatically be paid in newly-issued full Shares of the Trust plus cash in lieu of any fraction of a Share, unless otherwise instructed by the Shareholder. The Trust's transfer agent delivers an election card and instructions to each registered Shareholder in connection with each distribution. For shareholders other than registered shareholders with book entry accounts at the Trust's transfer agent, fractional shares will generally be settled in cash. The number of Shares issued will be determined by dividing the dollar amount of the distribution by the lower of net asset value or market value on the pricing date. If a Shareholder elects to receive a distribution in cash, rather than in Shares, the Shareholder's relative ownership in the Trust will be reduced. Distributions in stock will not relieve shareholders of any federal, state or local income taxes that may be payable on such distributions.

If, for any taxable year, the total distributions required for the Trust's distribution policy exceed the Trust's annual investment company taxable income and net long-term capital gains, the excess will generally be treated as a return of capital (up to the amount of the Shareholder's adjusted tax basis in his or her Shares). The amount treated as a tax-free return of capital will reduce a Shareholder's adjusted basis in his or her own Shares, thereby increasing his or her potential gain or reducing his or her potential loss on the sale of his or her Shares.

If the Trust's investment company taxable income and net long-term capital gains for any taxable year or calendar year exceed the amount required to be distributed under the distribution policy, the Trust will at a minimum make distributions necessary to permit it to qualify for treatment as a regulated investment company under the Code. The Trust has the discretion to retain for reinvestment net long-term capital gains in excess of net short-term capital losses, to the extent that it does not need to distribute these gains to meet its managed distribution obligation or tax requirements. Any retained

gains may be subject to taxation, although Shareholders may receive credit for

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

taxes paid by the Trust. It is anticipated that net realized capital gains in excess of the total distributed under this policy would be included in the December distribution.

This distribution policy may, under certain circumstances, have certain adverse consequences to the Trust and its Shareholders. To make such distributions, the Trust may have to sell a portion of its investment portfolio at a time when independent investment judgment might not dictate such action. The Trust's quarterly distribution policy may be changed by the Board of Trustees without Shareholder approval.

The Trust's most recent distribution of \$0.35 per Share was payable to Shareholders of record on June 9, 2006. That distribution was paid in Shares on June 30, 2006. For the 2005 calendar year, the Trust distributed a total of \$2.06 per Share. The first regular quarterly distribution to be paid on Shares acquired upon exercise of Rights will be the first quarterly distribution the record date for which occurs after the issuance of the Shares. The Shares issued in the Offer will not be entitled to the distribution to be declared to Shareholders of record on September 8, 2006 which is payable in September 2006.

DIVIDEND REINVESTMENT PLAN

Since the Fund's managed distribution policy was adopted in May 1999, the Fund's distributions have been made under the managed distribution policy rather than the Dividend Reinvestment Plan (the "Plan"). The Plan is currently inactive. Under the Plan each Shareholder holding Shares of the Trust would automatically be a participant in the Trust's Plan, unless the Shareholder elects not to participate in the Plan. Under the Plan, whenever the Trust declared a distribution of dividends and capital gains payable in Shares or cash, the distribution of dividends and capital gains was automatically reinvested by Computershare Shareholder Services, Inc. (the "Plan Agent"), in whole or fractional Shares of the Trust, as the case may be, for the accounts of the participating shareholders. Shareholders who specifically elected not to participate in the Plan received all distributions of dividends and capital gains in cash paid by check in U.S. dollars mailed directly to the shareholders (or if the Shares are held in street or other nominee name, then to the nominee) by the Dividend Disbursing Agent. Shareholders may receive more detailed information regarding the Plan from the Plan Agent.

The Plan Agent served as agent for the Shareholders in administering the Plan. Participants in the Plan would receive Shares valued on the valuation date, generally at the lower of market price or NAV, except as specified below. The valuation date will be the dividend or distribution payment date or a date determined by the Board of Trustees. Whenever the market price per Share is equal to or exceeds NAV on the valuation date, participants will be issued Shares at the greater of (i) NAV or (ii) 95% of the then-current market price of the Shares. If the NAV of the Shares on the valuation date exceeded the market price of the Shares at that time, participants will received Shares from the Trust valued at the market price. The market price of the Shares on a particular date was the last sales price on the NYSE on that date or, if no sale occurred on the NYSE on that date, then the mean between the closing bid and asked quotations for the Shares on the NYSE on such date; and NAV per Share on a particular date as determined by or on behalf of the Trust.

Experience under the Plan may indicate that changes are desirable. Accordingly, the terms and conditions of the Plan may be amended or supplemented by the Plan Agent or the Trust at any time or times but, except when necessary or appropriate to comply with applicable law or the rules or policies of the Commission or any other regulatory authority, only by mailing to the Shareholders appropriate written notice at least 90 days before the effective date of the change. All correspondence concerning the Plan should be directed to the Plan Agent, Computershare at P.O. Box 43010, Providence, RI 02940-3010

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Shareholders may also contact the Plan Agent toll-free by telephone at (800) 426-5523.

The current distribution policy is to declare distributions in stock. Stock distributions will automatically be paid in newly-issued full Shares of the Trust plus cash in lieu of any fraction of a

48

Share, unless otherwise instructed by the Shareholder. If a Shareholder elects to receive a distribution in cash, rather than in Shares, the Shareholder's relative ownership in the Trust will be reduced.

TAXATION

The following discussion is based upon the advice of Dechert LLP, counsel for the Trust, and is a general summary of the principal U.S. federal income tax considerations regarding an investment in the Trust. The discussion is based on laws, regulations, rulings and decisions currently in effect, all of which are subject to change (possibly with retroactive effect) or different interpretations. The discussion below does not purport to deal with all of the federal income tax consequences applicable to the Trust, or to all categories of investors, some of which may be subject to special rules. Each prospective shareholder is urged to consult with his or her own tax adviser with respect to the specific federal, state, local, foreign and other tax consequences of investing in Shares of the Trust.

TAXATION OF THE TRUST

The Trust intends to qualify and has elected to be treated each taxable year as a regulated investment company ("RIC") under the Code. The principal federal income tax benefits of qualifying as a RIC, as compared to an ordinary taxable corporation, are that a RIC generally is not itself subject to federal income tax on ordinary investment income and net capital gains that are currently distributed to its shareholders, and that the character of long-term capital gains which are recognized and properly designated by a RIC flows through to its shareholders, who receive (or are deemed to receive) distributions of such income. However, the Trust would be subject to corporate income tax (currently at a maximum marginal rate of 35%) on any undistributed income.

DISTRIBUTIONS

Distributions of the excess, if any, of net long-term capital gains over net short-term capital losses designated by the Trust as capital gain dividends will be taxable to shareholders as long-term capital gains, whether paid in cash or reinvested in the Trust's Shares, regardless of how long the shareholders have held the Trust's Shares, and will not be eligible for the dividends received deduction for corporations.

Dividends paid from investment company taxable income generally, if any, will be taxable to shareholders generally as ordinary income whether paid in cash or reinvested in the Trust's Shares. The Trust intends to distribute to its shareholders substantially all of its investment company taxable income (including distributions of net short-term capital gains), if any, for each year. It is anticipated that the Trust's income distributions will be paid annually in additional Shares unless the shareholder elects payment in cash.

A portion of the dividends paid by the Trust may be treated as "qualified dividend income" which is taxable to individuals at the same rates that are applicable to long-term capital gains. A Trust distribution is treated as qualified dividend income to the extent that the Trust receives dividend income from taxable domestic corporations and certain qualified foreign corporations,

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

provided that certain holding period and other requirements are met by both the Trust and the Shareholder. Trust distributions generally will not qualify as qualified dividend income to the extent attributable to interest, capital gains, REIT distributions and distributions from certain non-U.S. corporations. The lower rates on qualified dividends and capital gains are scheduled to expire after 2008 in the absence of further legislation enacted by Congress.

If a portion of the Trust's income consists of dividends paid by U.S. corporations, a portion of the dividends paid by the Trust may be eligible for the corporate dividends-received deduction provided that certain holding period and other requirements are met by both the Trust and the corporate Shareholder.

49

Each year, Shareholders will be notified as to the amount and federal tax status of all dividends and capital gains paid during the prior year. Such dividends and capital gains may also be subject to state or local taxes. Dividends declared in October, November, or December with a record date in such month and paid during the following January will be treated as having been paid by the Trust and received by Shareholders on December 31 of the calendar year in which declared, rather than the calendar year in which the dividends are actually received.

Gain or loss realized upon the sale or exchange of Shares will be a capital gain or loss if the Shares are capital assets in the Shareholder's hands and generally will be long-term or short-term, depending upon the Shareholder's holding period for the Shares. You should be aware that any loss realized upon the sale or exchange of Shares held for six months or less will be treated as a long-term capital loss to the extent of any distributions or deemed distributions of long-term capital gain to the Shareholder with respect to such Shares. In addition, any loss realized on a sale or exchange of Shares will be disallowed to the extent the Shares disposed of are replaced within a period of 61 days beginning 30 days before and ending 30 days after the Shares are disposed of, such as pursuant to the Plan. In such case, the basis of Shares acquired will be adjusted to reflect the disallowed loss.

If a Shareholder has not furnished a certified correct taxpayer identification number (generally a Social Security number) and has not certified that withholding does not apply, or if the Internal Revenue Service has notified the Trust that the taxpayer identification number listed on the account is incorrect according to their records or that the Shareholder is subject to backup withholding, federal law generally requires the Trust to withhold 28% from any dividends and/or redemptions (including exchange redemptions). Amounts withheld are applied to federal tax liability; a refund may be obtained from the Service if withholding results in overpayment of taxes. Federal law also requires the Trust to withhold up to 30% or the applicable tax treaty rate from ordinary dividends paid to certain nonresident alien and other non-U.S. shareholder accounts.

This is a brief summary of some of the tax laws that affect an investment in the Trust. Moreover, the foregoing does not address the many factors that may determine whether an investor will be liable for the federal alternative minimum tax. Please see the SAI and a tax adviser for further information.

CUSTODIAN, ADMINISTRATOR, TRANSFER AGENT, DIVIDEND
DISBURSING AGENT, REGISTRAR, AND SUBSCRIPTION AGENT

The Trust's securities and cash are held under a custodian contract by State Street Bank and Trust Company (the "Custodian"), whose principal business address is 225 Franklin Street, Boston, MA 02110. The Custodian also performs certain accounting related functions for the Trust, including calculation of NAV and net income.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

State Street Bank and Trust Company (the "Administrator") also serves as administrator to the Trust pursuant to an Administration Agreement. Under the Administration Agreement the Trust's assets are combined with assets of HQH. The combined assets are charged fee computed and payable monthly at an annual rate of (i).034% of the first \$150 million; (ii) .024% of the next \$150 million; and (iii) .014% on assets in excess of \$300 million, subject to annual minimum fee of \$77,500. The Administrative Agreement covers administrative costs including out-of-pocket expenses incurred in the ordinary course of providing services under the Administration Agreement.

Computershare Shareholder Services, Inc. serves as Dividend Disbursing Agent. Computershare Shareholder Services, Inc, a fully owned subsidiary of Computershare Trust Company, N.A., serves as (1) the Plan Agent for the Trust's Dividend Reinvestment Plan, (2) the Transfer Agent and Registrar for Shares of the Trust and (3) the Subscription Agent in connection with the Offer. Computershare Shareholder Services, Inc. has its principal business at 250 Royal Street, Canton, MA 02021.

50

LEGAL MATTERS

The validity of the Shares offered hereby will be passed on for the Trust by Dechert LLP, 200 Clarendon Street, 27th Floor, Boston, Massachusetts 02116-5021.

EXPERTS

The audited financial statements of the Trust included in this prospectus have been audited by Deloitte & Touche LLP, independent registered public accounting firm, whose report dated November 18, 2005 expresses an unqualified opinion. The financial highlights for the years ended September 30, 2003, 2002 and 2001 were audited by PricewaterhouseCoopers LLP, whose report dated November 25, 2003 expresses an unqualified opinion. These highlights are included in reliance upon such reports and upon the authority of such firms as experts in accounting and auditing. Certain information appearing under the caption "Financial Highlights" for the fiscal years ended September 30, 2000, 1999, 1998, 1997 and 1996 were audited by Arthur Andersen LLP. Arthur Andersen LLP ceased operations in 2002.

REPORTS TO SHAREHOLDERS

The Trust will send unaudited semiannual reports and audited annual reports, including a list of investments held, to shareholders. The Trust has in the past also issued more abbreviated interim reports to Shareholders on a quarterly basis.

ADDITIONAL INFORMATION

The Trust is subject to the informational requirements of the Securities Exchange Act of 1934, as amended, and the Investment Company Act and in accordance therewith is required to file reports, proxy statements and other information with the Commission. Any such reports, proxy statements and other information filed by the Trust can be inspected and copied (at prescribed rates) at the public reference facilities of the Commission, 100 F Street, NE, Washington, DC 20549. The Trust's Shares are listed on the NYSE. Reports, proxy statements and other information concerning the Trust can also be inspected and copied at the Library of the NYSE, 20 Broad Street, New York, NY 10005.

This Prospectus constitutes a part of a registration statement on Form N-2 (together with the SAI and all the exhibits and appendices thereto, the "Registration Statement") filed by the Trust with the Commission under the

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Securities Act and the Investment Company Act. This Prospectus and the SAI do not contain all of the information set forth in the Registration Statement. Reference is hereby made to the Registration Statement and related exhibits for further information with respect to the Trust and the Shares offered hereby. Statements contained herein concerning the provisions of documents are necessarily summaries of such documents, and each statement is qualified in its entirety by reference to the copy of the applicable document filed with the Commission.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this Prospectus constitute forward-looking statements, which involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Trust to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, those listed under "Risks" and elsewhere in this Prospectus. As a result of the foregoing and other factors, no assurance can be given as to the future results, levels of activity or achievements, and neither the Trust nor any other person assumes responsibility for the accuracy and completeness of such statements. To the extent required by law, the Trust undertakes to supplement this Prospectus to reflect any material changes to the Trust after the date of this Prospectus.

51

TABLE OF CONTENTS OF STATEMENT OF ADDITIONAL INFORMATION

Additional Information About Investments, Investment Techniques and Risks.....	2
Investment Restrictions.....	10
Trustees and Officers.....	11
Compensation Table for the Fiscal Year Ended September 30, 2005.....	18
The Trust.....	19
Investment Adviser and Investment Advisory Agreement.....	21
Proxy Voting Policies and Procedures.....	25
Code of Ethics.....	25
Net Asset Value.....	26
Portfolio Transactions and Brokerage.....	27
Quarterly Distribution Policy.....	30
Tax Matters.....	31
Administration, Custodian and Transfer Agent, Dividend Disbursing Agent and Registrar.....	36
Financial Statements.....	37
Appendix A--Trustee and Investment Adviser Proxy Voting Policies and Procedures.....	38

52

FINANCIAL STATEMENTS

H&Q LIFE SCIENCES INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2006

(UNAUDITED)

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

SHARES

VALUE

CONVERTIBLE SECURITIES--16.1% OF NET ASSETS

CONVERTIBLE PREFERRED (RESTRICTED)--15.1%

DRUG DISCOVERY TECHNOLOGIES--1.7%

1,587,302	Agilix Corporation Series B(a) (b)	\$ 380,952
250,000	Ceres, Inc. Series C(a)	1,500,000
21,462	Ceres, Inc. Series C-1(a)	128,772
175,540	Ceres, Inc. Series D(a)	1,053,240
455,203	Cougar Biotechnology Inc. Series A(a)	787,501
932,488	Galileo Pharmaceuticals, Inc. Series F-1(a)	93
200,000	Zyomyx, Inc. Series A New(a)	20,000
200	Zyomyx, Inc. Series B New(a)	20

EMERGING BIOPHARMACEUTICALS--4.6%

744,921	Agensys, Inc. Series C(a)	2,200,201
1,724,138	Corus Pharma, Inc. Series C(a)	1,000,000
1,212,121	Raven biotechnologies, Inc. Series B(a)	1,006,060
1,872,772	Raven biotechnologies, Inc. Series C(a)	1,554,401
2,722,014	Raven biotechnologies, Inc. Series D(a)	800,000
1,415,385	TargeGen, Inc. Series C(a)	1,840,001
30,920	Therion Biologics Corporation Series A(a)	37,722
160,000	Therion Biologics Corporation Series B(a)	195,200
271,808	Therion Biologics Corporation Series C(a) (c)	331,606
22,224	Therion Biologics Corporation Series C-2(a) (c)	27,113
28,991	Therion Biologics Corporation Sinking Fund(a)	290
1,645,000	Xanthus Life Sciences, Inc. Series B(a)	1,645,000

HEALTHCARE SERVICES--3.3%

1,051,429	CardioNet, Inc. Series C(a)	3,680,001
322,168	CytoLogix Corporation Series A(a) (b)	265,789
151,420	CytoLogix Corporation Series B(a) (b) (c)	124,922
3,589,744	PHT Corporation Series D(a) (b)	2,800,000
802,996	PHT Corporation Series E(a) (b)	626,337

MEDICAL DEVICES AND DIAGNOSTICS--5.5%

3,235,293	Concentric Medical, Inc. Series B(a) (b)	4,529,410
1,162,790	Concentric Medical, Inc. Series C(a) (b)	1,627,906
455,333	Concentric Medical, Inc. Series D(a) (b)	637,466
177,778	EPR, Inc. Series A(a)	1,778
2,446,016	Labcyte, Inc. Series C(a)	1,280,000
130,000	Masimo Corporation Series D	1,430,000

The accompanying notes are an integral part of these financial statements.

FINANCIAL STATEMENTS (CONTINUED)

H&Q LIFE SCIENCES INVESTORS

SCHEDULE OF INVESTMENTS

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

MARCH 31, 2006

(UNAUDITED)

SHARES -----		VALUE -----
1,088,436	OmniSonics Medical Technologies, Inc. Series B(a).....	\$ 1,454,151
1,031,992	OmniSonics Medical Technologies, Inc. Series C(a).....	1,200,000
43,478	TherOx, Inc. Series H(a).....	165,217
99,646	TherOx, Inc. Series I(a) (c).....	384,733

		\$34,715,882

PRINCIPAL AMOUNT -----		
	CONVERTIBLE NOTES (RESTRICTED)--1.0%	
	DRUG DISCOVERY TECHNOLOGIES--0.9%	
\$2,000,000	Matritech Inc., 15.00% due 2009(c).....	\$ 2,000,000
	HEALTHCARE SERVICES--0.1%	
200,000	CardioNet, Inc. Cvt. Note, 8.00% due 2006(c).....	200,000
112,224	CytoLogix Corporation Cvt. Note, 6.75% (b) (d).....	112,224

		\$ 2,312,224

	TOTAL CONVERTIBLE SECURITIES (COST \$44,781,381).....	\$37,028,106

SHARES -----		
	COMMON STOCKS--80.5%	
	BIOPHARMACEUTICALS--25.5%	
311,111	Akorn, Inc. (Restricted) (a) (c).....	\$ 1,285,200
201,250	Alexza Pharmaceuticals, Inc.(a).....	1,962,180
52,500	Amgen, Inc.(a).....	3,819,370
468,500	Bioenvision, Inc.(a).....	3,340,400
534,805	Critical Therapeutics, Inc.(a).....	2,722,150
282,253	Cubist Pharmaceuticals, Inc.(a).....	6,483,350
28,200	Curis, Inc.(a).....	67,110
269,341	Encysive Pharmaceuticals Inc.(a).....	1,317,070
26,500	Genentech, Inc.(a).....	2,239,510
95,107	Genzyme Corporation(a).....	6,393,090

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

140,675	Gilead Sciences, Inc.(a).....	8,752,79
217,825	Idenix Pharmaceuticals Inc.(a).....	2,955,88
132,797	Inhibitex Inc.(a).....	964,10
400,950	Insmmed Inc.(a).....	781,85
540,559	Inspire Pharmaceuticals, Inc.(a).....	2,827,12
93,810	MedImmune, Inc.(a).....	3,431,57

The accompanying notes are an integral part of these financial statements.

54

FINANCIAL STATEMENTS (CONTINUED)

H&Q LIFE SCIENCES INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2006

(UNAUDITED)

SHARES		VALUE
-----		-----
94,540	Myriad Genetics Inc.(a).....	\$ 2,466,54
670,000	Point Therapeutics, Inc.(a).....	2,318,20
378,480	SGX Pharmaceuticals, Inc.(a).....	3,603,13
263,751	Vivus, Inc.(a).....	878,29

		58,608,98

	DRUG DELIVERY--2.9%	
526,855	DepoMed, Inc.(a).....	3,440,36
141,710	Noven Pharmaceuticals, Inc.(a).....	2,552,19
29,594	Penwest Pharmaceuticals Co.(a).....	641,89

		6,634,45

	DRUG DISCOVERY TECHNOLOGIES--5.5%	
46,560	Avalon Pharmaceuticals, Inc.(a).....	235,12
138,288	Avalon Pharmaceuticals, Inc. (Restricted)(a).....	663,43
50,578	Cougar Biotechnology Inc. (Restricted)(a).....	87,50
436,232	deCODE Genetics, Inc.(a).....	3,782,13
531,700	Pharmacoepia Drug Discovery, Inc.(a).....	3,152,98
120,737	Senomyx, Inc.(a).....	1,987,33
128,050	ZymoGenetics, Inc.(a).....	2,768,44
200,000	Zyomyx, Inc. (Restricted)(a).....	2,00

		12,678,94

	EMERGING BIOPHARMACEUTICALS--22.2%	
213,170	ACADIA Pharmaceuticals, Inc.(a).....	3,406,45
427,604	Ariad Pharmaceuticals, Inc.(a).....	2,813,63
243,828	Barrier Therapeutics, Inc.(a).....	2,360,25

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

368,929	Cytokinetics, Inc.(a).....	2,689,49
45,570	DOV Pharmaceutical, Inc.(a).....	728,20
588,800	Epix Pharmaceuticals, Inc.(a).....	2,060,80
319,380	Exelixis, Inc.(a).....	3,835,75
456,549	Kosan Biosciences, Inc.(a).....	2,689,07
970,000	Lexicon Genetics, Inc.(a).....	5,373,80
31,059	Momenta Pharmaceuticals, Inc.(a).....	610,62
41,707	Myogen, Inc.(a).....	1,511,04
51,080	Myogen, Inc. warrants(a).....	1,452,20
322,410	Neurogen Corporation(a).....	1,995,71
158,337	Nitromed, Inc.(a).....	1,330,03
153,300	Rigel Pharmaceuticals, Inc.(a).....	1,761,41
595,700	Sangamo BioSciences, Inc.(a).....	3,544,41

The accompanying notes are an integral part of these financial statements.

55

FINANCIAL STATEMENTS (CONTINUED)

H&Q LIFE SCIENCES INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2006

(UNAUDITED)

SHARES		VALUE
-----		-----
455,320	Seattle Genetics, Inc.(a).....	2,349,45
296,924	Sirna Therapeutics, Inc.(a).....	\$ 2,001,26
28,604	Telik, Inc.(a).....	553,77
375,384	Tercica, Inc.(a).....	2,515,07
194,916	Theravance, Inc.(a).....	5,465,44
146,982	Therion Biologics Corporation (Restricted)(a).....	1,47

		51,049,40

	GENERIC PHARMACEUTICALS--5.0%	
305,100	Caraco Pharmaceutical Laboratories, Ltd.(a).....	3,966,30
429,582	Impax Laboratories, Inc.(a).....	4,291,52
76,608	Teva Pharmaceutical Industries, Ltd. ADR.....	3,154,71

		11,412,54

	HEALTHCARE SERVICES--3.7%	
148,148	Aveta, Inc. (Restricted)(a).....	1,999,99
17,416	DakoCytomation, Inc. (Restricted)(e).....	181,30
204,805	Emageon, Inc.(a).....	3,479,63
106,500	National Medical Health Card Systems, Inc.(a).....	2,982,00
204,139	Syntiro Healthcare Services (Restricted)(a).....	20

		8,643,14

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

MEDICAL DEVICES AND DIAGNOSTICS--15.7%		
99,720	Adeza Biomedical Corporation (a).....	2,107,08
87,850	Affymetrix, Inc. (a).....	2,892,90
458,850	Align Technology, Inc. (a).....	4,207,65
298,577	Conor Medsystems, Inc. (a).....	8,778,16
58,800	Conor Medsystems, Inc. (Restricted) (a).....	1,642,28
57,920	IDEXX Laboratories, Inc. (a).....	5,001,97
130,000	Masimo Corporation (Restricted).....	1,30
447,080	Medwave, Inc. (Restricted) (a) (c).....	1,448,53
195,217	Orchid Cellmark, Inc. (a).....	1,120,54
784,900	Orthovita, Inc. (a).....	3,249,48
139,019	Songbird Hearing, Inc. (Restricted) (a).....	1,39
927,713	Third Wave Technologies, Inc. (a).....	2,903,74
382,583	VNUS Medical Technologies, Inc. (a).....	2,903,80

		36,258,86

	TOTAL COMMON STOCKS	
	(COST \$145,340,739).....	\$185,286,33
		=====

The accompanying notes are an integral part of these financial statements.

56

FINANCIAL STATEMENTS (CONTINUED)

H&Q LIFE SCIENCES INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2006

(UNAUDITED)

PRINCIPAL AMOUNT -----		VALUE -----
	REPURCHASE AGREEMENT--0.1%	
\$ 128,000	State Street Bank and Trust Co. (collateralized by U.S. Treasury Bond 4.25%, 8/15/15, market value \$133,854); 1.40% due 04/03/06 (Cost \$128,000).....	\$ 128,000
	SHORT-TERM INVESTMENT--3.9%	
9,000,000	General Electric Capital Corp.; 4.63% due 04/03/06 (Cost \$8,997,685).....	8,997,68
	TOTAL INVESTMENTS--100.6%	
	(COST \$199,247,805).....	\$231,440,12
	OTHER LIABILITIES IN EXCESS OF ASSETS--(0.6%).....	(1,350,07
	NET ASSETS--100%.....	\$230,090,05
		=====

-
- (a) Non-income producing security.
 - (b) Affiliated issuers in which the Fund holds 5% or more of the voting securities (Total Market Value of \$11,105,006).
 - (c) Including associated warrants.
 - (d) Variable maturity.
 - (e) Foreign Security.

ADR American Depositary Receipt.

The accompanying notes are an integral part of these financial statements.

57

H&Q LIFE SCIENCES INVESTORS
STATEMENT OF ASSETS AND LIABILITIES

March 31, 2006

(UNAUDITED)

ASSETS:

Investments in non affiliated issuers, at value (identified cost \$188,252,243; see Schedule of Investments).....	\$220,335,121
Investments in affiliated issuers, at value (identified cost \$10,995,562; see Schedule of Investments).....	11,105,006
Cash.....	973
Interest receivable.....	102,764
Receivable for investments sold.....	548,396
Prepaid expenses.....	37,208

Total assets.....	\$232,129,468

LIABILITIES:

Payable for investments purchased.....	\$ 1,653,882
Accrued advisory fee.....	240,181
Accrued audit fee.....	44,680
Accrued administration fee.....	5,200
Accrued legal fees.....	8,035
Accrued shareholder reporting fees.....	60,373
Accrued other.....	27,064

Total liabilities.....	\$ 2,039,415

NET ASSETS.....	\$230,090,053
	=====

SOURCES OF NET ASSETS:

Shares of beneficial interest, par value \$.01 per share, unlimited number of shares authorized, amount paid in on 13,262,472 shares issued and outstanding.....	\$187,923,589
Accumulated net investment income.....	75,059
Accumulated net realized gain on investments.....	9,899,085
Net unrealized gain on investments.....	32,192,320

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Total net assets (equivalent to \$17.35 per share based on 13,262,472 shares outstanding)	\$230,090,053 =====
--	------------------------

The accompanying notes are an integral part of these financial statements.

58

H&Q LIFE SCIENCES INVESTORS

STATEMENT OF OPERATIONS

For the Six Months Ended March 31, 2006

(UNAUDITED)

INVESTMENT INCOME:	
Dividend income (net of foreign tax of \$1,678)	\$ 8,260
Special dividend	1,312,446
Interest income from non affiliated issuers	553,391
Interest income from affiliated issuers	3,788

Total investment income	\$ 1,877,885 -----
EXPENSES:	
Advisory fees	\$ 1,387,445
Trustees' fees and expenses	83,887
Accounting, administration and auditing fees	76,311
Shareholder reporting	51,688
Legal fees	47,320
Custodian fees	41,314
Transfer agent fees	27,300
Stock exchange listing fee	13,177
Other (see note (3))	74,370

Total expenses	1,802,812 -----
Net investment income	\$ 75,073 -----
NET REALIZED AND UNREALIZED GAIN (LOSS) ON INVESTMENTS:	
Net realized gain on investments	\$14,303,339
Decrease in net unrealized gain on investments	(6,035,540)

Net realized and unrealized gain on investments	\$ 8,267,799 -----
Net increase in net assets resulting from operations	\$ 8,342,872 =====

The accompanying notes are an integral part of these financial statements.

59

H&Q LIFE SCIENCES INVESTORS

STATEMENTS OF CHANGES IN NET ASSETS

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

	FOR THE SIX MONTHS ENDED MARCH 31, 2006	FOR THE YEAR ENDED SEPTEMBER 30, 2005
	----- (UNAUDITED)	-----
NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS:		
Net investment income (loss).....	\$ 75,073	\$ (2,587,561)
Net realized gain on investments.....	14,303,339	26,035,268
Decrease/increase in net unrealized gain on investments...	(6,035,540)	21,315,662
	-----	-----
Net increase in net assets resulting from operations....	\$ 8,342,872	\$ 44,763,369
	-----	-----
DISTRIBUTIONS TO SHAREHOLDERS FROM:		
Net realized capital gains.....	\$ (17,939,117)	\$ (15,828,633)
	-----	-----
CAPITAL SHARE TRANSACTIONS:		
Value of shares issued in reinvestment of distributions (657,268 and 538,795 shares, respectively).....	\$ 10,394,972	\$ 8,518,606
	-----	-----
Net increase in net assets.....	\$ 798,727	\$ 37,453,342
NET ASSETS:		
Beginning of period.....	229,291,326	191,837,984
	-----	-----
End of period.....	\$230,090,053	\$229,291,326
	=====	=====
ACCUMULATED NET INVESTMENT INCOME INCLUDED IN NET ASSETS AT END OF THE PERIOD.....		
	\$ 75,059	\$ (14)

The accompanying notes are an integral part of these financial statements.

60

H&Q LIFE SCIENCES INVESTORS

STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED MARCH 31, 2006

(UNAUDITED)

CASH FLOWS PROVIDED FROM OPERATING ACTIVITIES:	
Purchases of portfolio securities.....	\$ (58,577,431)
Net maturities of short-term investments.....	6,600,807
Sales of portfolio securities.....	59,998,463
Interest income received.....	13,868
Dividends received.....	1,320,706
Operating expenses paid.....	(1,832,590)

Net cash provided from operating activities.....	\$ 7,523,823

CASH FLOWS USED FOR FINANCING ACTIVITIES:	
Cash distributions paid, net.....	\$ (7,544,145)

Net cash used in financing activities.....	\$ (7,544,145)

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

NET DECREASE IN CASH.....	\$	(20,322)
CASH AT BEGINNING OF PERIOD.....		21,295

CASH AT END OF PERIOD.....	\$	973
		=====
RECONCILIATION OF NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS TO NET CASH PROVIDED FROM OPERATING ACTIVITIES:		
Net increase in net assets resulting from operations.....	\$	8,342,872
Purchases of portfolio securities.....		(58,577,431)
Net maturities of short-term investments.....		6,600,807
Sales of portfolio securities.....		59,998,463
Accretion of discount.....		(476,255)
Net realized gain on investments.....		(14,303,339)
Decrease in net unrealized gain on investments.....		6,035,540
Increase in dividends and interest receivable.....		(67,056)
Decrease in accrued expenses.....		(41,947)
Decrease in prepaid expenses.....		12,169

Net cash provided from operating activities.....	\$	7,523,823
		=====

Noncash financing activities not included herein consist of reinvested distributions of \$10,394,972.

Noncash operating activities not included herein consist of one conversion of restricted preferred stock with a cost of \$2,005,767 to restricted common stock of the same issuer.

The accompanying notes are an integral part of these financial statements.

61

H&Q LIFE SCIENCES INVESTORS

FINANCIAL HIGHLIGHTS

(SELECTED DATA FOR EACH SHARE OF BENEFICIAL INTEREST OUTSTANDING THROUGHOUT THE PERIOD INDICATED)

	FOR THE SIX MONTHS ENDED MARCH 31, 2006	FOR THE YEAR ENDED SEPTEMBER 30,		
	(UNAUDITED)	2005	2004	2003
Net asset value per share:				
Beginning of period.....	\$ 18.19	\$ 15.90	\$ 16.68	\$ 15.14
Net investment income (loss) (2).....	\$ 0.01 (3)	\$ (0.21)	\$ (0.26)	\$ (0.21)
Net realized and unrealized gain (loss) on investments.....	0.56	3.79	0.86	3.55
Total increase (decrease) from investment				

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

operations.....	\$ 0.57	\$ 3.58	\$ 0.60	\$ 3.34
Capital gains distributions to shareholders.....	\$ (1.41)	\$ (1.29)	\$ (1.38)	\$ (1.80)
Net asset value per share: End of period.....	\$ 17.35	\$ 18.19	\$ 15.90	\$ 16.68
Per share market value: End of period.....	\$ 17.11	\$ 16.85	\$ 16.20	\$ 15.28
Total investment return at market value.....	10.73%	12.77%	15.52%	47.65%
RATIOS AND SUPPLEMENTAL DATA:				
Net assets at end of period.....	\$230,090,053	\$229,291,326	\$191,837,984	\$190,352,471
Ratio of operating expenses to average net assets....	1.67%*	1.74%	1.73%	1.74%
Ratio of net investment income/ (loss) to average net assets.....	0.07%*(3)	(1.29)%	(1.56)%	(1.38)%
Portfolio turnover rate.....	27.97%	73.79%	34.93%	32.36%
Number of shares outstanding at end of period.....	13,262,472	12,605,204	12,066,409	11,412,475

(1) In 2002, the Fund adopted the provisions of the AICPA Audit and Accounting Guide for Investment Companies and began accreting discounts and amortizing premiums on all debt securities. The effect of this change for the year ended September 30, 2002 was a decrease in net investment loss per share of \$.006, an increase in net realized and unrealized loss on investments per share of \$.006, and a decrease in the ratio of net investment loss to average net assets from (1.28%) to (1.25%). Per share data and ratios for the periods prior to October 1, 2001 have not been restated to reflect this change in presentation.

(2) Net investment income/(loss) per share has been computed using average shares outstanding.

(3) Includes a special dividend from an issuer in the amount of \$0.10 per share. Excluding the special dividend, the ratio of net investment income/(loss) to average net assets would have been (1.14%) annualized.

* Annualized.

The accompanying notes are an integral part of these financial statements.

62

H&Q LIFE SCIENCES INVESTORS

NOTES TO FINANCIAL STATEMENTS

March 31, 2006

(UNAUDITED)

(1) ORGANIZATION

H&Q Life Sciences Investors (the Fund) is a Massachusetts business trust

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

registered under the Investment Company Act of 1940 as a diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in securities of companies in the healthcare industries. The Fund invests primarily in securities of public and private companies that are believed to have significant potential for above-average growth. The Fund was organized on February 20, 1992 and commenced operations on May 8, 1992.

The preparation of these financial statements requires the use of certain estimates by management in determining the Fund's assets, liabilities, revenues and expenses. Actual results could differ from these estimates. The following is a summary of significant accounting policies consistently followed by the Fund, which are in conformity with accounting principles generally accepted in the United States of America.

INVESTMENT SECURITIES & INVESTMENT INCOME

Investments traded on national securities exchanges or in the over-the-counter market that are National Market System securities are valued at the last sale price or, lacking any sales, at the mean between the last bid and asked prices. Other over-the-counter securities are valued at the most recent bid prices as obtained from one or more dealers that make markets in the securities. Exchange traded investments for which market quotations are not readily available is valued at fair value as determined in good faith by the Trustees of the Fund. The value of venture capital and other restricted securities is determined in good faith by the Trustees. However, because of the uncertainty of venture capital and other restricted security valuations, these estimated values may differ significantly from the values that would have been used had a ready market for these securities existed, and the differences could be material. See note 4 below. Short-term investments with maturity of 60 days or less are valued at amortized cost.

Investment transactions are recorded on a trade date basis. Gains and losses from sales of investments are recorded using the "identified cost" method. Interest income is recorded on the accrual basis, adjusted for amortization of premiums and accretion of discounts. Dividend income is recorded on the ex-dividend date.

REPURCHASE AGREEMENTS

In managing short-term investments the Fund may from time to time enter into transactions in repurchase agreements. In a repurchase agreement, the Fund's custodian takes possession of the underlying collateral securities, the market value of which is at least equal to the principal, including accrued interest, of the repurchase transaction at all times. In the event of default or bankruptcy by the other party to the agreement, realization and/or retention of the collateral by the Fund may be delayed or limited.

FEDERAL INCOME TAXES

It is the Fund's policy to comply with the requirements of the Internal Revenue Code applicable to regulated investment companies and to distribute to its shareholders substantially all of its taxable

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

(UNAUDITED)

income and its net realized capital gains, if any. Therefore, no Federal income or excise tax provision is required.

DISTRIBUTIONS

The Fund records all distributions to shareholders from net investment income, if any, and realized gains on the ex-dividend date. Such distributions are determined in conformity with income tax regulations. Due to permanent book/tax differences in accounting for certain transactions, certain distributions may be treated as distributions from capital as opposed to distributions of net investment income or realized capital gains.

DISTRIBUTION POLICY

Distributions will automatically be paid in newly issued shares of the Fund unless otherwise instructed by the shareholder. Pursuant to an SEC exemptive order, the Fund has implemented a fixed distribution policy that permits the Fund to make quarterly distributions at a rate of 2% of the Fund's net assets to shareholders of record. The Fund intends to use net realized capital gains when making quarterly distributions. This could result in a return of capital to shareholders if the amount of the distribution exceeds the Fund's net investment income and realized capital gains. It is anticipated that net realized capital gains in excess of the total distributed under this policy would be included in the December distribution.

STATEMENT OF CASH FLOWS

The cash amount shown in the Statement of Cash Flows is the amount included in the Fund's Statement of Assets and Liabilities and represents cash on hand at its custodian and does not include short-term investments at March 31, 2006.

INDEMNIFICATIONS

Under the Fund's organizational documents, its officers and Trustees may be indemnified against certain liabilities and expenses arising out of the performance of their duties to the Fund. Additionally, in the normal course of business, the Fund enters into agreements with service providers that may contain indemnification clauses. The Fund's maximum exposure under these agreements is unknown as this would involve future claims that may be made against the fund that have not yet occurred. However, based on experience, the Fund expects the risk of loss to be remote.

(2) SECURITIES TRANSACTIONS

The aggregate cost of purchases and proceeds from sales of investment securities (other than short-term investments) for the six months ended March 31, 2006 totaled \$59,673,874 and \$57,818,230 respectively.

At March 31, 2006, the total cost of securities for Federal income tax purposes was \$199,247,805. The net unrealized gain for Federal income tax purposes on securities held by the Fund was \$32,192,320 including gross unrealized gain of \$61,780,901 and gross unrealized loss of \$29,588,581.

64

H&Q LIFE SCIENCES INVESTORS

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

March 31, 2006

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

(UNAUDITED)

(3) INVESTMENT ADVISORY FEES AND OTHER TRANSACTIONS WITH AFFILIATES

The Fund has entered into an Investment Advisory Agreement (the Advisory Agreement) with Hambrecht & Quist Capital Management, LLC (the Adviser). Pursuant to the terms of the Advisory Agreement, the Fund pays the Adviser a monthly fee at the rate when annualized of (i) 2.5% of the average net assets for the month of its venture capital and other restricted securities up to 25% of net assets and (ii) for the month, for all other assets, 1.0% of the average net assets up to \$250 million, 0.9% of the average net assets for the next \$250 million, 0.8% of the average net assets for the next \$500 million and 0.7% of the average net assets thereafter. The aggregate fee may not exceed a rate when annualized of 1.375%. Beginning July 1, 2006 the Fund will pay a monthly rate when annualized of (i) 2.5% of the average net assets for the month of its venture capital and other restricted securities up to 25% of net assets and (ii) for the month, for all other assets, 0.98% of the average net assets up to \$250 million, 0.88% of the average net assets for the next \$250 million, 0.80% of the average net assets for the next \$500 million and 0.70% of the average net assets thereafter. The aggregate fee may not exceed a rate when annualized of 1.375%

As of February 2005, Daniel R. Omstead, Ph.D, Christopher F. Brinzey, M.B.A., Frank T. Gentile, Ph.D. and Jason C. Akus, M.D./M.B.A. are members of the team that makes investments on behalf of the Fund. These members also perform other duties, including making investment decisions on behalf of another closed-end investment Company, H&Q Healthcare Investors, which invests in the healthcare industries.

The Fund has entered into a Services Agreement (the "Agreement") with the Adviser. Pursuant to the terms of the Agreement, the Fund reimburses the Adviser for certain services related to a portion of the payment of salary and provision of benefits to the Fund's Chief Compliance Officer. During the six months ended March 31, 2006 these payments amounted to \$29,694 and are included in the "other" category in the Statement of Operations, together with insurance expenses of \$26,464 incurred to unaffiliated entities. Such expenses are the major components of "other" in the Statement of Operations. Expenses incurred pursuant to the Agreement as well as certain expenses paid for by the Adviser are allocated in an equitable fashion to the Fund.

Certain officers and Trustees of the Fund are also officers of the Adviser. Trustees who are not affiliates of the Adviser receive an annual fee of \$20,000 plus \$500 for each Committee on which they serve and \$500 for each meeting attended.

An affiliate company is a company in which the Fund holds 5% or more of the voting securities. Transactions with such companies, all of which are venture capital companies, during the six months ended March 31, 2006 were as follows:

ISSUER	VALUE ON OCTOBER 1, 2005	PURCHASES	SALES	INCOME	VALU MARCH 31
-----	-----	-----	-----	-----	-----
Agilix Corporation.....	\$ 380,952	\$ --	\$ --	\$ --	\$ 3
Concentric Medical, Inc.....	6,794,782	--	--	--	6,7
CytoLogix Corporation.....	502,935	--	--	3,788	5
PHT Corporation.....	3,426,337	--	--	--	3,4
	-----	-----	-----	-----	-----
	\$11,105,006	\$ 0	\$ 0	\$3,788	\$11,1

H&Q LIFE SCIENCES INVESTORS

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

March 31, 2006

(UNAUDITED)

(4) VENTURE CAPITAL AND OTHER RESTRICTED SECURITIES

The Fund may invest in venture capital and other restricted securities if these securities would currently constitute 40% or less of net assets. The value of these securities represents 19% of the Fund's net assets at March 31, 2006.

During the year ended September 30, 2004, restricted securities from one issuer were exchanged for cash in connection with a corporate action, a portion of which has been retained by the issuer in an escrow account pending resolution of certain contingencies and whose estimated value of \$456,340 at March 31, 2006 has been determined by the Trustees. The value of the escrow account is included in the Receivable for Investments Sold in the Statement of Assets and Liabilities.

The following table details the acquisition date, cost, carrying value per unit, and value of the Fund's venture capital and other restricted securities at March 31, 2006, as determined by the Trustees of the Fund. With the exception of Conor Medsystems, Inc. Restricted common stock the Fund on its own does not have the right to demand that such securities be registered. Subject to certain conditions the Fund has the right to request registration of Conor Medsystems, Inc. Restricted common stock.

SECURITY (F)	ACQUISITION DATE	COST	CARRYING VALUE PER UNIT	VALUE
Agensys, Inc.				
Series C Cvt. Pfd.....	2/14/02, 9/27/05	\$ 2,204,684	\$ 2.95	\$ 2,200,200
Agilix Corporation				
Series B Cvt. Pfd.....	11/8/01	2,009,507	0.24	380,950
Akorn, Inc.				
Restricted Common.....	3/7/06	1,400,000	4.13	1,285,200
Avalon Pharmaceuticals, Inc.				
Restricted Common.....	10/22/01-2/11/05	2,145,319	4.80	663,430
Aveta, Inc.				
Restricted Common.....	12/21/05	1,999,998	13.50	1,999,990
CardioNet, Inc.				
Series C Cvt. Pfd.....	5/3/01-3/25/03	3,700,899	3.50	3,680,000
Convertible Note.....	8/15/05	200,000	1.00	200,000
Ceres, Inc.				
Series C Cvt. Pfd.....	12/23/98	1,000,875	6.00	1,500,000
Series C-1 Cvt. Pfd.....	3/31/01	74,325	6.00	128,770
Series D Cvt. Pfd.....	3/14/01	1,046,778	6.00	1,053,240
Concentric Medical, Inc.				
Series B Cvt. Pfd.....	5/7/02-1/24/03	2,219,473	1.40	4,529,410
Series C Cvt. Pfd.....	12/19/03	999,999	1.40	1,627,900
Series D Cvt. Pfd.....	9/30/05	638,511	1.40	637,460

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Conor Medsystems, Inc.				
Restricted Common.....	10/23/03-8/6/04	351,643	27.93	1,642,28
Corus Pharma, Inc.				
Series C Cvt. Pfd.....	4/8/04	2,001,540	0.58	1,000,00

66

H&Q LIFE SCIENCES INVESTORS

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

March 31, 2006

(UNAUDITED)

SECURITY (F)	ACQUISITION DATE	COST	CARRYING VALUE PER UNIT	VALUE
-----	-----	-----	-----	-----
Cougar Biotechnology Inc.				
Series A Cvt. Pfd.....	3/30/06	\$ 787,501	\$ 1.73	\$ 787,50
Restricted Common.....	3/30/06	87,500	1.73	87,50
CytoLogix Corporation				
Series A Cvt. Pfd.....	1/13/98-7/21/99	1,077,912	0.83	265,78
Series B Cvt. Pfd.....	1/11/01	506,622	0.83	124,92
Convertible Note.....	5/29/02	112,224	1.00	112,22
Dako A/S				
Restricted Common.....	6/14/04	734,913	10.41	181,30
EPR, Inc.				
Series A Cvt. Pfd.....	3/9/94	800,331	0.01	1,77
Galileo Pharmaceuticals, Inc.				
Series F-1 Cvt. Pfd.....	8/18/00	2,001,929	0.00	9
Labcyte, Inc.				
Series C Cvt. Pfd.....	7/18/05	1,282,337	0.52	1,280,00
Masimo Corporation				
Series D Cvt. Pfd.....	8/14/96	910,176	11.00	1,430,00
Restricted Common.....	3/31/98	0	0.01	1,30
Matritech, Inc.				
Convertible Note.....	1/17/06	2,000,000	1.00	2,000,00
Medwave, Inc.				
Restricted Common.....	2/21/06	1,224,999	3.24	1,448,53
Omnisonics Medical Technologies, Inc.				
Series B Cvt. Pfd.....	5/24/01	1,606,312	1.34	1,454,15
Series C Cvt. Pfd.....	10/1/03	1,200,224	1.16	1,200,00
PHT Corporation				
Series D Cvt. Pfd.....	7/23/01	2,803,841	0.78	2,800,00
Series E Cvt. Pfd.....	9/12/03-12/17/03	627,472	0.78	626,33
Raven biotechnologies, Inc.				
Series B Cvt. Pfd.....	12/12/00	2,001,150	0.83	1,006,06
Series C Cvt. Pfd.....	11/26/02	1,554,400	0.83	1,554,40
Series D Cvt. Pfd.....	6/23/05	803,610	0.29	800,00
Songbird Hearing, Inc.				
Restricted Common.....	12/14/00	2,003,239	0.01	1,39
Syntiro Healthcare Services				
Restricted Common.....	2/5/97	800,325	0.001	20
TargeGen, Inc.				
Series C Cvt. Pfd.....	8/30/05	1,842,205	1.30	1,840,00

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

67

H&Q LIFE SCIENCES INVESTORS

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

March 31, 2006

(UNAUDITED)

SECURITY (F)	ACQUISITION DATE	COST	CARRYING VALUE PER UNIT	VALUE
Therion Biologics Corporation				
Series A Cvt. Pfd.....	8/20/96-10/16/96	\$ 289,847	\$ 1.22	\$ 37,72
Series B Cvt. Pfd.....	6/22/99	600,929	1.22	195,20
Series C Cvt. Pfd.....	9/26/01-10/15/01	1,019,568	1.22	331,60
Series C-2 Cvt. Pfd.....	8/13/03	40,003	1.22	27,11
Sinking Fund Cvt. Pfd.....	10/18/94-4/3/96	582,505	0.01	29
Restricted Common.....	6/30/93	251,642	0.01	1,47
TherOx, Inc.				
Series H Cvt. Pfd.....	9/11/00	2,001,626	3.80	165,21
Series I Cvt. Pfd.....	7/8/05	386,273	3.86	384,73
Xanthus Life Sciences, Inc.				
Series B Cvt. Pfd.....	12/5/03-3/23/06	1,645,880	1.00	1,645,00
Zyomyx, Inc.				
Series A New Cvt. Pfd.....	2/19/99-1/12/04	199,800	0.10	20,00
Series B New Cvt. Pfd.....	3/31/04	112	0.10	2
New Restricted Common.....	2/19/99-7/22/02	2,401,101	0.01	2,00
		-----		-----
		\$58,182,059		\$44,342,72
		=====		=====

(f) See Schedule of Investments and corresponding footnotes for more information on each issuer.

(g) Represents 19% of the Fund's net assets as of March 31, 2006.

68

H&Q LIFE SCIENCES INVESTORS

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

March 31, 2006

(UNAUDITED)

(5) SOURCES OF NET ASSETS

The changes in the sources of net assets for the period from October 1, 2005 through March 31, 2006 are as follows:

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

	CAPITAL PAID IN ON SHARES OF BENEFICIAL INTEREST	ACCUMULATED NET INVESTMENT GAIN	ACCUMULATED NET REALIZED GAIN ON INVESTMENTS	NET UNREALIZED GAIN ON INVESTMENTS	TOTAL ASS
	-----	-----	-----	-----	-----
As of October 1, 2005:....	\$177,528,617	\$ (14)	\$ 13,534,863	\$38,227,860	\$229,2
For the period from October 1, 2005 through March 31, 2006:					
Net investment income...	--	75,073	--	--	
Net realized gains.....	--	--	14,303,339	--	14,3
Distributions.....	--	--	(17,939,117)	--	(17,9
Value of shares issued in reinvestment of dividends.....	10,394,972	--	--	--	10,3
Decrease in net unrealized gain on investments.....	--	--	--	(6,035,540)	(6,0
As of March 31, 2006:.....	\$187,923,589	\$75,059	\$ 9,899,085	\$32,192,320	\$230,0
	=====	=====	=====	=====	=====

69

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

TO THE TRUSTEES AND SHAREHOLDERS OF H&Q LIFE SCIENCES INVESTORS:

We have audited the accompanying statement of assets and liabilities of H&Q Life Sciences Investors (the "Fund"), including the schedule of investments, as of September 30, 2005, and the related statements of operations and cash flows for the year then ended, and the statements of changes in net assets and the financial highlights for each of the two years in the period then ended. These financial statements and financial highlights are the responsibility of the Fund's management. Our responsibility is to express an opinion on these financial statements and financial highlights based on our audits. The financial highlights for the years ended September 30, 2003, 2002, and 2001 were audited by other auditors whose report, dated November 23, 2003, expressed an unqualified opinion on the financial highlights.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements and financial highlights are free of material misstatement. The Fund is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Fund's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. Our procedures included confirmation of securities owned as of September 30, 2005, by correspondence with the custodian and brokers; where replies were not received from brokers, we performed other auditing procedures. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements and financial highlights referred

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

to above present fairly, in all material respects, the financial position of H&Q Life Sciences Investors as of September 30, 2005, the results of its operations and its cash flows for the year then ended, and the changes in its net assets and the financial highlights for each of the two years in the period then ended, in conformity with accounting principles generally accepted in the United States of America.

DELOITTE & TOUCHE LLP
 Boston, Massachusetts
 November 18, 2005

The following are the financial statements and related notes from the Trust's September 30, 2005 Annual Report to Shareholders, including the Schedule of Investments, the Statement of Assets and Liabilities, the Statement of Operations, the Statement of Changes in Net Assets, the Statement of Cash Flows and the five year Financial Highlights. It is expected that the unaudited financial statements included in the Trust's Semi-Annual Report to Shareholders for the six months ended March 31, 2006 will be mailed to Shareholders and available on the Trust's website (www.hqcm.com) on or around June 1, 2006.

70

H&Q LIFE SCIENCES INVESTORS

SCHEDULE OF INVESTMENTS

SEPTEMBER 30, 2005

SHAES

VALUE

CONVERTIBLE SECURITIES--15.8% OF NET ASSETS

CONVERTIBLE PREFERRED (RESTRICTED)--15.6%

DRUG DISCOVERY TECHNOLOGIES--1.8%

1,587,302	Agilix Corporation Series B(a) (b)	\$ 380,95
566,958	Avalon Pharmaceuticals, Inc. Series B(a)	871,87
250,000	Ceres, Inc. Series C(a)	1,500,00
18,296	Ceres, Inc. Series C-1(a) (c)	109,77
174,200	Ceres, Inc. Series D(a) (c)	1,045,20
932,488	Galileo Pharmaceuticals, Inc. Series F-1(a)	326,37
200,000	Zyomyx, Inc. Series A New(a)	20,00
200	Zyomyx, Inc. Series B New(a)	2

EMERGING BIOPHARMACEUTICALS--5.0%

744,921	Agensys, Inc. Series C(a)	2,200,20
1,724,138	Corus Pharma, Inc. Series C(a)	2,000,00
1,212,121	Raven biotechnologies, Inc. Series B(a)	1,006,06
1,872,772	Raven biotechnologies, Inc. Series C(a)	1,554,40
2,431,611	Raven biotechnologies, Inc. Series D(a)	800,00
1,415,385	TargeGen, Inc. Series C(a)	1,840,00
30,920	Therion Biologics Corporation Series A(a)	37,72
160,000	Therion Biologics Corporation Series B(a)	195,20
271,808	Therion Biologics Corporation Series C(a) (c)	331,60
22,224	Therion Biologics Corporation Series C-2(a) (c)	27,11
28,991	Therion Biologics Corporation Sinking Fund(a)	29
1,400,000	Xanthus Life Sciences, Inc. Series B(a)	1,400,00

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

HEALTHCARE SERVICES--3.3%		
1,051,429	CardioNet, Inc. Series C(a) (c).....	3,680,000
322,168	CytoLogix Corporation Series A(a) (b).....	265,780
151,420	CytoLogix Corporation Series B(a) (b) (c).....	124,920
3,589,744	PHT Corporation Series D(a) (b).....	2,800,000
802,996	PHT Corporation Series E(a) (b).....	626,330
MEDICAL DEVICES AND DIAGNOSTICS--5.5%		
3,235,293	Concentric Medical, Inc. Series B(a) (b).....	4,529,410
1,162,790	Concentric Medical, Inc. Series C(a) (b).....	1,627,900
455,333	Concentric Medical, Inc. Series D(a) (b).....	637,460
177,778	EPR, Inc. Series A(a).....	1,770
2,446,016	Labcyte, Inc. Series C(a).....	1,280,000
130,000	Masimo Corporation Series D(a).....	1,430,000
1,088,436	OmniSonics Medical Technologies, Inc. Series B(a).....	1,454,150
1,031,992	OmniSonics Medical Technologies, Inc. Series C(a).....	1,200,000

The accompanying notes are an integral part of these financial statements.

71

H&Q LIFE SCIENCES INVESTORS

SCHEDULE OF INVESTMENTS

SEPTEMBER 30, 2005

SHAES		VALUE
-----		-----
43,478	TherOx, Inc. Series H(a).....	\$ 165,210
99,646	TherOx, Inc. Series I(a) (c).....	384,730

		\$ 35,854,490

PRINCIPAL		
AMOUNT		

DRUG DISCOVERY TECHNOLOGIES--0.0%		
\$ 132,340	Avalon Pharmaceuticals, Inc. 8% Cvt. Note, due 2006.....	\$ 85,490
HEALTHCARE SERVICES--0.2%		
200,000	CardioNet, Inc. 8% Cvt. Note, due 2006.....	200,000
112,225	CytoLogix Corporation 6.75% Cvt. Note (b) (d).....	112,220

		\$ 397,720

TOTAL CONVERTIBLE SECURITIES		
	(COST \$43,873,557).....	\$ 36,252,220

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

SHARES

COMMON STOCKS--76.9%

BIOPHARMACEUTICALS--15.4%

385,500	Bioenvision, Inc.(a).....	\$ 3,095,56
518,905	Critical Therapeutics, Inc.(a).....	4,888,08
159,672	Critical Therapeutics warrants(a).....	453,46
390,603	Cubist Pharmaceuticals, Inc.(a).....	8,413,58
33,807	Genzyme Corporation(a).....	2,421,93
140,675	Gilead Sciences, Inc.(a).....	6,859,31
300,809	Inspire Pharmaceuticals, Inc.(a).....	2,286,14
170,850	MedImmune, Inc.(a).....	5,749,10
312,200	Vivus, Inc.(a).....	1,120,79

		35,288,00

DRUG DELIVERY--3.6%

112,360	Connetics Corporation(a).....	1,900,00
499,955	DepoMed, Inc.(a).....	3,239,70
141,710	Noven Pharmaceuticals, Inc.(a)	1,983,94
58,626	Penwest Pharmaceuticals Co.(a).....	1,027,71

		8,151,37

DRUG DISCOVERY TECHNOLOGIES--4.3%

46,560	Avalon Pharmaceuticals, Inc. (Restricted)(a).....	368,05
439,232	deCODE Genetics, Inc.(a).....	3,685,15

The accompanying notes are an integral part of these financial statements.

72

H&Q LIFE SCIENCES INVESTORS

SCHEDULE OF INVESTMENTS

SEPTEMBER 30, 2005

SHARES

245,200	Pharmacopeia Drug Discovery, Inc.(a).....	\$ 877,81
120,737	Senomyx, Inc.(a).....	2,056,15
180,050	ZymoGenetics, Inc.(a).....	2,970,82
200,000	Zyomyx, Inc. (Restricted)(a).....	2,00

		9,960,00

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

EMERGING BIOPHARMACEUTICALS--29.0%

277,235	ACADIA Pharmaceuticals, Inc.(a).....	3,152,16
187,600	Applera Corporation--Celera Genomics Group(a).....	2,275,58
366,659	Ariad Pharmaceuticals, Inc.(a).....	2,724,27
239,420	Barrier Therapeutics, Inc.(a).....	2,008,73
409,329	Cytokinetix, Inc.(a).....	3,331,93
177,000	DOV Pharmaceutical, Inc.(a).....	3,005,46
97,704	Dyax Corporation(a).....	546,16
442,800	Epix Pharmaceuticals, Inc.(a).....	3,409,56
500,925	Exelixis, Inc.(a).....	3,842,09
94,680	Incyte Corporation(a).....	444,99
501,100	Kosan Biosciences, Inc.(a).....	3,642,99
815,000	Lexicon Genetics, Inc.(a).....	3,243,70
31,059	Momenta Pharmaceuticals, Inc.(a).....	846,35
219,740	Myogen, Inc.(a).....	5,163,89
51,080	Myogen, Inc. warrants(a).....	801,95
158,810	Neurogen Corporation(a).....	1,092,61
61,077	Nitromed, Inc.(a).....	1,099,38
270,044	Nuvelo, Inc.(a).....	2,592,42
78,100	Protein Design Labs, Inc.(a).....	2,186,80
153,300	Rigel Pharmaceuticals, Inc.(a).....	3,643,94
340,700	Sangamo BioSciences, Inc.(a).....	1,495,67
455,320	Seattle Genetics, Inc.(a).....	2,390,43
526,924	Sirna Therapeutics, Inc.(a).....	2,318,46
192,354	Telik, Inc.(a).....	3,146,91
226,384	Tercica, Inc.(a).....	2,553,61
259,216	Theravance, Inc.(a).....	5,453,90
146,982	Therion Biologics Corporation (Restricted)(a).....	1,47

66,415,50

GENERIC PHARMACEUTICALS--4.0%

277,300	Caraco Pharmaceutical Laboratories, Ltd.(a).....	2,409,73
240,882	Impax Laboratories, Inc.(a).....	2,921,89
48,300	IVAX Corporation(a).....	1,273,18
79,300	Teva Pharmaceutical Industries, Ltd. ADR.....	2,650,20

9,255,03

The accompanying notes are an integral part of these financial statements.

73

H&Q LIFE SCIENCES INVESTORS

SCHEDULE OF INVESTMENTS

SEPTEMBER 30, 2005

SHARES

VALUE

	HEALTHCARE SERVICES--1.5%	
17,416	DakoCytomation, Inc. (Restricted)(e).....	\$ 181,30
233,705	Emageon, Inc.(a).....	3,169,04
204,139	Syntiro Healthcare Services (Restricted)(a).....	20

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

		3,350,54

	MEDICAL DEVICES AND DIAGNOSTICS--19.1%	
64,095	Adeza Biomedical Corporation(a).....	1,115,89
74,250	Affymetrix, Inc.(a).....	3,432,57
458,850	Align Technology, Inc.(a).....	3,083,47
618,799	Conor Medsystems, Inc. (Restricted) (a).....	13,814,68
83,350	IDEXX Laboratories, Inc.(a).....	5,574,44
169,413	Intralase Corporation(a).....	2,492,06
130,000	Masimo Corporation (Restricted) (a).....	1,30
36,455	Molecular Devices Corporation(a).....	761,54
123,562	Natus Medical, Inc.(a).....	1,503,75
260,227	Orchid Cellmark, Inc.(a).....	2,211,93
784,900	Orthovita, Inc.(a).....	3,359,37
139,019	Songbird Hearing, Inc. (Restricted) (a).....	1,39
499,050	Third Wave Technologies, Inc.(a).....	2,470,29
382,583	VNUS Medical Technologies, Inc.(a).....	3,986,51

		43,809,24

	TOTAL COMMON STOCKS	
	(COST \$130,380,503).....	\$176,229,69

PRINCIPAL
AMOUNT

	SHORT-TERM INVESTMENTS--6.6%	
\$7,300,000	American Express Credit Corp.; 3.58%--3.74%, due 10/03/05--10/14/05.....	\$ 7,296,22
7,950,000	General Electric Capital Corp.; 3.69%--3.72%, due 10/05/05--10/14/05.....	7,943,86

	TOTAL SHORT-TERM INVESTMENTS (COST \$15,240,085).....	\$ 15,240,08

	TOTAL INVESTMENTS--99.3% (COST \$189,494,145).....	\$227,722,00

	OTHER ASSETS IN EXCESS OF LIABILITIES--0.7%.....	1,569,32

	NET ASSETS--100%.....	\$229,291,32
		=====

(a) Non-income producing security.

(b) Affiliated issuers in which the Fund holds 5% or more of the voting securities (Total Market Value of \$11,105,006).

(c) Including associated warrants.

(d) Variable maturity.

(e) Foreign Security.

ADR American Depository Receipt.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

The accompanying notes are an integral part of these financial statements.

74

H&Q LIFE SCIENCES INVESTORS STATEMENT OF ASSETS AND LIABILITIES

SEPTEMBER 30, 2005

ASSETS:

Investments in non affiliated issuers, at value (identified cost \$178,499,628; see Schedule of Investments).....	\$216,616,999
Investments in affiliated issuers, at value (identified cost \$10,994,517; see Schedule of Investments).....	11,105,006
Cash.....	21,295
Interest receivable.....	35,708
Receivable for investments sold.....	2,447,860
Prepaid expenses.....	49,377

Total assets.....	\$230,276,245

LIABILITIES:

Payable for investments purchased.....	\$ 557,439
Accrued advisory fee.....	243,838
Accrued audit fee.....	57,285
Accrued legal fees.....	20,368
Accrued shareholder reporting fees.....	38,691
Accrued other.....	67,298

Total liabilities.....	\$ 984,919

NET ASSETS.....	\$229,291,326
	=====

SOURCES OF NET ASSETS:

Shares of beneficial interest, par value \$.01 per share, unlimited number of shares authorized, amount paid in on 12,605,204 shares issued and outstanding.....	\$177,528,617
Accumulated net investment loss.....	(14)
Accumulated net realized gain on investments.....	13,534,863
Net unrealized gain on investments.....	38,227,860

Total net assets (equivalent to \$18.19 per share based on 12,605,204 shares outstanding).....	\$229,291,326
	=====

The accompanying notes are an integral part of these financial statements.

75

H&Q LIFE SCIENCES INVESTORS STATEMENT OF OPERATIONS FOR THE YEAR ENDED SEPTEMBER 30, 2005

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

INVESTMENT INCOME:		
Dividend income (net of foreign tax of \$3,893).....	\$	229,637
Interest income from non affiliated issuers.....		648,031
Interest income from affiliated issuers.....		8,847

Total investment income.....	\$	886,515
EXPENSES:		
Advisory fees.....	\$2,676,602	
Trustees' fees and expenses.....	163,474	
Legal fees.....	126,922	
Custodian fees.....	74,195	
Shareholder reporting.....	96,470	
Accounting, administration and auditing fees.....	93,021	
Transfer agent fees.....	55,597	
Stock exchange listing fee.....	27,114	
Other (see note (3)).....	160,681	

Total expenses.....		3,474,076

Net investment loss.....	\$	(2,587,561)

NET REALIZED AND UNREALIZED GAIN (LOSS) ON INVESTMENTS:		
Net realized gain on investments.....	\$26,035,268	
Increase in net unrealized gain on investments.....	21,315,662	

Net realized and unrealized gain on investments.....	\$47,350,930	

Net increase in net assets resulting from operations.....	\$44,763,369	
		=====

The accompanying notes are an integral part of these financial statements.

76

H&Q LIFE SCIENCES INVESTORS
STATEMENTS OF CHANGES IN NET ASSETS

	FOR THE YEAR ENDED SEPTEMBER 30, 2005	FOR THE YEAR ENDED SEPTEMBER 30, 2004
	-----	-----
NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS:		
Net investment loss.....	\$ (2,587,561)	\$ (3,070,147)
Net realized gain on investments.....	26,035,268	22,434,597
Increase/decrease in net unrealized gain on investments...	21,315,662	(12,204,850)
	-----	-----
Net increase in net assets resulting from operations....	\$ 44,763,369	\$ 7,159,600
	-----	-----
DISTRIBUTIONS TO SHAREHOLDERS FROM:		
Net realized capital gains.....	\$ (15,828,633)	\$ (16,063,421)
	-----	-----
CAPITAL SHARE TRANSACTIONS:		
Value of shares issued in reinvestment of distributions (538,795 and 653,934 shares, respectively).....	\$ 8,518,606	\$ 10,389,334
Net increase in net assets.....	\$ 37,453,342	\$ 1,485,513

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

NET ASSETS:		
Beginning of year.....	191,837,984	190,352,471
	-----	-----
End of year.....	\$229,291,326	\$191,837,984
	=====	=====
Accumulated net investment loss included in net assets at end of year.....	\$ (14)	\$ 0
	=====	=====

The accompanying notes are an integral part of these financial statements.

77

H&Q LIFE SCIENCES INVESTORS

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED SEPTEMBER 30, 2005

CASH FLOWS PROVIDED FROM OPERATING ACTIVITIES:	
Purchases of portfolio securities.....	\$ (138,246,171)
Net maturities of short-term investments.....	(1,325,186)
Sales and maturities of portfolio securities.....	149,331,532

Interest income received.....	25,360
Dividends received.....	229,637
Operating expenses paid.....	(3,415,021)

Net cash provided from operating activities.....	\$ 6,600,151

CASH FLOWS USED FOR FINANCING ACTIVITIES:	
Cash distributions paid, net.....	\$ (7,310,027)

Net cash used for financing activities.....	\$ (7,310,027)

NET DECREASE IN CASH.....	\$ (709,876)
CASH AT BEGINNING OF YEAR.....	731,171

CASH AT END OF YEAR.....	\$ 21,295
	=====
RECONCILIATION OF NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS TO NET CASH PROVIDED FROM OPERATING ACTIVITIES:	
Net increase in net assets resulting from operations.....	\$ 44,763,369
Purchases of portfolio securities.....	\$ (138,246,171)
Net maturities of short-term investments.....	(1,325,186)
Sales and maturities of portfolio securities.....	149,331,532
Accretion of discount.....	(618,892)
Net realized gain on investments.....	(26,035,268)
Increase in net unrealized gain on investments.....	(21,315,662)
Increase in interest receivable.....	(12,626)
Increase in accrued expenses.....	58,953
Decrease in prepaid expenses.....	102

Net cash provided from operating activities.....	\$ 6,600,151
	=====

Noncash financing activities not included herein consist of reinvested distributions of \$8,518,606.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Noncash operating activities not included herein consist of three conversions of restricted preferred stock with a cost of \$7,156,360 to restricted common stock each of the same issuer.

The accompanying notes are an integral part of these financial statements.

78

H&Q LIFE SCIENCES INVESTORS

FINANCIAL HIGHLIGHTS

(SELECTED DATA FOR EACH SHARE OF BENEFICIAL INTEREST OUTSTANDING THROUGHOUT THE PERIOD INDICATED)

	FOR THE YEAR ENDED SEPTEMBER 30,			
	2005	2004	2003	2002 (1)
	-----	-----	-----	-----
Net asset value per share:				
Beginning of year.....	\$ 15.90	\$ 16.68	\$ 15.14	\$ 23.09
	-----	-----	-----	-----
Net investment loss(2).....	\$ (0.21)	\$ (0.26)	\$ (0.21)	\$ (0.26)
Net realized and unrealized gain (loss) on investments.....	3.79	0.86	3.55	(4.83)
	-----	-----	-----	-----
Total increase (decrease) from investment operations.....	\$ 3.58	\$ 0.60	\$ 3.34	\$ (5.09)
	-----	-----	-----	-----
Capital gain distributions to shareholders.....	\$ (1.29)	\$ (1.38)	\$ (1.80)	\$ (2.86)
	-----	-----	-----	-----
Net asset value per share:				
End of year.....	\$ 18.19	\$ 15.90	\$ 16.68	\$ 15.14
	=====	=====	=====	=====
Per share market value:				
End of year.....	\$ 16.85	\$ 16.20	\$ 15.28	\$ 11.79
Total investment return at market value.....	12.77%	15.52%	47.65%	(25.82)%
RATIOS AND SUPPLEMENTAL DATA:				
Net assets at end of year.....	\$229,291,326	\$191,837,984	\$190,352,471	\$157,585,450
Ratio of operating expenses to average net assets....	1.74%	1.73%	1.74%	1.71%
Ratio of net investment loss to average net assets.....	(1.29)%	(1.56)%	(1.38)%	(1.25)%
Portfolio turnover rate....	73.79%	34.93%	32.36%	17.36%
Number of shares outstanding at end of year.....	12,605,204	12,066,409	11,412,475	10,409,622

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

- (1) In 2002, the Fund adopted the provisions of the AICPA Audit and Accounting Guide for Investment Companies and began accreting discounts and amortizing premiums on all debt securities. The effect of this change for the year ended September 30, 2002 was a decrease in net investment loss per share of \$.006, an increase in net realized and unrealized loss on investments per share of \$.006, and a decrease in the ratio of net investment loss to average net assets from (1.28%) to (1.25%). Per share data and ratios for the period prior to October 1, 2001 have not been restated to reflect this change in presentation.
- (2) Net investment loss per share has been computed using average shares outstanding.

The accompanying notes are an integral part of these financial statements.

79

H&Q LIFE SCIENCES INVESTORS

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2005

(1) ORGANIZATION

H&Q Life Sciences Investors (the Fund) is a Massachusetts business trust registered under the Investment Company Act of 1940 as a diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in securities of companies in the healthcare industries. The Fund invests primarily in securities of public and private companies that are believed to have significant potential for above-average growth. The Fund was organized on February 20, 1992 and commenced operations on May 8, 1992.

The preparation of these financial statements requires the use of certain estimates by management in determining the Fund's assets, liabilities, revenues and expenses. Actual results could differ from these estimates. The following is a summary of significant accounting policies consistently followed by the Fund, which are in conformity with accounting principles generally accepted in the United States of America.

INVESTMENT SECURITIES & INVESTMENT INCOME

Investments traded on national securities exchanges or in the over-the-counter market that are National Market System securities are valued at the last sale price or, lacking any sales, at the mean between the last bid and asked prices. Other over-the-counter securities are valued at the most recent bid prices as obtained from one or more dealers that make markets in the securities. Exchange traded investments for which market quotations are not readily available are valued at fair value as determined in good faith by the Trustees of the Fund. The value of venture capital and other restricted securities is determined in good faith by the Trustees. However, because of the uncertainty of venture capital and other restricted security valuations, these estimated values may differ significantly from the values that would have been used had a ready market for these securities existed, and the differences could be material. See note 4 below. Short-term investments with maturity of 60 days or less are valued at amortized cost.

Investment transactions are recorded on a trade date basis. Gains and losses from sales of investments are recorded using the "identified cost" method. Interest income is recorded on the accrual basis, adjusted for amortization of premiums and accretion of discounts. Dividend income is recorded on the

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

ex-dividend date.

REPURCHASE AGREEMENTS

In connection with transactions in repurchase agreements, the Fund's custodian takes possession of the underlying collateral securities, the market value of which is at least equal to the principal, including accrued interest, of the repurchase transaction at all times. In the event of default or bankruptcy by the other party to the agreement, realization and/or retention of the collateral by the Fund may be delayed or limited.

FEDERAL INCOME TAXES

It is the Fund's policy to comply with the requirements of the Internal Revenue Code applicable to regulated investment companies and to distribute to its shareholders substantially all of its taxable income and its net realized capital gains, if any. Therefore, no Federal income or excise tax provision is required.

80

H&Q LIFE SCIENCES INVESTORS

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

SEPTEMBER 30, 2005

DISTRIBUTIONS

The Fund records all distributions to shareholders from net investment income, if any, and realized gains on the ex-dividend date. Such distributions are determined in conformity with income tax regulations. Due to permanent book/tax differences in accounting for certain transactions, certain distributions may be treated as distributions from capital as opposed to distributions of net investment income or realized capital gains.

DISTRIBUTION POLICY

Distributions will automatically be paid in newly issued shares of the Fund unless otherwise instructed by the shareholder. Pursuant to an SEC exemptive order, the Fund has implemented a fixed distribution policy that permits the Fund to make quarterly distributions at a rate of 2% of the Fund's net assets to shareholders of record. The Fund intends to use net realized capital gains when making quarterly distributions. This could result in a return of capital to shareholders if the amount of the distribution exceeds the Fund's net investment income and realized capital gains. It is anticipated that net realized capital gains in excess of the total distributed under this policy would be included in the December distribution.

Pursuant to Section 852 of the Internal Revenue Code, the Fund has designated \$15,828,633 as a long-term capital gain distribution for its taxable year ended September 30, 2005.

STATEMENT OF CASH FLOWS

The cash amount shown in the Statement of Cash Flows is the amount included in the Fund's Statement of Assets and Liabilities and represents cash on hand at its custodian and does not include short-term investments at September 30, 2005.

INDEMNIFICATIONS

Under the Fund's organizational documents, its officers and Trustees may be

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

indemnified against certain liabilities and expenses arising out of the performance of their duties to the Fund. Additionally, in the normal course of business, the Fund enters into agreements with service providers that may contain indemnification clauses. The Fund's maximum exposure under these agreements is unknown as this would involve future claims that may be made against the fund that have not yet occurred. However, based on experience, the Fund expects the risk of loss to be remote.

(2) SECURITIES TRANSACTIONS

The aggregate cost of purchases and proceeds from sales of investment securities (other than short-term investments) for the year ended September 30, 2005 totaled \$137,914,676 and \$151,209,219 respectively.

At September 30, 2005, the total cost of securities for Federal income tax purposes was \$189,728,428. The net unrealized gain for Federal income tax purposes on securities held by the Fund was \$37,993,577 including gross unrealized gain of \$61,132,191 and gross unrealized loss of \$23,138,614.

81

H&Q LIFE SCIENCES INVESTORS

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

SEPTEMBER 30, 2005

(3) INVESTMENT ADVISORY FEES AND OTHER TRANSACTIONS WITH AFFILIATES

The Fund has entered into an Investment Advisory Agreement (the Advisory Agreement) with Hambrecht & Quist Capital Management, LLC (the Adviser). Pursuant to the terms of the Advisory Agreement, the Fund pays the Adviser a monthly fee at the rate when annualized of (i) 2.5% of the average net assets for the month of its venture capital and other restricted securities up to 25% of net assets and (ii) for the month, for all other assets, 1.0% of the average net assets up to \$250 million, 0.9% of the average net assets for the next \$250 million, 0.8% of the average net assets for the next \$500 million and 0.7% of the average net assets thereafter. The aggregate fee may not exceed a rate when annualized of 1.375%.

As of February 2005, Daniel R. Omstead, Ph.D, Christopher F. Brinzey, M.B.A., Frank T. Gentile, Ph.D. and Jason C. Akus, M.D./M.B.A. are members of the team that makes investments on behalf of the Fund. These members also perform other duties, including making investment decisions on behalf of another closed-end investment Company, H&Q Healthcare Investors, which invests in companies in the healthcare industries.

The Fund has entered into a Services Agreement (the "Agreement") with the Adviser. Pursuant to the terms of the Agreement, the Fund reimburses the Adviser for a portion of the payment of salary and provision of benefits to the Fund's Chief Compliance Officer. During the year ended September 30, 2005 these payments amounted to \$66,017 and are included in the "other" category in the Statement of Operations, together with insurance expenses of \$55,489 incurred to unaffiliated entities. Such expenses are the major components of "other" in the Statement of Operations. Expenses incurred pursuant to the Agreement as well as certain expenses paid by the Adviser are allocated in an equitable fashion to the Fund.

Certain officers and Trustees of the Fund are also officers of the Adviser. Trustees who are not affiliates of the Adviser receive an annual fee of \$20,000 plus \$500 for each Committee on which they serve and \$500 for each meeting attended.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

An affiliate company is a company in which the Fund holds 5% or more of the voting securities. Transactions with such companies during the year ended September 30, 2005 were as follows:

ISSUER -----	VALUE ON OCTOBER 1, 2004 -----	PURCHASES -----	SALES -----	INCOME -----	V SEP -----
Agilix Corporation.....	\$ 380,952	\$ --	\$ --	\$ --	\$
Concentric Medical, Inc.....	3,782,351	637,466	--	--	
CytoLogix Corporation.....	502,935	--	--	8,847	
PHT Corporation.....	3,271,255	155,082	--	--	
	-----	-----	-----	-----	-----
	\$7,937,493	\$792,548	\$ --	\$8,847	\$1
	-----	-----	-----	-----	-----

(4) VENTURE CAPITAL AND OTHER RESTRICTED SECURITIES

The Fund may invest in venture capital and other restricted securities if these securities would currently comprise 40% or less of net assets. The value of these securities represents 22% of the Fund's net assets at September 30, 2005.

During the year ended September 30, 2004, restricted securities from one issuer were exchanged for cash in connection with a corporate action, a portion of which has been retained by the issuer in an

82

H&Q LIFE SCIENCES INVESTORS

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

SEPTEMBER 30, 2005

escrow account pending resolution of certain contingencies and whose estimated value of \$456,340 at September 30, 2005 has been determined by the Trustees. The value of the escrow account is included in the Receivable for Investments Sold in the Statement of Assets and Liabilities.

The following table details the acquisition date, cost, carrying value per unit, and value of the Fund's venture capital and other restricted securities at September 30, 2005, as determined by the Trustees of the Fund

SECURITY (F) -----	ACQUISITION DATE -----	COST -----	CARRYING VALUE PER UNIT -----	VALUE -----
Agensys, Inc. Series C Cvt. Pfd.....	2/14/02, 9/27/05	\$ 2,203,583	\$ 2.95	\$ 2,200,2
Agilix Corporation Series B Cvt. Pfd.....	11/8/01	2,009,507	0.24	380,9
Avalon Pharmaceuticals, Inc. Series B Cvt. Pfd.....	10/22/01	2,005,767	1.54	871,8

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Convertible Note.....	2/11/05	132,340	0.65	85,4
Restricted Common.....	9/29/05	488,880	7.91	368,0
CardioNet, Inc.				
Series C Cvt. Pfd.....	5/3/01-3/25/03	3,699,455	3.50	3,680,0
Convertible Note.....	8/14/05	200,000	1.00	200,0
Ceres, Inc.				
Series C Cvt. Pfd.....	12/23/98	1,000,875	6.00	1,500,0
Series C-1 Cvt. Pfd.....	3/31/01	74,325	6.00	109,7
Series D Cvt. Pfd.....	3/14/01	1,046,778	6.00	1,045,2
Concentric Medical, Inc.				
Series B Cvt. Pfd.....	5/7/02-1/24/03	2,219,473	1.40	4,529,4
Series C Cvt. Pfd.....	12/19/03	999,999	1.40	1,627,9
Series D Cvt. Pfd.....	9/30/05	637,466	1.40	637,4
Conor Medsystems, Inc.				
Restricted Common.....	10/23/03-8/6/04	1,954,131	22.33	13,814,6
Corus Pharma, Inc.				
Series C Cvt. Pfd.....	4/8/04	2,001,540	1.16	2,000,0
CytoLogix Corporation				
Series A Cvt. Pfd.....	1/13/98-7/21/99	1,077,912	0.83	265,7
Series B Cvt. Pfd.....	1/11/01	506,622	0.83	124,9
Convertible Note.....	5/29/02	112,224	1.00	112,2
DakoCytomation, Inc.				
Restricted Common.....	6/14/04	734,913	10.41	181,3
EPR, Inc.				
Series A Cvt. Pfd.....	3/9/94	800,331	0.01	1,7
Galileo Pharmaceuticals, Inc.				
Series F-1 Cvt. Pfd.....	8/18/00	2,001,929	0.35	326,3
Labcyte, Inc.				
Series C Cvt. Pfd.....	7/18/05	1,280,000	0.52	1,280,0

83

H&Q LIFE SCIENCES INVESTORS

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

SEPTEMBER 30, 2005

SECURITY (F)	ACQUISITION DATE	COST	CARRYING VALUE PER UNIT	VALUE
Masimo Corporation				
Series D Cvt. Pfd.....	8/14/96	\$ 910,027	\$11.00	\$ 1,430,0
Restricted Common.....	3/31/98	0	0.01	1,3
Omnisonics Medical Technologies, Inc.				
Series B Cvt. Pfd.....	5/24/01	1,606,312	1.34	1,454,1
Series C Cvt. Pfd.....	10/1/03	1,200,224	1.16	1,200,0
PHT Corporation				
Series D Cvt. Pfd.....	7/23/01	2,803,841	0.78	2,800,0
Series E Cvt. Pfd.....	9/12/03-12/17/03	627,472	0.78	626,3
Raven biotechnologies, Inc.				
Series B Cvt. Pfd.....	12/12/00	2,001,150	0.83	1,006,0
Series C Cvt. Pfd.....	11/26/02	1,554,400	0.83	1,554,4
Series D Cvt. Pfd.....	6/23/05	800,000	0.33	800,0
Songbird Hearing, Inc.				
Restricted Common.....	12/14/00	2,003,239	0.01	1,3
Syntiro Heathcare Services				

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Restricted Common.....	2/5/97	800,325	0.001	2
TargeGen, Inc.				
Series C Cvt. Pfd.....	8/30/05	1,840,001	1.30	1,840,0
Therion Biologics Corporation				
Series A Cvt. Pfd.....	8/20/96-10/16/96	289,847	1.22	37,7
Series B Cvt. Pfd.....	6/22/99	600,929	1.22	195,2
Series C Cvt. Pfd.....	9/26/01-10/15/01	1,019,568	1.22	331,6
Series C-2 Cvt. Pfd.....	8/13/03	40,003	1.22	27,1
Sinking Fund Cvt. Pfd.....	10/18/94-4/3/96	582,505	0.01	2
Restricted Common.....	6/30/93	251,642	0.01	1,4
TherOx, Inc.				
Series H Cvt. Pfd.....	9/11/00	2,001,626	3.80	165,2
Series I Cvt. Pfd.....	7/8/05	384,734	3.86	384,7
Xanthus Life Sciences, Inc.				
Series B Cvt. Pfd.....	12/5/03	1,400,880	1.00	1,400,0
Zyomyx, Inc.				
Series A New Cvt. Pfd.....	2/19/99-1/12/04	199,800	0.10	20,0
Series B New Cvt. Pfd.....	3/31/04	112	0.10	
New Restricted Common.....	2/19/99-7/22/02	2,401,101	0.01	2,0
		-----		-----
		\$52,507,788		\$50,622,6
		=====		=====

(f) See Schedule of Investments and corresponding footnotes for more information on each issuer.

(g) Represents 22% of the Fund's net assets as of September 30, 2005.

84

H&Q LIFE SCIENCES INVESTORS

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

SEPTEMBER 30, 2005

(5) SOURCES OF NET ASSETS

The changes in the sources of net assets for the period from October 1, 2004 through September 30, 2005 are as follows:

	CAPITAL PAID IN ON SHARES OF BENEFICIAL INTEREST	ACCUMULATED NET INVESTMENT LOSS	ACCUMULATED NET REALIZED GAIN ON INVESTMENTS	NET UNREALIZED GAIN ON INVESTMENTS	TO
	-----	-----	-----	-----	-----
As of October 1, 2004:.....	\$169,010,011	\$ --	\$ 5,915,775	\$16,912,198	\$19
For the period from October 1, 2004 through September 30, 2005:					
Net investment loss.....	--	(2,587,561)	--	--	(
Net realized gains.....	--	--	26,035,268	--	2
Distributions.....	--	--	(15,828,633)	--	(1
Value of shares issued in reinvestment of dividends....	8,518,606	--	--	--	
Increase in net unrealized gain					

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

on investments.....	--	--	--	21,315,662	2
Reclassification for federal income tax purposes.....	--	2,587,547	(2,587,547)	--	--
As of September 30, 2005:.....	\$177,528,617	\$ (14)	\$ 13,534,863	\$38,227,860	\$22
	=====	=====	=====	=====	=====

NO DEALER, SALESPERSON OR OTHER PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS OTHER THAN THOSE CONTAINED IN THIS PROSPECTUS IN CONNECTION WITH THE OFFER MADE BY THIS PROSPECTUS AND, IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATIONS MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE TRUST OR THE TRUST'S INVESTMENT ADVISER. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF ANY OFFER TO BUY ANY SECURITY OTHER THAN THE SHARES OF BENEFICIAL INTEREST OFFERED BY THIS PROSPECTUS, NOR DOES IT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF ANY OFFER TO BUY THE SHARES OF BENEFICIAL INTEREST BY ANYONE IN ANY JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION IS NOT AUTHORIZED, OR IN WHICH THE PERSON MAKING SUCH OFFER OR SOLICITATION IS NOT QUALIFIED TO DO SO, OR TO ANY SUCH PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION. NEITHER THE DELIVERY OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME AFTER THE DATE HEREOF. HOWEVER, IF ANY MATERIAL CHANGE OCCURS WHILE THIS PROSPECTUS IS REQUIRED BY LAW TO BE DELIVERED, THE PROSPECTUS WILL BE AMENDED OR SUPPLEMENTED ACCORDINGLY.

TABLE OF CONTENTS

	PAGE

Prospectus Summary.....	1
Trust Expenses.....	11
Financial Highlights and Investment Performance.....	12
The Offer.....	16
Use of Proceeds.....	26
Investment Objective and Policies.....	26
Risk Factors.....	31
Investment Techniques.....	39
Management of the Trust.....	41
Description of the Trust.....	44
Portfolio Transactions and Brokerage.....	44
Net Asset Value.....	45
Dividends and Distributions.....	47
Taxation.....	49
Custodian, Administrator, Transfer Agent, Dividend Disbursing Agent, Registrar, And Subscription Agent.....	50
Legal Matters.....	51
Experts.....	51
Reports to Shareholders.....	51
Additional Information.....	51

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Special Note Regarding Forward-Looking Statements.....	51
Table of Contents of Statement of Additional Information.....	52
Financial Statements.....	53
Report of Independent Registered Public Accounting Firm.....	70

4,484,838 SHARES

H&Q LIFE SCIENCES
INVESTORS

ISSUABLE UPON EXERCISE OF
NON-TRANSFERABLE RIGHTS TO
SUBSCRIBE FOR SUCH SHARES

PROSPECTUS

August 17, 2006

H&Q LIFE SCIENCES INVESTORS
STATEMENT OF ADDITIONAL INFORMATION
AUGUST 17, 2006

H&Q Life Sciences Investors (the "Trust") is a diversified, closed-end, management investment company registered under the Investment Company Act of 1940, as amended (the "Investment Company Act"). The Trust's investment objective is to seek long-term capital appreciation by investing primarily in equity and related securities (including securities subject to legal or contractual restrictions as to resale) of U.S. and foreign companies principally engaged in the development, production or distribution of products or services related to scientific advances in life sciences (including biotechnology, pharmaceuticals, diagnostics, managed healthcare and medical equipment, hospitals, healthcare and information technology and services, devices, supplies and other healthcare-related subsectors), agriculture and environmental management ("Life Sciences Companies"). The Trust will invest primarily in securities of U.S. and foreign companies that are believed by the Investment Adviser to have significant potential for above-average, long-term growth in revenues and earnings. The Trust emphasizes investment in securities of emerging growth Life Sciences Companies, some of which may offer limited products or services or which are at the research and development stage with no marketable or approved products or technologies. The securities of most emerging growth Life Sciences Companies in which the Trust will invest are expected to be traded in the over-the-counter market. The Trust may also invest up to 40% of its net assets in securities subject to legal or contractual restrictions as to resale ("Restricted Securities"), including venture capital investments. Such

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

securities may be acquired in connection with venture capital opportunities, as well as in private placements of public companies. No assurance can be given that the Trust will achieve its investment objective. The Trust's investment adviser is Hambrecht & Quist Capital Management, LLC (the "Investment Adviser").

This Statement of Additional Information ("SAI") is not a prospectus, but should be read in conjunction with the Prospectus for the Trust dated August 17, 2006 (the "Prospectus"). This SAI does not include all information that a prospective investor should consider before purchasing shares of beneficial interest ("Shares") of the Trust, and investors should obtain and read the Prospectus prior to purchasing Shares. A copy of the Prospectus may be obtained without charge, by calling the Information Agent at (800) 870-0126. This SAI incorporates by reference the entire Prospectus.

The Prospectus and this SAI omit certain of the information contained in the Trust's registration statement filed with the Securities and Exchange Commission (the "Commission"). Information about the Trust can be reviewed and copied at the Commission's Public Reference Room in Washington, DC. Call (202) 942-8090 for information on the operation of the Public Reference Room. This information is also available in the Commission's Internet site at <http://www.sec.gov>, and copies may be obtained upon payment of a duplicating fee by writing the Public Reference Section of the Commission, Washington, DC 20549-0102.

TABLE OF CONTENTS

Additional Information About Investment, Investment Techniques and Risks.....	2
Investment Restrictions.....	10
Trustees and Officers.....	11
Compensation Table for the Fiscal Year Ended September 30, 2005.....	18
The Trust.....	19
Investment Adviser and Investment Advisory Agreement.....	21
Proxy Voting Policies and Procedures.....	25
Code of Ethics.....	25
Net Asset Value.....	26
Portfolio Transactions and Brokerage.....	27
Quarterly Distribution Policy.....	30
Tax Matters.....	31
Administrator, Custodian and Transfer Agent, Dividend Disbursing Agent and Registrar.....	36
Financial Statements.....	37
Appendix A--- Trustee and Investment Adviser Proxy Voting Policies and Procedures.....	38

ADDITIONAL INFORMATION ABOUT INVESTMENTS, INVESTMENT TECHNIQUES AND RISKS

Some of the different types of securities in which the Trust may invest, subject to its investment objective, policies and restrictions, are described in the Prospectus under "Investment Objective and Policies" and "Risk Factors." Additional information concerning certain of the Trust's investments, investment techniques and investment restrictions is set forth below.

The Trust may utilize the following investment practices:

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

SHORT SALES

In furtherance of its objective of capital appreciation, the Trust may effect short sales of any securities that it has the authority to purchase, subject to the limitation that the Trust will not effect a short sale if, as a result of such sale, the current market value of securities sold short would exceed 25% of the Trust's net assets. Short sales are transactions in which the Trust sells a security it does not own in anticipation of an expected decline in the price of that security. In such a transaction, the Trust must borrow the security to make delivery to the buyer. The Trust is obligated to replace the borrowed security and may realize a gain if it purchases the security for replacement at a lower price. However, the price at which the Trust purchases the security may be more or less than the price at which the security was sold. The Trust will incur a loss as a result of a short sale if the cost of purchasing the borrowed security, and transaction and carrying costs associated with the short sale, are more than the amount realized from the short sale. Although the Trust's potential for gain as a result of a short sale is limited to the price at which it sold the security short less the cost of borrowing the security, its potential for loss is theoretically unlimited because there is no limit to the cost of replacing the borrowed security.

If the Trust borrows a security in order to enter into a short sale, the proceeds of the short sale will be retained by a broker, as security for the borrowing to the extent necessary to meet margin requirements, until the short position is closed out. The Trust is also required to pay to the lender of the security the amount of any dividends or interest paid on the borrowed security. To borrow the security, the Trust also may be required to pay a premium, which would increase the cost of the security sold short. The amount of any gain will be decreased, and the amount of any loss increased, by the amount of any premium or dividends or interest paid on the borrowed security that the Trust may be required to pay in connection with the short sale.

A short sale "against the box" is a transaction in which the Trust enters into a short sale of a security that the Trust owns or has the right to acquire at no additional cost. The proceeds of a short sale are held by a broker until the Trust delivers the security to close the short position, at which time the Trust will receive the net proceeds from the sale. A short sale "against the box" may be used to defer recognition for federal income tax purposes of any net gain or loss in the securities while the securities are subject to such a position. The diversification requirements applicable to the Trust to maintain its status as a regulated investment company under the federal income tax laws may limit the extent to which the Trust will be able to engage in short sales. See "Tax Matters."

When the Trust engages in short sales other than "against the box," the Trust will "cover" its position. For example, the Trust may cover by holding a call option on the security sold short having a strike price no higher than the price at which the security was sold or, the Trust may maintain in an account with its custodian a segregated amount of cash or U.S. Government Securities, high quality debt obligations or other liquid securities equal to the excess of (1) the market value of the securities sold short at the time they were sold short, over (2) any cash, U.S. Government Securities, high quality debt obligations or other liquid securities required by the broker to be deposited as collateral in connection with the short sale (not including the proceeds from the short sale). Until the borrowed security is replaced, the Trust will maintain this account at a level so that the amount deposited in the account, plus the collateral deposited with the broker, will equal the current market value of the securities sold short, but not less than the market value of the securities at the time they were sold short.

WHEN-ISSUED AND DELAYED DELIVERY TRANSACTIONS

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

The Trust may purchase securities on a "when issued" basis or a "delayed delivery" basis. "When-issued" securities are securities whose terms are available and for which a market exists, but which are not available for immediate delivery. "Delayed delivery" transactions are those in which the Trust purchases a security but settlement of the transaction is to occur after the customary settlement date. The Trust will enter into such transactions for the purpose of acquiring securities that it wishes to purchase but that are not currently available for purchase. The Trust may dispose of a commitment to purchase prior to settlement. However, the Trust does not intend to make such purchases for speculative purposes. When such transactions are negotiated, the purchase price is fixed at the time the commitment is made, but delivery and payment for the securities take place at a later date. During the period between commitment and settlement, no payment is made for the securities purchased, and no interest or dividends accrue to the Trust. However, the securities are subject to market fluctuation, and the value at settlement may be less than the purchase price. While awaiting settlement, the Trust will cover its position consistent with Commission guidelines. For example, the Trust could maintain with in segregated account cash, U.S. Government Securities, high quality debt obligations or other liquid securities having a value at least equal to its purchase commitments. The commitment to purchase a security for which payment will be made on a future date may be deemed a separate security and involves a risk of loss if the security declines prior to the settlement date, which risk is in addition to the risk of decline of the Trust's other assets.

REPURCHASE AGREEMENT

A repurchase agreement is an arrangement under which the Trust acquires a security subject to the obligation of the seller to repurchase and the Trust to resell such security at a fixed time and price (representing the Trust's cost and interest). It is the Trust's present intention to enter into repurchase agreements for a relatively short period (usually not more than one week) only with commercial banks and registered broker-dealers and only with respect to U.S. Government Securities and money market instruments. The Repurchase agreements may also be viewed as loans made by the Trust, which are collateralized by the securities subject to repurchase. The Trust intends to take possession of collateral, and the Investment Adviser will monitor repurchase transactions to ensure that the value of the underlying securities will at all times be at least equal to the total amount of the repurchase obligation, including the interest factor. If the seller defaults the Trust could realize a loss on the sale of the underlying security to the extent that the proceeds of sale, including accrued interest, are less than the resale price provided in the agreement, including interest. In addition, if the seller should be involved in bankruptcy or insolvency proceedings, the Trust may incur delay and costs in selling the underlying security or may suffer a loss of principal and interest if the Trust is treated as an unsecured creditor and required to return the underlying collateral to the seller. The Trust may not enter into repurchase agreements with respect to more than 10% of its net assets.

LOANS OF PORTFOLIO SECURITIES

In an attempt to make productive use of its assets, the Trust may lend its portfolio securities, subject to the limitation that the Trust will not lend a security if, as a result of such loan, all securities then subject to loans would exceed 20% of the Trust's net assets. Under applicable regulatory requirements (which are subject to change), the loan collateral must, on each business day, be at least equal to the value of the loaned securities and must consist of cash, bank letters of credit or U.S. Government Securities. To be acceptable as collateral, letters of credit must obligate a bank to pay amounts demanded by the Trust if the demand meets the terms of the letter. Such terms and the issuing bank must be satisfactory to the Trust. When the Trust lends a security, it continues to be entitled to receive any dividends or interest on

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

the loaned security and also receives one or more of: (i) a negotiated loan fee; (ii) interest on securities used as collateral for the loan; or (iii) interest on short-term debt securities purchased with the loan collateral. Either type of interest may be shared with the borrower of the security. The Trust may also pay reasonable finder's, custodian and administrative fees. The terms of the Trust's loans of securities must meet certain requirements under the Internal Revenue Code of 1986, as amended, such as providing that the Trust may terminate the loan upon no more than five days' notice, and must permit the Trust to reacquire loaned securities in time to vote on any important matter. The Trust will make such loans only to banks and dealers with which it may enter into repurchase agreements. If the borrower fails to return the loaned security, the Trust's risks include: (1) any costs in disposing of the collateral; (2) loss from a decline in value of the collateral to an amount less than 100% of the securities loaned; (3) being unable to exercise its voting or consent rights with respect to the security; (4) any loss arising from the Trust being unable to settle a sale of such securities in a timely manner; and (5) the inability of the Trust to reacquire the loaned securities.

HEDGING

In order to hedge against changes in the value of its portfolio securities, the Trust may from time to time engage in certain hedging strategies. The Trust will engage in hedging activities from time to time in the Investment Adviser's discretion, and may not necessarily be engaging in such activities when movements in the securities markets, foreign exchange rates, or interest rates that could affect the value of the assets of the Trust occur. The Trust's ability to pursue certain of these strategies may be limited by applicable regulations of the Commodity Futures Trading Commission ("CFTC") and the federal income tax requirements applicable to regulated investment companies.

Although the Trust believes that use of such strategies will benefit the Trust, if the Investment Adviser's judgment about the general direction of securities market movements, foreign exchange rates or interest rates is incorrect the Trust's overall performance could be poorer than if it had not pursued those strategies. Moreover, changes in the value of the instruments that the Trust purchases to hedge its portfolio securities may not correlate precisely with changes in the value of the portfolio securities the Trust is attempting to hedge. In addition, in situations where the Trust has insufficient cash, it may have to sell assets from its portfolio to meet margin requirements at a time when it may be disadvantageous to do so. The Trust's hedging activities may also result in a higher portfolio turnover rate and additional brokerage costs.

OPTIONS ON SECURITIES. The Trust may purchase and sell (or write) put or call options on any security in which it is permitted to invest or on any security the change in value of which has positive or negative correlation with the changes in value of the Trust's portfolio securities.

PURCHASING PUT AND CALL OPTIONS. By purchasing a call option on a security, the Trust will obtain the right to buy the securities underlying the option from its counterparty at a specified exercise price prior to or at the expiration of the option. The Trust might for example, purchase call options in anticipation of an increase in the price of the security. Conversely, when the Trust purchases a put option on a security it gives the Trust the right to sell the securities underlying the option to its counterparty at the exercise price prior to or at the expiration of the option. The Trust might for example, purchase put options in anticipation of a decline in the market value of securities in its portfolio (or which the Trust intends to or has the right to acquire).

In case of either put or call options that it has purchased, if the

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

option expires without being sold or exercised, the Trust will experience a loss in the amount of the option premium plus any related commissions.

WRITING PUT AND CALL OPTIONS. When the Trust sells (writes) put and call options, it receives a premium as the writer of the option. By selling (writing) a call option, the Trust will obligate itself to sell the securities underlying the option to its counterparty at the specified exercise price prior to or at the expiration of the option if it is assigned an exercise notice. If the price of the underlying securities at expiration of the option is below the exercise price, the Trust will retain the full amount of the option premium. That amount, less the commission paid for the option, provides a partial hedge against any decline that may have occurred in the Trust's portfolio securities. During the term of the option, however, a covered call writer has, in return for the premium on the option, given up the opportunity for capital appreciation above the exercise price of the option if the value of the underlying securities increases, but has retained the risk of loss should the price of the underlying security decline. Conversely, by selling (writing) a put option, the Trust obligates itself to buy the securities underlying the option from its counterparty at the exercise price prior to or at the expiration if it is assigned an exercise notice. Writing a put option constitutes a partial hedge against increasing prices of securities the Trust intends to purchase. If the price of the securities at the expiration of the option is higher than the exercise price, the Trust will retain the full amount of the option premium which provides a partial hedge against any increase in the price of securities which the Trust intends to purchase. A secured put writer, however, retains the risk of loss should the market value of the underlying security decline below the exercise price of the option, less the premium received on the sale of the option.

CLOSING PURCHASE OR SALE TRANSACTIONS. Prior to exercise or expiration, an option position can be terminated only by entering into a closing purchase or sale transaction. Closing purchase transactions are ordinarily effected to realize a profit on an outstanding call option, to prevent an underlying security from being called, to permit the sale of an underlying security or to enable another call option on the underlying security (with either a different exercise price or expiration date or both) to be written. If the Trust is not able to enter into a closing transaction or an offsetting position, it will be required to maintain the securities subject to the call, or the collateral underlying the put, even though it might not be advantageous to do so, until a closing transaction can be entered into or the option is exercised or expires.

The Trust's ability to close out its position as a writer of an option is dependent upon the existence of a liquid secondary market. There is no assurance that a liquid market will exist, particularly in the case of OTC options, since OTC options will generally be closed out only by entering into a closing transaction with a dealer. In the case of OTC options, the Trust is also subject to the credit risk associated with its counterparties.

STOCK INDEX OPTIONS. The Trust may purchase and sell (write) options on stock indices ("index options"). Index options are similar to options on securities except that, rather than taking or making delivery of securities underlying the option at a specified price upon exercise, an index option gives the holder the right to receive cash upon exercise of the option if the level of the stock index upon which the option is based is greater, in the case of a call, or less, in the case of a put, than the exercise price of the option.

The Trust will enter into transactions in index options for a number of reasons including, for example, to hedge against adverse price movements in the stock market generally or in particular market segments. If the Investment Adviser anticipates a general market decline, the Trust could purchase a stock index put option. If the expected market decline materialized, the resulting decrease in the value of the Trust's portfolio securities would be offset to the

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

extent of the increase in the value of the put option. If the Investment Adviser anticipates a market rise, the Trust may purchase a stock index call option to enable the Trust to participate in the rise until the Trust completes anticipated purchases of securities. Purchasing and selling stock index options may also enable the Investment Adviser to achieve changes in equity positions more efficiently. Stock index options involve risks similar to those associated with options on securities. Because exercises of stock index options are settled in cash, however, call writers such as the Trust cannot provide in advance for their potential settlement obligations by acquiring and holding the underlying securities.

FUTURES CONTRACTS AND OPTIONS ON FUTURES CONTRACTS

FUTURES CONTRACTS. The Trust may enter into contracts for the purchase or sale for future delivery (a "futures contract") of baskets of securities, financial indices, financial instruments or foreign currencies. The Trust would purchase or sell futures contracts to attempt to protect the value of its securities from market-wide price movements and fluctuations in interest or foreign exchange rates without actually buying or selling securities or foreign currency.

A "sale" of a futures contract (or a "short" futures position) means the assumption of a contractual obligation to deliver the securities or currency underlying the contract at a specified price at a specified future time. A "purchase" of a futures contract (or a "long" futures position) means the assumption of a contractual obligation to acquire the securities or currency underlying the contract at a specified price at a specified future time.

OPTIONS ON FUTURES CONTRACTS. Upon exercise of a call option, the Trust receives a long position in the underlying futures contract. As with the purchase of futures contracts, when the Trust is not fully invested it may purchase a call option on a futures contract to hedge against a market advance in which it would not otherwise participate. The purchase of a put option on a futures contract is similar in some respects to the purchase of protective put options on portfolio securities. Upon exercise of a put option, the Trust receives a short position in the underlying futures contract. For example, the Trust may purchase a put option on a futures contract to hedge the Trust's portfolio against the risk of declining securities values. The writing of a call option on a futures contract constitutes a partial hedge against declining prices of the components of the futures contract, whereas the writing of a put option on a futures contract constitutes a partial hedge against increasing prices of the financial instrument which is deliverable upon termination of the futures contracts. If the options expire unexercised, the Trust will retain the full amount of the option premium, which provides a partial hedge against any increase in the price of securities which the Trust intends to purchase. If a put or call option the Trust has written is exercised, the Trust will incur a loss which will be reduced by the amount of the premium it receives.

MARGIN REQUIREMENTS. At the time a futures contract is purchase or sold, the Trust must allocate cash or securities as a deposit payment ("initial margin"). It is expected that the initial margin on U.S. exchanges may range from approximately 3% to approximately 15% of the value of the securities or commodities underlying the contract. Under certain circumstances, however, such as periods of high volatility, the Trust may be required by an exchange to increase the level of its initial margin payment. Additionally, initial margin requirements may be increased generally in the future by regulatory action. An outstanding futures contract is valued daily and the payment in cash of "variation margin" may be required, a process known as "mark to the market".

REGULATORY LIMITATIONS ON THE USE OF FUTURES CONTRACTS AND OPTIONS ON FUTURES CONTRACTS. Regulations of the CFTC applicable to the Trust currently require that all of the Trust's futures and options on futures transactions

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

constitute bona fide hedging transactions or be undertaken incidental to the Trust's activities in the securities markets. In accordance with CFTC regulations, the Trust may not purchase or sell futures contracts or options thereon if immediately thereafter the sum of the amounts of initial margin deposits on the Trust's existing futures and options on futures positions and premiums paid for options on futures would exceed 5% of the fair market value of the Trust's total assets. The Investment Adviser reserves the right to comply with such different standard as may be established by CFTC rules and regulations with respect to the purchase or sale of futures contracts or options thereon.

CONSIDERATIONS CONCERNING FUTURES CONTRACTS AND OPTIONS ON FUTURES CONTRACTS. Futures contracts entail special risks. The ordinary spreads between values in the cash and futures markets, due to differences in the character of these markets, are subject to distortions relating to (1) investor's obligations to meet additional variation margin requirements, (2) decisions to make or take delivery, rather than entering into offsetting transactions and (3) the difference between margin requirements in the securities markets and margin deposit requirements in the futures markets. The possibility of such distortion means that a correct forecast of general market, foreign exchange rate or interest rate trends by the Investment Adviser may still not result in a successful transaction. The Trust's ability to establish and close out positions in futures contracts and options on futures contracts will be subject to the development and maintenance of a liquid market. Although the Trust generally will purchase or sell only those futures contracts and options thereon for which there appears to be a liquid market, there is no assurance that a liquid market on an exchange will exist for any particular futures contract or option thereon at any particular time. Under certain circumstances, exchanges may establish daily limits in the amount that the price of a futures contract or related options contract may vary either up or down from the previous day's settlement price. Once the daily limit has been reached in a particular contract, no trades may be made that day at a price beyond that limit.

EXCHANGE RATE RISK

The Trust may enter into forward foreign currency exchange contracts ("forward contracts") and may purchase and sell (or write) exchange-traded or OTC options on currencies, foreign currency futures contracts and options on foreign currency futures contracts to protect against a decline in the U.S. Dollar equivalent value of its foreign currency portfolio securities or the payments thereon that may result from an adverse change in foreign currency exchange rates. The accurate projection of short-term currency market movements is extremely difficult, and the successful execution of a short-term hedging strategy is highly uncertain.

FORWARD CONTRACTS. A forward contract obligates one party to purchase and the other party to sell a definite amount of a given foreign currency at some specified future date. In some circumstances the purchase or sale of appropriate forward contracts may help offset declines in the U.S. Dollar equivalent value of the Trust's foreign currency denominated assets and income available for distribution to the Trust's shareholders that result from adverse changes in the exchange rate between the U.S. Dollar and the various foreign currencies in which the Trust's assets or income may be denominated. The U.S. Dollar equivalent value of the principal of and rate of return on foreign currency denominated securities will decline if the exchange rate of the U.S. Dollar rises in relation to that currency. Such declines could be partially or completely offset by an increase in the value of a forward contract on that foreign currency.

While the use of foreign currency forward contracts may protect the Trust against declines in the U.S. Dollar equivalent value of its assets, their use will reduce the possible gain from advantageous changes in the value of the U.S. Dollar against particular currencies in which their assets are denominated.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Moreover, the use of foreign currency forward contracts will not eliminate fluctuations in the underlying U.S. Dollar equivalent value of the prices of or rates of return on the assets held in the portfolio and the use of such techniques will subject the Trust to certain risks.

The foreign exchange markets can be highly volatile, subject to sharp price fluctuations. In addition, trading forward contracts can involve a degree of leverage. As a result, relatively small movements in the rates of exchange between the currencies underlying a contract could result in immediate and substantial losses to the Trust. Trading losses that are not offset by corresponding gains in assets being hedged could sharply reduce the value of the Trust's portfolio.

OPTIONS ON FOREIGN CURRENCIES. Similarly, the Trust may purchase and sell (or write) put and call options on foreign currencies to protect against a decline in the U.S. Dollar equivalent value of its portfolio securities or payments due thereon or a rise in the U.S. Dollar equivalent cost of securities that it intends to purchase. A foreign currency put option grants the holder the right, but not the obligation, at a future date to sell a specified amount of a foreign currency to its counterparty at a predetermined price. Conversely, a foreign currency call option grants the holder the right, but not the obligation, to purchase at a future date a specified amount of a foreign currency at a predetermined price. Where currency exchange rates do not move in the direction or to the extent anticipated, however, the Trust could sustain losses on transactions in foreign currency options which would require it to forego a portion or all of the benefits of advantageous changes in such rates.

As with options on securities or futures contracts, the Trust may write options on foreign currencies in order to receive a premium that may wholly or partially offset any declines in the value of its portfolio securities denominated in foreign currencies. When the Trust writes options on foreign currencies, the Trust also may be required to forego all or a portion of the benefits that might otherwise have been obtained from favorable movements in exchange rates.

FUTURES CONTRACTS AND OPTIONS ON FUTURES CONTRACTS ON FOREIGN CURRENCIES. Buyers and sellers of foreign currency futures contracts are subject to the same risks that apply to the use of futures generally. In addition, there are risks associated with foreign currency futures contracts and their use as hedging devices similar to those associated with options on foreign currencies described above. Further, settlement of a foreign currency futures contract must occur within the country issuing the underlying currency. Thus, the Trust must accept or make delivery of the underlying foreign currency in accordance with any U.S. or foreign restrictions or regulations regarding the maintenance of foreign banking arrangements by U.S. residents and may be required to pay any fees, taxes or charges associated with such delivery that are assessed in the country of the underlying currency.

Options on foreign currency futures contracts may involve certain additional risks. Trading options on foreign currency futures contracts is relatively new. The ability to establish and close out positions in such options is subject to the maintenance of a liquid secondary market. To mitigate this problem, the Trust will not purchase or write options on foreign currency futures contracts unless and until, in the Investment Adviser's opinion, the market for such options has developed sufficiently that the risks in connection with such options are not greater than the risks in connection with transactions in the underlying foreign currency futures contracts. Compared to the purchase or sale of foreign currency futures contracts, the purchase of call or put options thereon involves less potential risk to the Trust because the maximum amount at risk is the premium paid for the option (plus transaction costs). However, there may be circumstances when the purchase of a call or put option on a foreign currency futures contract would result in a loss, such as when there

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

is no movement in the price of the underlying currency or futures contract, whereas use of the underlying futures contract would not result in a loss.

COVERAGE REQUIREMENTS

All options on securities, securities indices, other indices and foreign currencies written by the Trust are required to be covered. When the Trust writes a call option during the life of the option, the Trust may own or have the contractual right to acquire the securities or foreign currency subject to the option, or may maintain with the Trust's custodian in a segregated account cash, U.S. Government Securities, other appropriate high quality liquid debt obligations or other liquid securities in an amount at least equal to the market value of the securities or foreign currency underlying the option or may utilize any other instrument or transaction consistent with Commission guidelines. When the Trust writes a put option, the Trust may maintain with the Trust's custodian in a segregated account cash, U.S. Government Securities, other appropriate high quality debt obligations or other liquid securities in an amount at least equal to the exercise price of the option or may utilize any other instrument or transaction consistent with Commission guidelines.

All futures and forward currency contracts purchased or sold by the Trust are also required to be covered. When the Trust purchases a futures or forward currency contract, the Trust will maintain with the Trust's custodian in a segregated account an amount of cash, U.S. Government Securities, other appropriate high quality liquid debt obligations or other liquid securities so that the amount so segregated, plus the amount of initial and variation margin held in the account of its broker, if applicable, equals the market value of the futures or forward currency contract or may utilize any other instrument or transaction consistent with Commission guidelines.

When the Trust sells a futures or forward currency contract, during the life of the futures or forward currency contract, the Trust will own or have the contractual right to acquire the securities or foreign currency subject to the futures or forward currency contract, or will maintain with the Trust's custodian in a segregated account cash, U.S. Government Securities, other appropriate high quality liquid debt obligations or other liquid securities in an amount at least equal to the market value of the securities or foreign currency underlying the futures or forward currency contract or may utilize any other instrument or transaction consistent with Commission guidelines.

If the market value of the contract moves adversely to the Trust, or if the value of the securities in the segregated account declines, the Trust will be required to deposit additional cash or securities in the segregated account at a time when it may be disadvantageous to do so.

INVESTMENT RESTRICTIONS

The Trust has adopted certain fundamental restrictions, which, like its investment objective, may not be changed without the affirmative vote of the holders of a majority of the Trust's outstanding Shares. As used in this Statement of Additional Information, a "majority of the Trust's outstanding Shares" means the lesser of (i) 67% of the Shares represented at a meeting at which more than 50% of the outstanding Shares are represented or (ii) more than 50% of the outstanding Shares. The Trust may not:

1. With respect to 75% of its total assets, invest in securities of any one

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

issuer if immediately after and as a result of such investment more than 5% of the total assets of the Trust, taken at market value, would be invested in the securities of such issuer, or purchase more than 10% of the outstanding voting securities of any one issuer. These restrictions do not apply to investments in U.S. Government Securities.

2. Purchase or sell physical commodities or physical commodities contracts.

3. Purchase or sell real estate; provided that the Trust may invest in securities secured by real estate or interests therein or issued by companies which invest in real estate or interests therein.

4. Underwrite securities of other issuers, except to the extent that, in connection with the disposition of its portfolio securities, the Trust may be deemed an underwriter under federal or state securities laws.

5. Issue senior securities or borrow amounts in excess of 10% of its net assets at the time of borrowing, and then only from banks (except in the case of reverse repurchase agreements) as a temporary measure for extraordinary or emergency purposes or for the repurchase of its securities. The Trust will not repurchase its securities during periods when it has outstanding borrowings in excess of 5% of its net assets. The Trust will not borrow for investment purposes.

6. Make loans of money, which for the purposes of this restriction does not include the purchase of debt obligations in which the Trust may invest consistent with its investment objective and policies. The Trust reserves the authority to enter into repurchase agreements and to make loans of its portfolio securities to qualified institutional investors, brokers, dealers, banks or other financial institutions, so long as the terms of the loans are not inconsistent with the requirements of the Investment Company Act. Such loans of portfolio securities may not exceed an aggregate amount of 20% of the Trust's net assets.

7. Purchase securities of other investment companies, if (a) more than 10% of its total assets would be invested in securities of other investment companies, (b) more than 5% of its total assets would be invested in the securities of any one investment company, or (c) the Trust would own more than 3% of any other investment company's securities.

8. Invest less than 25% of its net assets in securities of Life Sciences Companies in the healthcare industry, except that, during periods in which the Investment Adviser believes the healthcare industry is affected by adverse economic conditions, the Trust may temporarily have less than 25% of the value of its net assets so invested.

Except as otherwise noted, all percentage limitations set forth above apply immediately after a purchase and a subsequent change in the applicable percentage resulting from market fluctuations does not require elimination of any security from the portfolio. For purposes of the investment restriction that prohibits the Trust from purchasing more than 10% of the outstanding voting securities of any issuer indicated in item number 1 above, the Board of Trustees has determined that for purposes of that restriction, the Trust will consider outstanding voting securities of an issuer to include any security of the issuer that entitles the owner or holder to vote for the election of directors of the issuer (a "voting security") and any other outstanding security of the issuer that is exercisable for or convertible into a voting security within 60 days from the date of the calculation.

TRUSTEES AND OFFICERS

The Trust's Declaration of Trust provides that the Trust will indemnify

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Trustees and officers and may indemnify employees and agents of the Trust against liabilities and expenses incurred in connection with claims or litigation in which they may be involved because of their offices with the Trust. However, nothing in the Declaration of Trust or the By-laws of the Trust protects or indemnifies a Trustee, officer, employee or agent against any liability to which he would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of his office.

The names of the Trustees and officers of the Trust, their addresses, age and principal occupations during the past five years, and, in the case of the Trustees, their positions with certain other organizations and publicly-held companies, are provided in the tables below. Trustees that are deemed "interested persons" (as that term is defined in Section 2(a)(19) of the Investment Company Act) of the Trust or the Investment Adviser are included in the table titled "Interested Trustees." Trustees who are not interested persons as described above are referred to as "Independent Trustees". The Trust and H&Q Healthcare Investors ("HQH"), another closed-end investment company advised by the Investment Adviser, are the only two portfolios in the Fund Complex.

TRUSTEES

NAME, ADDRESS (1) AND AGE	POSITION(S) HELD WITH TRUST, TERM OF OFFICE (2) AND LENGTH OF TIME SERVED	PRINCIPAL OCCUPATION(S) DURING PAST 5 YEARS AND OTHER DIRECTORSHIPS HELD
INDEPENDENT TRUSTEES:		
Lawrence S. Lewin Age:68	Trustee (since 1992) and Chairman (since 2000)	Executive Consultant (since 1999) of The Lewin Group (healthcare public policy and management consulting), a subsidiary of Quintiles Transnational Corp.; Director (since 2003) of Medco Health Solutions, Inc.; Director (since 2001) of CardioNet, Inc.(mobile cardiac outpatient telemetry); Director (since 2005) of Care Fusion (provides solutions for patient care providers) and Director (since 1984) of Intermountain Healthcare (non-profit organization).
Robert P. Mack Age:70	Trustee (since 1992)	Orthopedic Surgeon at Orthopedic Associates of Aspen (since 2000).

NAME, ADDRESS (1) AND AGE	POSITION(S) HELD WITH TRUST, TERM OF OFFICE (2) AND LENGTH OF TIME SERVED	PRINCIPAL OCCUPATION(S) DURING PAST 5 YEARS AND OTHER DIRECTORSHIPS HELD
Eric Oddleifson	Trustee (since 1992)	Self-employed Consultant (since

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Age:71			November 2005); Investment Committee Chair (from 2003-2005) and Partner (from 1997-2003) of GMO Renewable Resources LLC (timber investment management).
Oleg M. Pohotsky Age:59	rustee (since 2000)	T	Self-employed Financial Consultant (since 2002). Senior Vice President (from 1991-2001) of FAC/Equities, a division of First Albany Corporation (investment bank).
Uwe E. Reinhardt, Ph.D. Age:68	rustee (since 1992)	T	rofessor of Economics (since 1968) at Princeton University; Director (since P000) of Triad Hospitals, Inc.; 2irector of Boston Scientific (since D002); Director of Amerigroup, Inc. 2since 2002); Director of Duke (niversity (since 2001); Director of Uhe Duke University Health System Tsince 2001) and Director of the (ational Bureau of Economic Research Nsince 2002).
Lucinda Stebbins, CPA Age: 60	rustee (since 2006)		(elf-employed Financial Consultant Ssince 2004); Director of Deutsche (sset Management (2002-2004); Senior Aice President Scudder Investments V2000-2002).
Henri A. Termeer Age:60	rustee (since 1992)	T	(hairman (since 1988), Chief Executive fficer (since 1985) and President since 1983) of Genzyme Corporation human healthcare products); Director Csince 1987) of ABIOMED, Inc.; Director O1996-2002) of Diaqirl.
		T	((((

INTERESTED TRUSTEES:

NAME, ADDRESS (1) AND AGE	POSITION(S) HELD WITH TRUST, TERM OF OFFICE (2) AND LENGTH OF TIME SERVED	PRINCIPAL OCCUPATION(S) DURING PAST 5 YEARS AND OTHER DIRECTORSHIPS HELD
Daniel R. Omstead, Ph.D. (3) Age:53	President (since 001); Trustee (since 003)	President of HQH and HQL (since 2001); Trustee of HQH and HQL (since 2003); President, Chief Executive Officer and Managing Member of Hambrecht & Quist Capital Management LLC (since 2002); President and Chief Executive Officer (2001-2002) and Managing Director

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

	(2000-2002) of Hambrecht & Quist Capital Management, Inc.; Director (since 2003) of Concentric Medical, Inc.; President and Chief Executive Officer (from 1998-2000) of Replenogenesis, Inc. (biotech company).
2	
2	

(1) The address for each Trustee is c/o the Trust at the Trust's address as set forth above. (2) Each Trustee currently is serving a three year term. (3) Trustee considered to be an "interested person" within the meaning of the Investment Company Act of 1940, as amended (the "1940 Act") through position or affiliation with Hambrecht & Quist Capital Management, LLC, the Trust's investment adviser. Trustee also serves as Executive Officer. Each Officer serves in such capacity for an indefinite period of time at the pleasure of the Trustees.

EXECUTIVE OFFICERS WHO ARE NOT TRUSTEES

NAME, ADDRESS (1) AND AGE	POSITION(S) HELD WITH TRUST, TERM OF OFFICE (2) AND LENGTH OF TIME SERVED	PRINCIPAL OCCUPATION(S) DURING PAST 5 YEARS AND OTHER DIRECTORSHIPS HELD
Kathleen M. Eckert Age:39	Chief Compliance Officer (since 2004); Treasurer and Secretary (since 2005)	Chief Compliance Officer of Hambrecht & Quist Capital Management, LLC (since October 2004); Chief Compliance Officer (since October 2004), Treasurer and Secretary (since February 2005) of HQH and HQL (since October 2004); Senior Vice President of Ivy Mackenzie Services Corp. (mutual fund distributor and administrator), from June 2002 to January 2004. Chief Compliance Officer of Mackenzie Investment Management, Inc. from June 2002 to June 2003. Director of Fund Administration of Mackenzie Investment Management, Inc. from 1999 to June 2003.
	O T S	

(1) The address for each Executive Officer is c/o the Trust at the Trust's address as set forth above.

(2) Each Officer serves in such capacity for an indefinite period of time at the pleasure of the Trustees.

OWNERSHIP OF SECURITIES

As of March 15, 2006, the Trust's Trustees and executive officers, as a group, beneficially owned less than 1% of the Trust's outstanding Shares. The information as to beneficial ownership of securities which appears below is based on statements furnished to the Trust by its Trustees and executive

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

officers.

To the knowledge of the Trust, as of August 7, 2006, there were no control persons of the Trust and no persons were known to own, either beneficially or of record, 5% or more of the Shares of the Trust.

As of March 15, 2006, the dollar range of equity securities owned beneficially by each Trustee in the Trust and in any registered investment companies overseen by the Trustee within the same family of investment companies as the Trust is as follows:

INDEPENDENT TRUSTEES

NAME OF DIRECTOR	DOLLAR RANGE OF EQUITY SECURITIES IN THE TRUST	AGGREGATE DOLLAR EQUITY SECURITI REGISTERED INV COMPANIES OVERSEEN IN FAMILY OF IN COMPANIE
Lawrence S. Lewin	\$10,0001-\$50,000	\$50,001-\$100,000
Robert P. Mack, M.D.	None	\$50,001-\$100,000
Eric Oddleifson	\$50,001-\$100,000	Over \$100,000
Oleg M. Pohotsky	None	None
Uwe E. Reinhardt, Ph.D.	\$1-\$10,000	\$10,001-\$50,000
Lucinda H. Stebbins, CPA	None	None
Henri A. Termeer	None	None

INTERESTED TRUSTEES

NAME OF DIRECTOR	DOLLAR RANGE OF EQUITY SECURITIES IN THE TRUST	AGGREGATE DOLLAR EQUITY SECURITI REGISTERED INV COMPANIES OVERSEEN IN FAMILY OF IN COMPANIE
Daniel R. Omstead, Ph.D.	\$50,001-\$100,000	Over \$100,000

Dr. Omstead and Ms. Eckert serve as executive officers of the Trust. As of December 31, 2005, the executive officers of the Trust beneficially owned 3,999 Shares of the Trust, or less than 1% of the Shares outstanding on that date.

STANDING COMMITTEES

AUDIT COMMITTEE. The Trust has an Audit Committee comprised solely of Trustees who are not "interested persons" (as that term is defined in Section 2(a)(19) of the Investment Company Act) of the Trust or the Investment Adviser and who are "independent" as defined in the New York Stock Exchange ("NYSE") Listing Standards (each an "Independent Trustee"). The Trust's Board of Trustees has adopted a written charter for the Audit Committee. The principal purpose of the Trust's Audit Committee is to assist the Board of Trustees in fulfilling its responsibility to oversee the integrity of the Trust's financial statements and

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

the Trust's compliance with legal and regulatory requirements to oversee management's conduct of the Trust's financial reporting process, including reviewing the financial reports and other financial information provided by the Trust, the Trust's systems of internal accounting and financial controls and the annual independent audit process.

For the Trust, the Audit Committee's role is one of oversight, and it is recognized that the Trust's management is responsible for preparing the Trust's financial statements and that the outside auditor is responsible for auditing those financial statements. Although the Audit Committee member must be financially literate and one member must have accounting or financial management expertise (as determined by the Board of Trustees in its business judgment), Audit Committee members are not professionally engaged in the practice of accounting or auditing and are not experts in the fields of accounting or auditing, including with respect to auditor independence. Audit Committee members rely, without independent verification, on the information provided to them and on the representations made by management and the Trust's independent public accountants.

The members of the Trust's Audit Committee are Messrs. Oddleifson, Pohotsky, Reinhardt and Ms. Stebbins. Mr. Pohotsky is the Chairman of the Trust's Audit Committee. The Trust's Audit Committee held five meetings during the fiscal year ended September 30, 2005.

GOVERNANCE COMMITTEE. The Trust has a Governance Committee comprised solely of Independent Trustees who are "independent" as defined in the NYSE Listing Standards. The Trust's Board of Trustees has adopted a written charter for the Governance Committee. The Trust's Governance Committee's mission under its charter is to review, evaluate, and enhance the effectiveness of the Trust's Board of Trustees in its role in governing the Trust and to oversee management of the Trust in accordance with the Corporate Governance Guidelines, which have been adopted by the Trust's Board of Trustees.

The Trust's Governance Committee shall review, discuss and make recommendations to the Board of Trustees relating to those issues that pertain to the effectiveness of the Board of Trustees in carrying out its responsibilities in governing each Trust and overseeing each Trust's management. The members of the Trust's Governance Committee are Messrs. Lewin, Termeer, Dr. Mack and Ms. Stebbins. Mr. Lewin is the Chairman of the Trust's Governance Committee. The Trust's Governance Committee met twice during the fiscal year ended September 30, 2005.

NOMINATING COMMITTEE. The Trust has a Nominating Committee comprised solely of Independent Trustees who are "independent" as defined in the NYSE Listing Standards. The Trust's Board of Trustees has adopted a written charter for the Nominating Committee. The Nominating Committee charter is not available on the Trust's website, but was included as Exhibit A to the Trust's Joint Proxy dated May 10, 2006.

The charter of the Nominating Committee provides that each prospective trustee candidate have a college degree or equivalent business experience, and that each candidate is not serving in a similar capacity on the board of a registered investment company which (i) is not sponsored or advised by the Trust's investment adviser or its affiliates and (ii) the Board in its discretion has determined to be competitive with the Fund taking into account such registered investment company's investment mandate. The Trust's Nominating Committee may also take into account other factors when considering and evaluating potential trustee candidates, including but not limited to: (i) availability and commitment to attend meetings and perform responsibilities of the Board; (ii) relevant industry and related experience; (iii) educational background; (iv) financial expertise; (v) the candidate's ability, judgment and expertise; and (vi) the overall diversity of the Board's composition.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

The Trust's Nominating Committee may identify prospective trustees from any reasonable source, including, but not limited to, the consultation of third-party trustee search services. The Trust's Nominating Committee will consider potential trustee candidates recommended by shareholders, provided that the proposed candidates (i) satisfy any minimum qualifications of the Trust for its trustees; (ii) are not "interested persons" (as that term is defined in Section 2(a)(19) of the 1940 Act) of the Trust or the Investment Adviser; and (iii) are "independent" as defined in the NYSE Listing Standards. In order to be evaluated by the appropriate Committee, trustee candidates recommended by shareholders must also meet certain eligibility requirements as set out in the Committee's Charter. Other than those eligibility requirements, the Committee shall not evaluate shareholder trustee nominees in a different manner than other nominees. The standard of the Committee is to treat all equally qualified nominees in the same manner.

All shareholder recommended nominee submissions must be received by the Trust by the deadline for submission of any shareholder proposals which would be included in the Trust's proxy statement for the next annual meeting of the Trust. Each nominating shareholder or shareholder group must meet the requirements stated in the Nominating Committee Charter. A nominating shareholder or shareholder group may not submit more than one nominee per year. When nominating a trustee candidate, shareholders must include in their notice to the Trusts' Secretary: (i) the shareholder's contact information; (ii) the trustee candidate's contact information and the number of fund shares owned by the proposed candidate; (iii) all information regarding the candidate that would be required to be disclosed in solicitations of proxies for elections of trustees required by Regulation 14A of the Securities Act of 1934, as amended; and (iv) a notarized letter executed by the trustee candidate, stating his or her intention to serve as nominee and be named in the Trust's proxy statement, if nominated by the Board of Trustees, and to be named as a trustee if so elected. Once a nomination has been timely received in proper form, the nominee will be asked to complete an eligibility questionnaire to assist the Trust in assessing the nominee's qualifications as a potential Independent Trustees and as someone who is "independent" under the NYSE Listing Standards. The Nominating Committee will make such determinations in its sole discretion and such determinations shall be final.

The members of each Trust's Nominating Committee are Messrs. Lewin and Termeer and Dr. Mack. Mr. Lewin is the Chairman of each Trust's Nominating Committee. The Trust's Nominating Committee met one time during the fiscal year ended September 30, 2005.

VALUATION COMMITTEE. The Board has delegated to the Trust's Valuation Committee general responsibility for determining, in accordance with the Trust's valuation procedures, the value of assets held by the Trust on any day on which the net asset value per share is determined. The Valuation Committee may appoint, and has appointed, a Sub-Committee made up of employees and officers of the Investment Adviser, to deal in the first instance with day to day valuation decisions, subject to oversight by the Valuation Committee. The Valuation Committee shall meet as often as necessary to ensure that each action taken by the Sub-Committee is reviewed within approximately a calendar quarter of the occurrence. In connection with its review, the Valuation Committee shall ratify or revise the pricing methodologies authorized by the Sub-Committee since the last meeting of the Valuation Committee. The Valuation Committee is charged with the responsibility of determining the fair value of the Trust's securities or other assets in situations set forth in the Trust's valuation procedures.

The members of the Trust's Valuation Committee are Messrs. Oddleifson and Pohotsky and Dr. Mack. The Trust's Valuation Committee held four meetings during the fiscal year ended September 30, 2005.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

QUALIFIED LEGAL COMPLIANCE COMMITTEE. The Trust has a Qualified Legal Compliance Committee ("QLCC") comprised solely of Independent Trustees. The Trust's Board of Trustees has adopted a written charter for the QLCC. The principal purpose of the Trust's QLCC is to review and respond to reports of Evidence of a Material Violation (as defined in the QLCC charter). Reporting Evidence of a Material Violation is required under the Standards of Professional Conduct for Attorneys adopted by the Commission under the Sarbanes-Oxley Act of 2002 (the "Standards"). Under the Standards, if an attorney appearing and practicing before the Commission in the representation of an issuer, such as the Trust, becomes aware of Evidence of a Material Violation by the issuer or by any officer, trustee, employee or agent of the issuer, the Standards provide for the attorney to report such evidence to the issuer's QLCC forthwith. In discharging its role, the QLCC is granted the power to investigate any Evidence of a Material Violation brought to its attention with full access to all books, records, facilities and personnel of the Trust and the power to retain outside counsel, auditors or other experts for this purpose.

The members of the Trust's QLCC are Messrs. Lewin, Oddleifson and Pohotsky. Mr. Pohotsky is the Chairman of the Trust's QLCC. The Trust's QLCC did not meet during the fiscal year ended September 30, 2005.

COMPENSATION OF TRUSTEES

For the fiscal year ended September 30, 2005, the Trust paid its Independent Trustees a retainer fee of \$20,000. The Trust currently pays each Independent Trustee \$500 for each Board and Committee meeting attended in person and \$250 for each Board and Committee meeting attended by phone. The Chairman of the Board of Trustees, the Chairman of the Audit Committee and the Chairman of the Valuation Committee of the Trust each receives an additional annual fee of \$2,500. Currently, the Chairman of the Nominating Committee and the Chairman of the Governance Committee receives an additional fee of \$1,250. Independent Trustees are also reimbursed for travel expenses incurred in connection with attending such meetings. For the fiscal year ended September 30, 2005, the Independent Trustees as a group received \$155,958 for fees and reimbursed expenses. The Trust did not pay any additional compensation to the Trustees for the fiscal year ended September 30, 2005. The Trust has entered into a Services Agreement (the "Agreement") with the Investment Adviser. Pursuant to the terms of the Agreement, the Trust reimburses the Investment Adviser for a portion of payment of salary and provision of benefits to the Trust's Chief Compliance Officer. During the year ended September 30, 2005 these payments amounted to \$66,017. Trustees and officers of the Trust other than the Chief Compliance Officer, who hold positions with the Investment Adviser, receive indirect compensation from the Trust in the form of the investment advisory fee paid to the Investment Adviser. The following table sets forth information regarding compensation of Trustees by the Trust for the year ended September 30, 2005, but does not include expenses.

COMPENSATION TABLE
FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2005

NAME OF TRUSTEE	AGGREGATE COMPENSATION FROM TRUST	PENSION OR RETIREMENT BENEFITS ACCRUED AS PART OF TRUST EXPENSE	ESTIMATED ANNUAL BENEFITS UPON RETIREMENT	F

INDEPENDENT TRUSTEES:

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Lawrence S. Lewin	\$	27,000	N/A	N/A	\$
Robert P. Mack, M.D.	\$	24,250	N/A	N/A	\$
Eric Oddleifson	\$	27,000	N/A	N/A	\$
Oleg M. Pohotsky	\$	31,000	N/A	N/A	\$
Uwe E. Reinhardt, Ph.D.	\$	22,000	N/A	N/A	\$
Henri A. Termeer	\$	22,000	N/A	N/A	\$
INTERESTED TRUSTEE:					
Daniel R. Omstead, Ph.D.	\$	0	N/A	N/A	\$

THE TRUST

The Trust's capitalization consists of an unlimited number of Shares, \$.01 par value. Each Share represents an equal proportionate beneficial interest in the Trust and, when issued and outstanding, will be fully paid and non-assessable by the Trust. Upon any liquidation of the Trust, Shareholders will be entitled to share pro rata in the net assets of the Trust available for distribution after paying or adequately providing for the payment of all liabilities. The Trust will send annual and semi-annual financial statements to Shareholders and may also issue more abbreviated interim reports to update Shareholders on a quarterly basis. The Trust will hold annual meetings of its Shareholders in accordance with the provisions of the Trust's By-laws and the rules of the New York Stock Exchange ("NYSE").

Shareholders are entitled to one vote for each whole Share held and a proportionate fractional vote for each fractional Share held. The Trust's Shares do not have cumulative voting rights, which means that the holders of more than 50% of the Shares of the Trust voting for the election of Trustees can elect all of the Trustees, and, in such event, the holders of the remaining Shares will not be able to elect any Trustees. The Trust has a staggered Board, whereby one class of Trustees is elected each year.

The Trust is an entity of the type commonly known as a "Massachusetts business trust." Under Massachusetts law, shareholders of such a trust under certain circumstances may be determined to be personally liable as partners for the Trust's obligations. However, the Trust's Declaration of Trust contains an express disclaimer of shareholder liability for the acts or obligations of the Trust and provides for indemnification and reimbursement of expenses out of the Trust's property for any shareholder held personally liable for the obligations of the Trust. Thus, the risk of a shareholder incurring financial loss on account of a Trust liability is limited to circumstances in which the Trust is unable to meet its obligations from the liquidation of its portfolio investments.

The overall management of the Trust is vested in the Board. The Board approves all significant agreements between the Trust and persons or companies furnishing services to it, including the Trust's agreements with its Investment Adviser, Administrator, Custodian, any foreign sub-custodians, Registrar and Transfer Agent. The management of the day-to-day operations of the Trust is delegated to its officers and to the Investment Adviser, subject always to the investment objective and policies of the Trust and to general supervision by the Board.

In addition, the Declaration of Trust requires the affirmative vote or consent of the holders of 75% of the Shares of the Trust to authorize certain transactions with a person or entity that is directly, or indirectly through

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

affiliates, the beneficial owner of 5% or more of the outstanding Shares of the Trust unless the Board takes certain actions to approve such a transaction. These provisions could make it more difficult to change the management of the Trust and could have the effect of depriving Shareholders of an opportunity to sell their Shares at a premium over prevailing market prices by discouraging a third party from seeking to obtain control of the Trust in a tender offer or similar transaction. See "Risk Factors -- Certain Provisions of the Declaration of Trust" in the Trust's Prospectus.

REPURCHASE OF SHARES AND TENDER OFFERS

The Trust is a closed-end, management investment company and as such its Shareholders do not, and will not, have the right to redeem their Shares of the Trust. The Trustees, however, intend to consider, from time to time, but not less frequently than annually, the desirability of open market purchases or tender offers. Any such repurchases will be made in accordance with the applicable provisions of the Investment Company Act and Massachusetts law in open market transactions. Shares repurchased by the Trust will be held in its treasury. Although the Trust has no present intention of doing so, it reserves the right to incur debt to finance such repurchases or tender offers, provided that it will not repurchase securities during the periods when it has outstanding borrowings in excess of 5% of its net assets. See "Investment Restrictions." Interest on any borrowings to finance Share repurchase transactions will increase the Trust's expenses and will reduce the Trust's net income. There can be no assurance that Share repurchases, if any, will cause the Shares to trade at a price equal to or in excess of their net asset value. Nevertheless, the possibility that a portion of the Trust's outstanding Shares may be the subject of repurchases may reduce the spread between market price and net asset value that might otherwise exist. The Trust may not repurchase Shares except (1) on a securities exchange and after notification to Shareholders of its intent to purchase Shares within the six months preceding the purchase, (2) pursuant to a tender offer to all Shareholders, or (3) as otherwise permitted by the Commission.

The Shares of the Trust will trade in the open market at a price which will be a function of several factors, including their supply, demand, investment performance and yield. The shares of closed-end investment companies generally sell at market prices varying from their net asset value ("NAV") and such shares frequently trade at a discount to NAV, but in some cases trade at a premium. The market price of the Shares will be determined by factors including trading volume of such Shares, general market and economic conditions and other factors beyond the control of the Trust. Therefore, the Trust cannot predict whether its Shares will trade at, below or above NAV. When the Trust repurchases its Shares for a price below their NAV, the NAV of those Shares that remain outstanding will be enhanced, but this does not necessarily mean that the market price of those outstanding Shares will be affected, either positively or negatively.

CONVERSION TO OPEN-END INVESTMENT COMPANY STATUS

Under the Declaration of Trust, the conversion of the Trust from a closed-end to an open-end investment company would require (1) the approval of the Board of Trustees, and (2) the affirmative vote or consent of the holders of 66 2/3% of the Shares outstanding and entitled to vote. Such a vote would be in addition to any vote or consent required in addition to the vote or consent of Shareholders otherwise required by law or any agreement between the Trust and the NYSE. The Investment Company Act requires that the Trust receive a vote of a majority of its outstanding voting Shares in order to convert the Trust from a closed-end to an open-end investment company.

Such amendment would have to be approved by the Board prior to its submission to Shareholders. The Board is required under the Declaration of Trust

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

to consider and vote annually upon the proposal to convert to open-end status. A proposal to convert the Trust to an open-end company might be supported or opposed by the Board depending on the Board's judgment as to its advisability in light of circumstances prevailing at the time.

Shareholders of an open-end investment company may require the company to redeem their shares at any time (except in certain circumstances as authorized by or under the Investment Company Act) at their NAV, less such redemption charge, if any, as might be in effect at the time of a redemption. Conversion to an open-end investment company could require the disposal of illiquid investments to meet current requirements of the Commission that no more than 15% of an open-end investment company's assets consist of illiquid securities, and would likely require involuntary liquidation of portfolio securities, and the inherent realization of net long-term capital gains in connection therewith, to meet periodic requests for redemption. Moreover, Shares of the Trust would no longer be listed on the NYSE.

INVESTMENT ADVISER AND INVESTMENT ADVISORY AGREEMENT

Hambrecht & Quist Capital Management LLC, a limited liability company under the laws of the State of Delaware, serves as the investment adviser to the Trust. The Investment Adviser is an investment adviser registered under the Investment Advisers Act of 1940, as amended. The Investment Adviser is located at 30 Rowes Wharf, Fourth Floor, Boston, MA 02110-3328.

At inception, Hambrecht & Quist Capital Management Incorporated ("HQCM, Inc.") was the Trust's investment adviser. HQCM, Inc. was formed as a wholly-owned subsidiary of Hambrecht & Quist Group. HQCM, Inc. remained the Investment Adviser as The Chase Manhattan Corporation ("Chase") first acquired Hambrecht & Quist Group and then merged with J.P. Morgan Incorporated to form J.P. Morgan Chase & Co. In 2002, the management of HQCM, Inc. formed an independent entity, Hambrecht & Quist Capital Management LLC ("HQCM LLC"), to effect a buyout of HQCM, Inc. In this transaction, HQCM LLC acquired certain of the assets of HQCM, Inc., and substantially all of the management and staff of HQCM, Inc. became employees of HQCM LLC. HQCM LLC, the Trust's current investment adviser, is owned by Daniel R. Omstead, Mary Omstead and the Alan G. Carr Irrevocable Trust. Mr. Carr, a former portfolio manager, president and trustee of the Trust, passed away in October 2003. Dr. Omstead is currently the President and Chief Executive Officer of the Investment Adviser. Mary Omstead is Dr. Omstead's wife. Under the terms of HQCM LLC's current Amended and Restated Limited Liability Company Agreement, HQCM LLC will purchase the Alan G. Carr Irrevocable Family Trust's interest in HQCM LLC.

The Investment Advisory Agreement between the Investment Adviser and the Trust (the "Advisory Agreement") provides that, subject to the supervision and direction of the Board, the Investment Adviser is responsible for the actual management of the Trust's portfolio. The Investment Adviser is also obligated to supervise or perform certain administrative and management services for the Trust and is obligated to provide the office space, facilities, equipment and personnel necessary to perform its duties under the Advisory Agreement. The responsibility for making decisions to buy, sell or hold a particular security rests with the Investment Adviser. However, the Investment Adviser may consider investment analysis from various sources, including broker-dealers with which the Trust does business. See "Portfolio Transactions and Brokerage."

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Subject to the supervision and direction of the Board of Trustees of the Trust, the Investment Adviser manages the Trust's portfolio in accordance with the Trust's investment objective and policies as stated in the Trust's Prospectus; makes investment decisions for the Trust; places purchase and sale orders for portfolio transactions for the Trust; supplies the Trust with office facilities (which may be in the Investment Adviser's own offices), statistical and research data, data processing services, clerical, internal executive and administrative services, and stationery and office supplies; supplies or directs and supervises a third party administrator or custodian in the provision to the Trust of accounting and bookkeeping services, the calculation of the net asset value of shares of the Trust, internal auditing services, and other clerical services in connection therewith; and prepares or supervises and directs a third party administrator or custodian in the preparation of reports to shareholders of the Trust, tax returns and reports to and filings with the Commission and state Blue Sky authorities. In providing these services, the Investment Adviser provides investment research and supervision of the Trust's investments and conducts a continual program of investment, evaluation and, if appropriate, sale and reinvestment of the Trust's assets. In addition, the Investment Adviser furnishes the Trust with whatever statistical information the Trust may reasonably request with respect to the securities that the Trust may hold or contemplate purchasing.

Starting July 1, 2006, for the services provided by the Investment Adviser under the Advisory Agreement, the Trust pays a fee, computed and payable monthly, equal when annualized to (i) 2.5% of the average net assets for the month of its venture capital and other Restricted Securities (as defined) up to 25% of its net assets and (ii) for the month for all other assets, 0.98% of the average net assets up to \$250 million, 0.88% of the average net assets for the next \$250 million, 0.80% of the average net assets for the next \$500 million and 0.70% of the average net assets thereafter. The aggregate monthly fee may not exceed a rate when annualized of 1.375% (approximately 0.11% per month). Prior to July 1, 2006, the Trust paid a fee computed and payable monthly, equal, when annualized, to (i) 2.5% of the average net assets for the month of its venture capital and other Restricted Securities (as defined) up to 25% of net assets and (ii) for the month, for all other assets, 1.0% of the average net assets up to \$250 million, 0.90% of the average net assets for the next \$250 million, 0.80% of the average net assets for the next \$500 million and 0.70% of the average net assets thereafter. The aggregate fee could not exceed a rate when annualized of 1.375% (approximately 0.11% per month).

The Investment Adviser will not participate directly in the capital appreciation of Restricted Securities. The Investment Adviser may also provide managerial assistance to issuers of securities in which the Trust invests. For purposes of calculation of the investment advisory fee, "average net assets" for any month shall be equal to the average of the net asset value of such assets as of the last business day of such month and the net asset value of the appropriate assets as of the last business day of the preceding month. In determining average net assets for purposes of clauses (1) and (2) above, liabilities and expenses of the Trust shall be allocated pro rata based on the ratio that the assets referred to in each clause bear to the total assets of the Trust. Such fee shall be payable for each month within five business days after the end of such month.

For purposes of the calculation of the investment advisory fee, "venture capital and other Restricted Securities" shall be securities of issuers for which no market quotations are readily available and securities of companies for which market quotations are readily available but which are subject to legal or contractual restrictions on resale. Securities of companies for which public information is available but as to the sale of which the safe harbor provided by Rule 144(k) is not available shall be considered to be subject to legal or contractual restrictions on resale.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

The investment advisory fee paid by the Trust exceeds that paid by most registered investment companies to their investment advisers. The Trust believes that the fee is commensurate with the nature and quality of the services required for identifying, evaluating and monitoring the Trust's Restricted Securities investments.

The Advisory Agreement provides that the Investment Adviser shall not be liable for any loss incurred by any act or omission of any broker. The Advisory Agreement also provides that the Investment Adviser shall not be liable to the Trust or to any Shareholder of the Trust for any error or judgment or for any loss suffered by the Trust in connection with rendering services under the Advisory Agreement except (1) a loss resulting from a breach of fiduciary duty with respect to the receipt of compensation for services (in which case any award of damages shall be limited to the period and the amount set forth in Section 36(b)(3) of the Investment Company Act) or (2) a loss resulting from willful misfeasance, bad faith or gross negligence on the part of the Investment Adviser, or reckless disregard of its obligations and duties under the Advisory Agreement. Subject to the foregoing, the Advisory Agreement also provides that the Trust shall indemnify the Investment Adviser, and any officer, director and employee of the Investment Adviser to the maximum extent permitted by Article V of the Trust's Declaration of Trust.

For the fiscal years ended September 30, 2005, September 30, 2004 and September 30, 2003, the Trust paid the Adviser \$2,676,602, \$2,651,448 and \$2,320,306, respectively, in advisory fees.

The services of the Investment Adviser to the Trust are not deemed to be exclusive, and nothing in the Advisory Agreement prevents the Investment Adviser, or any affiliate thereof, from providing similar services to other companies and other clients or from engaging in other activities.

Under the Advisory Agreement, the Investment Adviser has agreed to bear all expenses in connection with the performance of its services under the Advisory Agreement, including compensation of and office space for officers and employees of the Trust connected with investment and economic research, trading and investment management of the Trust, as well as the fees of all Trustees of the Trust who are "affiliated persons" of the Investment Adviser, as that term is defined in the Investment Company Act, or any of its "affiliated persons."

Under the Advisory Agreement, the Trust must pay (or, in the event that such expenses are paid by the Investment Adviser, shall reimburse the Investment Adviser for) all other expenses incurred in the organization and operation of the Trust including, among other things, expenses for legal and auditing services, costs of printing proxy statements, prospectuses, stock certificates and shareholder reports, charges of the custodian, any sub-custodian and transfer agent, expenses in connection with the Dividend Reinvestment Plan, the Commission, and National Association of Securities Dealers, Inc. fees, fees and expenses of the Trustees who are not "affiliated persons" of the Investment Adviser or any of its "affiliated persons," accounting and valuation costs, administrator's fees, membership fees in trade associations, fidelity bond coverage for the Trust's officers and employees, errors and omissions insurance coverage for Trustees and officers, interest, brokerage costs, taxes, stock exchange listing fees and expenses, expenses of qualifying the Trust's Shares for sale in various states, expenses associated with personnel performing exclusively shareholder servicing functions, certain other organization expenses, litigation and other extraordinary or non-recurring expenses, and other expenses properly payable by the Trust. The Trust may enter into arrangements to have third parties assume any expenses for which it is responsible.

Unless earlier terminated as described below, the Advisory Agreement will remain in effect from year to year if approved annually (1) by the Board or

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

by the holders of a majority of the Trust's outstanding Shares and (2) by the majority of the Trustees who are not parties to the Advisory Agreement or interested persons of any such party. The Advisory Agreement may be terminated without penalty by (1) the Trust or the Investment Adviser at any time without penalty upon not less than 30 and no more than 60 days' written notice or (2) a vote of the holders of a majority of the Trust's outstanding Shares, and will automatically terminate in the event of its assignment. Action by the Trust under (1) above may be taken either by (i) vote of a majority of its Trustees, or (ii) the affirmative vote of a majority of the outstanding shares of the Trust.

The Investment Advisory Agreement (Advisory Agreement) between the Trust and the Adviser provides that the Advisory Agreement will continue in effect so long as its continuance is approved at least annually by (i) by the Trustees of the Trust or the shareholders by affirmative vote of a majority of the outstanding shares and (ii) a majority of the Trustees of the Trust who are not interested persons, by vote cast in person at a meeting called for the purpose of voting on such approval.

On April 20, 2006, the Board, and the independent Trustees voting separately, determined that the terms of the Advisory Agreement are fair and reasonable and approved the continuance of the Advisory Agreement as being in the best interests of the Trust and its shareholders. In making its determination, the Board considered materials that were specifically prepared by the Adviser at the request of the Board and Trust counsel for purposes of the contract review process, including comparisons of (i) the Trust's performance to its benchmark and to certain other investment companies, (ii) the Trust's expenses and expense ratios to those of a peer group of other investment companies, and (iii) the Adviser's profitability with respect to its services for the Trust to the profitability of other investment managers. The Trustees took into account that the Adviser presently provides investment management services only to the Trust and to H&Q and does not derive any benefit from its relationship with the Trust other than receipt of advisory fees pursuant to the Advisory Agreement. The Board also considered information received periodically about the portfolio, performance, investment strategy, portfolio management team and fees and expenses of the Trust.

The Investment Adviser's use of the term "H&Q" is pursuant to a written license agreement (the "License Agreement"), a copy of which the Investment Adviser has provided to the Trust. Under the License Agreement, the Investment Adviser may sublicense the term "H&Q" to an investment company for which it serves as investment adviser, for use as part of the investment company's name, pursuant to a written sublicense agreement that (a) is at least as protective of the rights of the licensor under the License Agreement as the License Agreement and (b) does not permit the investment company to sub-sublicense the term "H&Q". The Trust has agreed that its right to use the term "H&Q" is subject in all respects to the terms of the License Agreement. The Trust has also agreed that if the License Agreement terminates for any reason, or if the Investment Adviser ceases to act as investment adviser to the Trust, the Trust's sublicense to use the term "H&Q" as part of its name will terminate, at which time the Trust will take all necessary action to change its name to a name not including such term. The Investment Adviser may at any time permit others to use the term "H&Q" under a similar sublicense.

PORTFOLIO MANAGEMENT

Currently Daniel R. Omstead, Ph.D., Christopher F. Brinzey, M.B.A., Frank T. Gentile, Ph.D. and Jason C. Akus, M.D./M.B.A. are members of the team that makes investments on behalf of the Trust. These members also perform other duties, including making investment decisions on behalf of H&Q Healthcare Investors, a closed-end mutual fund, but do not otherwise manage any other accounts.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

SECURITY OWNERSHIP OF PORTFOLIO MANAGERS

As of March 15, 2006, the dollar range of Trust securities beneficial owned by Dr. Omstead was \$50,001 - \$100,000. As of August 15, 2006, none of the other members of the team owned securities of the Trust.

PORTFOLIO MANAGER COMPENSATION STRUCTURE

Dr. Omstead receives a base salary as compensation for his contribution to the portfolio management team and for his contribution to the general management of the Adviser. As part owner of the Investment Adviser, Dr. Omstead receives additional compensation from the Trust indirectly by virtue of the investment advisory fee paid to the Investment Adviser.

Mr. Brinzey, Dr. Gentile and Dr. Akus receive a combination of base compensation and discretionary compensation, in the form of a cash bonus paid annually. The methodology used to determine compensation is applied to all accounts managed by the team. Two components are described in detail below.

BASE SALARY COMPENSATION. The team members receive a base salary compensation linked to individual experience and responsibilities. The amount of base salary is reviewed annually.

DISCRETIONARY COMPENSATION. Discretionary Compensation is in the form of a cash bonus, paid annually, which may be up to 60% of the team member's base salary. Several factors affect discretionary compensation, which can vary by team member and circumstances. The discretionary compensation component is determined based on four factors including investment performance of accounts managed by the team relative to an appropriate benchmark and/or peer funds, performance of specific investments proposed by the individual, financial performance of the Investment Adviser and a qualitative assessment of the individual overall contribution to the investment team and to the Investment Adviser. Discretionary compensation is evaluated annually after the completion of the Trust's fiscal year.

PROXY VOTING POLICY AND PROCEDURES

The Board of Trustees of the Trust has adopted a proxy voting policy and procedure (the "Proxy Voting Policy"), pursuant to which the Trustees have delegated proxy voting responsibility to the Investment Adviser in accordance with the Fund's Proxy Voting Policy. A copy of the Proxy Voting Policy for the Trust and the Investment Adviser are attached as Appendix A to this SAI.

A description of the Trust's proxy voting policies and procedures and information on how the Trust voted proxies relating to portfolio securities during the most recent 12-month period ended June 30, 2005 is available (i) without charge, upon request by calling 1-800-451-2597; (ii) by writing to Hambrecht & Quist Capital Management, LLC at 30 Rowes Wharf, Suite 430, Boston, MA 02110-3328; (iii) on the Trust's website at www.hqcm.com; and (iv) on the SEC's website at www.sec.gov.

CODE OF ETHICS

The Trust's Board of Trustees and the Investment Adviser have approved a Code of Ethics under Rule 17j-1 of the Investment Company Act that covers certain personnel of the Trust and the Investment Adviser. The Code of Ethics establishes procedures for personal investing and restricts certain transactions by certain personnel covered by the Code of Ethics. Persons subject to the Code of Ethics may invest in securities for their personal investment accounts, including, in certain cases, securities that may be purchased or held by the Trust. The Code of Ethics applies to investments by covered persons in their

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

personal accounts, the accounts of family members living in the same household, and accounts in which the covered person has a beneficial interest (i.e., ownership, voting or investment control). Some of the restrictions set forth in the Code of Ethics do not apply to the Trust's Independent Trustees. In general terms, the Code of Ethics is designed to ensure that the investing activities of covered personnel are conducted in a manner that avoids potential or actual conflicts of interest with the Trust and its Shareholders and that covered personnel conduct their personal investing in a manner consistent with their fiduciary duty towards the Trust and its shareholders.

The Code of Ethics requires pre-clearance for certain investments in equities (not including mutual funds), imposes reporting requirements, and imposes sanctions for violations. Specifically, among other things, the Code of Ethics prohibits sales of securities to or purchases of securities from the Trust and prohibits the purchase or sale of any security under consideration for trading by the Trust within seven days before or after the Trust trades in the security.

The Trust's Code of Ethics is filed as an exhibit to this registration statement. In addition, you may read and copy the Code of Ethics at the Commission's Public Reference Room in Washington, DC. You may obtain information on operations of the Public Reference Room by calling the Commission at (202) 551-8090. In addition, the Code of Ethics is available on the EDGAR Database on the Commission Internet site at <http://www.sec.gov>. You may obtain copies of the Code of Ethics, after paying a duplicating fee, by electronic request at the following email address: publicinfo@sec.gov, or by writing to the Commission's Public Reference Section, 100 F Street, NE, Washington, DC 20549.

NET ASSET VALUE

The net asset value ("NAV") of the Trust's Shares is calculated at the close of regular trading on the NYSE (generally 4:00 p.m., Eastern time) every day that the NYSE is open. The Trust makes this information available daily by telephone (800) 451-2597, via its web site (www.hqcm.com) and through electronic distribution for media publication, including major internet-based financial services web sites and portals (bloomberg.com, yahoo.com, cbsmarketwatch.com, etc.). Currently, The Wall Street Journal, The New York Times and Barron's publish NAVs for closed-end investment companies at least weekly.

NAV is calculated by dividing the value of the securities held by the Trust plus any cash or other assets minus all liabilities, including accrued expenses, by the total number of Shares outstanding at such time. Securities for which market quotations are readily available are valued at market price. Portfolio securities that are traded on one or more U.S. national securities exchanges or in the over-the-counter market that are National Market System securities are valued at the last sale price or, lacking any sales, at the mean between last bid and asked prices. Other over-the-counter securities are valued at the most recent bid prices as obtained from one or more dealers that make markets in the securities. Redeemable securities issued by a registered open-end investment company are valued at net asset value per share. Other securities are valued at the mean between the closing bid and asked prices. Short-term investments that mature in 60 days or less are valued at amortized cost, unless the Board determines that such valuation does not constitute fair value.

Bonds, other than convertible bonds, are valued using a third-party pricing system. Convertible bonds are valued using this pricing system only on days when there is no sale reported. Temporary cash investments with maturity of 60 days or less are valued at amortized cost. Puts and calls generally are valued at the close of regular trading on the securities or commodities exchange on which they are primarily traded. Options on securities generally are valued at their last bid price in the case of exchange-traded options or, in the case of OTC-traded options, the average of the last bid price as obtained from two or

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

more dealers unless there is only one dealer, in which case that dealer's price is used. Forward foreign currency contracts are valued on the basis of the value of the underlying currencies at the prevailing currency exchange rate. The prevailing currency exchange rate shall be determined within one hour of when the most recently available exchange rate information has been received based on information obtained from a bank or banks.

Securities that are primarily traded on foreign securities exchanges generally are valued at the last sale price on the exchange on which they are primarily traded. Foreign securities that are primarily traded on the foreign over-the-counter market are generally valued at the last sale quotation, if market quotations are available, or the last reported bid price if there is no active trading in a particular security on a given day. However, if intervening events result in market volatility that significantly affects the value of any such foreign securities after the close of trading on the relevant foreign market, but before the Trust values its Shares on any particular day on which the Trust is required to value its Shares, the Trust may, but is not required to, determine the value of such securities at "fair value," as determined in good faith by or under the direction of the Board of Trustees.

Quotations of foreign securities in foreign currencies are converted, at current exchange rates, to their U.S. Dollar equivalents in order to determine their current value. In addition, to the extent that the Trust values its foreign securities (other than ADR's and ADS's) as of the close of trading on various exchanges and over-the-counter markets throughout the world, the calculation of the Trust's net asset value may not take place contemporaneously with the valuation of foreign securities held by the Trust.

The value of any security or other asset for which market quotations are not readily available shall be determined in a manner that most fairly reflects the security's (or asset's) "fair value." Each such determination is based on a consideration of all relevant factors, which are likely to vary from one pricing context to another. Examples of such factors may include, but are not limited to: (1) the type of the security; (2) the size of the holding (including percent of outstanding securities of issuer held by the Trust); (3) the initial cost of the security; (4) the existence of any contractual restrictions on the security's disposition and the time to freedom from such restrictions; (5) the price and extent of public trading in similar securities of the issuer or of comparable companies; (6) quotations or prices from broker-dealers and/or pricing services; (7) information obtained from the issuer, analysts, and/or the appropriate stock exchange (for exchange-traded securities); (8) an analysis of the company's financial statements; (9) an evaluation of the forces that influence the issuer and the market(s) in which the security is purchased and sold (e.g., the existence of pending merger activity, public offerings or tender offers that might affect the value of the security); and (10) the price of securities in a subsequent round of financing of an issuer in an arm's-length transaction, if the round includes a new third party investor.

Sometimes a "significant valuation event" may cause the market value of a security to differ from the fair market value of that security. A "significant valuation event" is an event that causes or is likely to cause a market quotation to be unavailable or unreliable, and may include: situations relating to a single issue in a market sector; significant fluctuations in U.S. or foreign markets; market disruptions or closings caused by human error, equipment failures, natural disasters, armed conflicts, acts of God, governmental actions or other developments, as well as the same or similar events which may affect specific issues or the securities markets even though not tied directly to the securities markets. A significant valuation event occurring after the close of trading but before the time of valuation may mean that the closing price for the security does not constitute a readily available market quotation. If a significant valuation event has occurred, the security will be valued at fair

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

value as determined in good faith by the Board in accordance with the procedures hereinafter described. Such valuations and procedures will be reviewed periodically by the Board.

The fair value of investments for which no market exists cannot be precisely determined. With respect to securities of a company in its early stage of development, valuation will typically be based upon the original cost to the Trust. This methodology will typically be used until significant developments affecting the portfolio company provide a basis for a change in valuation. The status of portfolio companies is monitored for progress against plan, advancement of the stage of product development, and other factors. When revenues and earnings are present they are monitored. Valuation changes are event driven. When an appropriate event occurs (e.g., the completion of a third party transaction or a significant change in business model) valuation is changed accordingly. In addition the Trust will typically base changes in valuation on actual transactions or on actual firm offers by sophisticated independent investors unaffiliated with the Investment Adviser. Legal or contractual restrictions on the sale of portfolio securities by the Trust will be considered in the valuation of such securities.

Other assets, which include cash, prepaid and accrued items, accounts receivable and income on investments and from the sale of portfolio securities, are carried in accordance with generally accepted accounting principles, as are all liabilities. Liabilities primarily include accrued expenses, sums owed for securities purchased and dividends payable.

PORTFOLIO TRANSACTIONS AND BROKERAGE

Subject to policies established by the Board, the Investment Adviser is primarily responsible for the execution of the Trust's portfolio transactions and the allocation of brokerage. In executing transactions for the portfolio and selecting brokers or dealers (which brokers or dealers may include any affiliate of the Investment Adviser to the extent permitted by the Investment Company Act), the Investment Adviser will use its best efforts to obtain the best price and execution for the Trust. In assessing the best price and execution available for any portfolio transaction, the Investment Adviser will consider all factors it deems relevant including, but not limited to, price (including any applicable brokerage commission or dealer spread), size of order, difficulty of execution, and operational facilities of the firm involved and the firm's risk in positioning a block of securities. The Investment Adviser may cause the Trust to pay a broker-dealer that furnishes brokerage and research services a higher commission than that which might be charged by another broker-dealer for effecting the same transaction, provided that the Investment Adviser determines in good faith that such commission is reasonable in relation to the value of the brokerage and research services provided by such broker-dealer, viewed in terms of either the particular transaction or the overall responsibilities of the Investment Adviser to the Trust. In selecting brokers or dealers to execute a particular transaction and in evaluating the best price and execution available, the Investment Adviser may consider the brokerage and research services (as those terms are defined in Section 28(e) of the Securities Exchange Act of 1934, as amended) provided to the Trust and/or other accounts over which the Investment Adviser exercises investment discretion. Such brokerage and research services might consist of reports and statistics on specific companies or industries, general summaries of groups of bonds and their comparative earnings and yields, or broad overviews of the securities markets and the economy. It is further understood that such services may be useful to the Investment Adviser in connection with its services to other clients. While the Investment Adviser generally seeks reasonably competitive commission rates, the Trust will not necessarily pay the lowest commission available.

The Trust has no obligation to deal with any broker or group of brokers in executing transactions in portfolio securities. Brokers who provide

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

supplemental research, market and statistical information to the Investment Adviser may receive orders for transactions by the Trust. The term "research, market and statistical information" includes advice as to the value of securities, the advisability of purchasing or selling securities and the availability of securities or purchasers or sellers of securities, and furnishing analyses and reports concerning issuers, industries, securities, economic factors and trends, portfolio strategy and the performance of accounts. Information so received will be in addition to and not in lieu of the services required to be performed by the Investment Adviser under the Advisory Agreement and the expenses of the Investment Adviser will not necessarily be reduced as a result of the receipt of such supplemental information. Such information may be useful to the Investment Adviser in providing services to clients other than the Trust, and not all such information may be used by the Investment Adviser in connection with the Trust. Conversely, such information provided to the Investment Adviser by brokers and dealers through whom other clients of the Investment Adviser in the future may effect securities transactions may be useful to the Investment Adviser in providing services to the Trust. To the extent the Investment Adviser receives valuable research, market and statistical information from a broker-dealer, the Investment Adviser intends to direct orders for Trust transactions to that broker-dealer, subject to the foregoing policies, regulatory constraints and the ability of broker dealers to provide competitive prices and commission rates.

The Investment Company Act restricts transactions involving the Trust and its "affiliates," including among others, the Trust's Trustees, officers and employees, the Investment Adviser and any "affiliates" of such affiliates. Subject to any such restrictions, investment companies advised by the Investment Adviser may concurrently invest with the Trust in Restricted Securities, and the Trust may also invest in companies in which directors of the Investment Adviser or Trustees of the Trust have invested or for which they serve as directors or executive officers. The Trust seeks to deal directly with the dealers who make markets in the securities involved, except as limited by applicable law and in those circumstances where better prices and execution are available elsewhere. Under the Investment Company Act, persons affiliated with the Trust are generally prohibited from dealing as principal with the Trust in the purchase and sale of securities. Under certain circumstances, affiliated persons of the Trust are permitted to serve as its broker in over-the-counter transactions conducted on an agency basis.

It is likely that, subject to applicable law, the Trust may invest in securities concurrently being purchased by other investment companies advised by the Investment Adviser. Such purchases would be made on terms no less favorable than those under which such investment companies would be acquiring the securities. In the case of concurrent purchases by the Trust and another investment company or companies managed by the Investment Adviser, such purchases would be made where the Investment Adviser has made an independent decision on behalf of the Trust and such other company that the purchase is appropriate in light of the investment objectives, policies, restrictions, current holdings, available cash and portfolio structure of and other factors affecting each. Such investments will be allocated among clients in a manner believed by the Investment Adviser to be equitable to each. The Trust may also from time to time invest in securities of companies in which affiliated persons of the Trust have invested, subject to the provisions of the Investment Company Act and the rules and regulations promulgated thereunder.

The Trust's portfolio transactions in Restricted Securities are generally subject to Rule 144 under the Securities Act. In general, under Rule 144 as currently in effect, if the Trust has beneficially owned Restricted Securities of a publicly held issuer for more than one but less than two years, it will be entitled to sell in any three-month period that number of such securities that will not exceed the greater of 1% of the then outstanding securities of that class or the average weekly trading volume in securities of

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

that class in any national securities exchange and/or in the over-the-counter market during the four calendar weeks immediately preceding the date on which notice of the sale is filed with the Commission. These volume limitations also apply to sales by the Trust of the securities of any issuer as to which it is deemed an affiliate, regardless of whether securities of such issuer are publicly traded. The above-described sales under Rule 144 are subject to certain requirements relating to manner of sale, notice and availability of current public information about the issuer. If the Trust is not deemed to have been an affiliate of the issuer at any time during the 90 days immediately preceding the sale and has beneficially owned Restricted Securities for at least two years, it is entitled to sell such securities under Rule 144(k) without regard to whether the issuer is publicly-held or to the volume limitations or other requirements described above. When Restricted Securities are sold to the public other than pursuant to Rule 144 or 144A, the Trust may be deemed an "underwriter" with respect thereto for purposes of the Securities Act and subject to liability as such thereunder.

On occasions when the Investment Adviser deems the purchase or sale of a security to be in the best interest of the Trust as well as other clients, the Investment Adviser, to the extent permitted by applicable laws and regulations, may, but shall be under no obligation to, aggregate the securities to be sold or purchased in order to obtain the most favorable price or lower brokerage commissions and efficient execution. In such event, allocation of the securities so purchased or sold, as well as the expenses incurred in the transaction, will be made by the Investment Adviser in the manner it considers to be the most equitable and consistent with its fiduciary obligations to the Trust and to such other clients.

Allocation of transactions, including their frequency, to various broker-dealers is determined by the Investment Adviser with respect to the Trust, based on its best judgment and in a manner deemed fair and reasonable to Shareholders. The primary consideration is prompt execution of orders in an effective manner at the most favorable price. Certain investments may be appropriate for the Trust and also for other clients advised by the Investment Adviser. Investment decisions for the Trust and for other investment accounts managed by the Investment Adviser are made independently of each other in the light of differing conditions. However, the same investment decision may be made for two or more of such accounts. When a purchase or sale of the same security is made at substantially the same time on behalf of the Trust and one or more other accounts, the transaction will be averaged as to price, and available investments allocated as to amount, in a manner the Investment Adviser believes to be equitable to each such account. Although the Investment Adviser seeks the most favorable overall net results for all of the accounts in any aggregated transaction, in some cases, this practice may adversely affect the price paid or received by the Trust or the size of the position obtained or sold by the Trust. To the extent permitted by law, the Investment Adviser may aggregate the securities to be sold or purchase for the Trust with those to be sold or purchased for other investment companies or accounts in order to obtain best execution.

For the fiscal years ended September 30, 2005, September 30, 2004 and September 30, 2003, the Trust paid \$813,281, \$330,000 and \$218,162, respectively, of brokerage commissions. The increase in commissions in September 30, 2005 was due to strategy specific reallocations and market opportunities.

As stated in the Prospectus, the Trust's portfolio turnover rate for the fiscal years ended September 30, 2005 and September 30, 2004 was 73.79% and 34.93%, respectively. The increase in portfolio turnover rate was due to strategy specific reallocations and market opportunities. For a description of the Trust's portfolio turnover policies, see "Portfolio Transactions and Brokerage" in the Trust's Prospectus.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

QUARTERLY DISTRIBUTION POLICY

In May 1999, the Trust's Board of Trustees adopted a managed distribution policy with respect to the Trust's Shares. Under the managed distribution policy, the Trust intends to make quarterly distributions to its Shareholders equal to 2.0% of the Trust's net asset value. The current distribution policy is to declare distributions in stock. Distributions will automatically be paid in newly-issued full Shares of the Trust plus cash in lieu of any fraction of a Share, unless otherwise instructed by the Shareholder. The Fund's transfer agent delivers an election card and instructions to each registered Shareholder in connection with each distribution. For shareholders other than registered shareholders with book entry accounts at the Trust's transfer agent, fractional shares will generally be settled in cash. The number of Shares issued will be determined by dividing the dollar amount of the distribution by the lower of net asset value or market value on the pricing date. If a shareholder elects to receive a distribution in cash, rather than in Shares, the Shareholder's relative ownership in the Trust will be reduced. The shares will be valued at the lower of net asset value or market price on the pricing date. Distributions in stock will not relieve shareholders of any federal, state or local income taxes that may be payable on such distributions.

If, for any taxable year, the total distributions required for the Trust's distribution policy exceed the Trust's annual investment company taxable income and net long-term capital gains, the excess will generally be treated as a return of capital (up to the amount of the Shareholder's adjusted tax basis in his or her Shares). The amount treated as a tax-free return of capital will reduce a Shareholder's adjusted basis in his or her own Shares, thereby increasing his or her potential gain or reducing his or her potential loss on the sale of his or her Shares.

If the Trust's investment company taxable income and net long-term capital gains for any taxable year or calendar year exceed the amount required to be distributed under the distribution policy, the Trust will, at a minimum, make distributions necessary to permit it to qualify for treatment as a regulated investment company under the Internal Revenue Code of 1986, as amended (the "Code"). The Trust has the discretion to retain for reinvestment net long-term capital gains in excess of net short-term capital losses, to the extent that it does not need to distribute these gains to meet its managed distribution obligation or tax requirements. Any retained gains may be subject to taxation, although Shareholders may receive credit for taxes paid by the Trust. It is anticipated that net realized capital gains in excess of the total distributed under this policy would be included in the December distribution.

This distribution policy may, under certain circumstances, have certain adverse consequences to the Trust and its Shareholders. To make such distributions, the Trust may have to sell a portion of its investment portfolio at a time when independent investment judgment might not dictate such action. The Trust's quarterly distribution policy may be changed by the Board of Trustees without Shareholder approval.

The Trust's most recent distribution of \$0.35 per Share was payable to Shareholders of record on June 9, 2006. That distribution was paid in Shares on June 30, 2006. For the 2005 calendar year, the Trust distributed a total of \$2.06 per Share.

TAX MATTERS

The following is only a summary of certain U.S. federal income tax considerations generally affecting the Trust and its shareholders. No attempt is made to present a detailed explanation of the tax treatment of the Trust or its shareholders, and the following discussion is not intended as a substitute for

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

careful tax planning. Shareholders should consult with their own tax advisers regarding the specific federal, state, local, foreign and other tax consequences of investing in the Trust.

TAXATION OF THE TRUST

The Trust intends to qualify and has elected to be treated each taxable year as a regulated investment company under the Code. The principal federal income tax benefits of qualifying as a regulated investment company ("RIC"), as compared to an ordinary taxable corporation, are that a RIC generally is not itself subject to federal income tax on ordinary investment income and net capital gains that are currently distributed to its shareholders, and that the character of long-term capital gains which are recognized and properly designated by a RIC flows through to its shareholders, who receive (or are deemed to receive) distributions of such income. However, the Trust is subject to corporate income tax (currently at a maximum marginal rate of 35%) on any undistributed income.

To qualify as a RIC, the Trust must, among other things, (a) derive in each taxable year at least 90% of its gross income from dividends, interest, payments with respect to securities loans, gains from the sale or other disposition of stock, securities or foreign currencies, net income derived from an interest in a qualified publicly traded partnership and other income derived with respect to its business of investing in such stock, securities or currencies (the "Qualifying Income Requirement"); (b) diversify its holdings so that, at the end of each quarter of the taxable year, (1) at least 50% of the market value of the Trust's assets is represented by cash and cash items, U.S. Government Securities, the securities of other RICs and other securities, with such other securities of any one issuer limited for the purposes of this calculation to an amount not greater than 5% of the value of the Trust's total assets and not greater than 10% of the outstanding voting securities of such issuer, and (2) not more than 25% of the value of its total assets is invested in the securities of (i) any one issuer (other than U.S. Government Securities or the securities of other RICs), (ii) two or more issuers (other than the securities of other RICs) which the taxpayer controls and which are determined to be in the same or similar trades or businesses; or (iii) one or more qualified publicly traded partnership; and (c) distribute at least 90% of its investment company taxable income (which includes, among other items, dividends, interest and net short-term capital gains in excess of net long-term capital losses) each taxable year. The U.S. Treasury Department has authority to promulgate regulations pursuant to which gains from foreign currency (and options, futures and forward contracts on foreign currency) not directly related to a RIC's business of investing in stocks and securities would not be treated as qualifying income for purposes of the Qualifying Income Requirement. To date, such regulations have not been promulgated.

If for any taxable year the Trust were to fail to qualify as a RIC, all of the Trust's taxable income would be subject to federal income tax at the rates applicable to corporations (with no deduction for distributions to Shareholders), and Trust distributions would be taxable to Shareholders as dividends to the extent of the Trust's earnings and profits.

Amounts not distributed on a timely basis in accordance with a calendar year distribution requirement are subject to a nondeductible 4% excise tax. To avoid the excise tax, the Trust must distribute during each calendar year an amount equal to the sum of (1) at least 98% of its ordinary income (not taking into account any capital gains or losses) for the calendar year, (2) at least 98% of its capital gains in excess of its capital losses (adjusted for certain ordinary losses) for the one-year period ending on October 31 of the calendar year, and (3) all ordinary income and capital gains for previous years that were not distributed during such years. To avoid application of the excise tax, the Trust intends to make its distributions in accordance with the calendar year

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

distribution requirement. A dividend will be treated as paid on December 31 of the calendar year if it is declared by the Trust in October, November or December of the year, payable to shareholders of record on a date in such a month and paid by the Trust during January of the following year. Such dividends will be taxable to shareholders as of December 31 of the calendar year in which the dividends are declared, rather than during the calendar year in which the dividends are received. If the Trust elects to retain net capital gains and treat such gains as having been distributed, all or a portion of such gains may not be treated as having been timely distributed for purposes of satisfying the excise tax calendar year distribution requirement.

DISTRIBUTIONS

Dividends paid from investment company taxable income generally will be taxable to shareholders generally as ordinary income whether paid in cash or reinvested in the Trust's Shares. The Trust intends to distribute to its shareholders substantially all of its investment company taxable income, if any, for each year. It is anticipated that the Trust's income distributions will be paid annually in additional Shares unless the shareholder elects payment in cash.

A portion of the dividends paid by the Trust may be treated as "qualified dividend income" which is taxable to individuals at the same rates that are applicable to long-term capital gains. A Trust distribution is treated as qualified dividend income to the extent that the Trust receives dividend income from taxable domestic corporations and certain qualified foreign corporations, provided that certain holding period and other requirements are met by both the Trust and the shareholder. Trust distributions generally will not qualify as qualified dividend income to the extent attributable to interest, capital gains, REIT distributions and distributions from certain non-U.S. corporations. The lower rates on qualified dividends and capital gains are scheduled to expire after 2008 in the absence of further legislation enacted by Congress.

Distributions of the excess, if any, of net long-term capital gains over net short-term capital losses ("net capital gains") designated by the Trust as capital gain dividends will be taxable to shareholders as long-term capital gains, whether paid in cash or reinvested in the Trust's Shares, regardless of how long the shareholders have held the Trust's Shares, and will not be eligible for the dividends received deduction for corporations. The Trust may elect to retain net capital gains. In such event, the Trust will be required to pay federal income taxes on the undistributed net capital gains, but intends to elect to treat such capital gains as having been distributed to shareholders. As a result, such amounts will be included in the gross income of the shareholders as long-term capital gains and shareholders will be able to claim their proportionate share of federal income taxes paid by the Trust on such gains as a credit against their own federal income tax liabilities, and will be entitled to increase the adjusted tax basis of their Shares of the Trust by an amount equal to approximately 65% of the amount of the undistributed capital gains included in their gross income. Organizations or persons not subject to federal income tax on such capital gains (such as, generally, qualified pension and profit-sharing funds, including Individual Retirement Accounts and Keogh plans, and certain trusts, nonresident aliens and foreign corporations) will be entitled to a refund of their pro rata share of such taxes paid by the Trust upon filing appropriate returns or claims for refund with the Internal Revenue Service ("IRS"). Even if the Trust makes such an election, it is possible that the Trust may incur an excise tax as a result of not having distributed sufficient net capital gains.

A distribution of an amount in excess of the Trust's current and accumulated earnings and profits will be treated by a Shareholder as a return of capital which is applied against and reduces the Shareholder's basis in his or

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

her Shares. To the extent that the amount of any such distribution exceeds the shareholder's basis in his or her Shares, the excess will be treated by the Shareholder as gain from a sale or exchange of the Shares.

If the value of the Trust's Shares is reduced below a Shareholder's cost as a result of a distribution of investment company taxable income or net capital gains by the Trust, such distribution will be taxable to the shareholder. The price of Shares purchased at this time may reflect the amount of the forthcoming distribution. Those purchasing just prior to a distribution of investment company taxable income or net capital gains will receive a distribution which will nevertheless be taxable to them.

Dividends (not including capital gain dividends) received by corporate shareholders from the Trust qualify for the dividends received deduction for corporate shareholders to the extent the Trust designates the amount distributed as eligible for the deduction. The aggregate amount designated by the Trust cannot exceed the aggregate amount of dividends received by the Trust from domestic corporations for the taxable year, and the designation of dividend income must generally be the same for all Shares. The dividends received deduction for corporate shareholders may be further reduced if the Shares with respect to which dividends are received are treated as debt-financed or if either those Shares or the Shares of the Trust are deemed to have been held by the Trust or its shareholders, respectively, for less than 46 days.

In addition to furnishing any other required tax statements, the Trust intends to send not later than 60 days after September 30 (the end of the tax and fiscal year of the Trust) written notices to shareholders regarding the tax status of all distributions made during such taxable year, the amount qualifying for the dividends received deduction for corporations and the amount of undistributed net capital gains and related tax credits.

SALE OF SHARES

Generally, gain or loss realized upon the sale or exchange of Shares will be capital gain or loss if the Shares are capital assets in the shareholder's hands and generally will be long-term or short-term, depending upon the shareholder's holding period for the Shares. Investors should be aware that any loss realized upon the sale or exchange of Shares held for six months or less will be treated as a long-term capital loss to the extent of any distributions or deemed distributions of long-term capital gain to the shareholder with respect to such Shares. In addition, any loss realized on a sale or exchange of Shares will be disallowed to the extent the Shares disposed of are replaced within a period of 61 days beginning 30 days before and ending 30 days after the Shares are disposed of, such as pursuant to the Plan. In such case, the basis of Shares acquired will be adjusted to reflect the disallowed loss.

The Trust may invest in shares of foreign corporations which may be classified under the Code as passive foreign investment companies ("PFICs"). In general, a foreign corporation is classified as a PFIC if at least one-half of its assets constitute investment-type assets, or 75% or more of its gross income is investment-type income. If the Trust receives a so-called "excess distribution" with respect to PFIC stock, the Trust itself may be subject to a tax on a portion of the excess distribution, whether or not the corresponding income is distributed by the Trust to shareholders. In general, under the PFIC rules, an excess distribution is treated as having been realized ratably over the period during which the Trust held the PFIC shares. The Trust itself will be subject to tax on the portion, if any, of an excess distribution that is so allocated to prior Trust taxable years and an interest factor will be added to the tax, as if the tax had been payable in such prior taxable years. Gain from the sale of PFIC shares is treated in the same manner as an excess distribution. Excess distributions and gain from the sale of PFIC shares are characterized as

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

ordinary income even though, absent application of the PFIC rules, such gains and certain excess distributions might have been classified as capital gain.

The Trust may elect to mark to market any PFIC shares in lieu of being subject to U.S. federal income taxation. At the end of each taxable year to which the election relates, the Trust would report as ordinary income the amount by which the fair market value of the PFIC stock exceeds the Trust's adjusted basis in the stock. Any mark-to-market losses and any loss from an actual disposition of shares would be deductible as ordinary losses to the extent of any net mark-to-market gains included in income in prior years. The effect of the election would be to treat excess distributions and gain on dispositions as ordinary income which is not subject to a Trust-level tax when distributed to shareholders as a dividend. Alternatively, the Trust may elect to include as income and gain its share of the ordinary earnings and net capital gain of certain PFICs in lieu of being taxed in the manner described above.

CURRENCY FLUCTUATIONS-"SECTION 988" GAINS OR LOSSES

Under the Code, the gains or losses attributable to fluctuations in exchange rates which occur between the time the Trust accrues receivables or liabilities denominated in a foreign currency and the time the Trust actually collects such receivables or pays such liabilities generally are treated as ordinary income or ordinary loss. Similarly, on disposition of foreign currency or debt securities denominated in a foreign currency and on disposition of certain futures and forward contracts, gains or losses attributable to fluctuations in the value of foreign currency between the date of acquisition of the currency, security or contract and the date of disposition also are treated as ordinary gain or loss. These gains or losses, referred to under the Code as "Section 988" gains or losses, may increase or decrease the amount of the Trust's investment company taxable income to be distributed to its Shareholders as ordinary income.

HEDGING TRANSACTIONS

Certain futures and foreign currency contracts in which the Trust may invest are "section 1256 contracts." While gains or losses on section 1256 contracts are considered 60% long-term and 40% short-term capital gains or losses, certain foreign currency futures and foreign currency contracts may give rise to ordinary income or loss, as described above. Also, section 1256 contracts held by the Trust at the end of each taxable year (and, generally, for purposes of the 4% excise tax, on October 31 of each year) are "marked-to-market" with the result that unrealized gains or losses are treated as though they were realized.

Generally, the hedging transactions undertaken by the Trust may result in "straddles" for U.S. federal income tax purposes. The straddle rules may affect the character of gains (or losses) realized by the Trust. In addition, losses realized by the Trust on positions that are part of a straddle may be deferred under the straddle rules, rather than being taken into account in calculating the taxable income for the taxable year in which the losses are realized. Because only a few regulations implementing the straddle rules have been promulgated, the tax consequences to the Trust of engaging in hedging transactions are not entirely clear.

The Trust may make one or more of the elections available under the Code which are applicable to straddles. If the Trust makes any of the elections, the amount, character and timing of the recognition of gains or losses from the affected straddle positions will be determined under the rules that vary according to the election(s) made. The rules applicable under certain of the elections may operate to accelerate the recognition of gains or losses from the affected straddle positions.

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

Notwithstanding any of the foregoing, the Trust may recognize gain (but not loss) from a constructive sale of certain "appreciated financial positions" if the Trust enters into a short sale, offsetting notional principal contract, futures or forward contract transaction with respect to the appreciated position or substantially identical property. Appreciated financial positions subject to this constructive sale treatment are interests (including options, futures and forward contracts and short sales) in stock, partnership interests, certain actively traded trust instruments and certain debt instruments. Constructive sale treatment does not apply to certain transactions closed before the end of the thirtieth day after the close of the taxable year, if certain conditions are met.

FOREIGN WITHHOLDING TAXES

Income received by the Trust from non-U.S. sources may be subject to withholding and other taxes imposed by other countries. Because it is not expected that more than 50% of the value of the Trust's total assets at the close of its taxable year will consist of stock and securities of non-U.S. corporations, it is not expected that the Trust will be eligible to elect to "pass-through" to the Trust's shareholders the amount of foreign income and similar taxes paid by the Trust. In the absence of such an election, the foreign taxes paid by the Trust will reduce its investment company taxable income, and distributions of investment company taxable income received by the Trust from non-U.S. sources will be treated as U.S. source income.

BACKUP WITHHOLDING

The Trust may be required to withhold U.S. federal income tax at the rate of 28% of all taxable distributions payable to shareholders who fail to provide the Trust with their correct taxpayer identification number or to make required certifications, or who have been notified by the IRS that they are subject to backup withholding. Backup withholding is not an additional tax. Any amounts withheld may be credited against a shareholder's U.S. federal income tax liability. Certain persons are exempt from the backup withholding requirements. Questions relating to backup withholding should be directed to your tax adviser.

FOREIGN SHAREHOLDERS

U.S. taxation of a shareholder who, as to the U.S., is a non-resident alien individual, a foreign trust or estate, a foreign corporation or foreign partnership ("foreign shareholder") depends on whether the income from the Trust is "effectively connected" with a U.S. trade or business carried on by such shareholder.

INCOME NOT EFFECTIVELY CONNECTED

If the income from the Trust is not "effectively connected" with a U.S. trade or business carried on by the foreign shareholder, distributions of investment company taxable income will be subject to a U.S. tax of 30% (or lower treaty rate), which tax is generally withheld from such distributions.

Distributions of capital gain dividends and amounts retained by the Trust which are designated as undistributed capital gains will not be subject to U.S. tax at the rate of 30% (or lower treaty rate) unless the foreign shareholder is a non-resident alien individual and is physically present in the U.S. for more than 182 days during the taxable year and meets certain other requirements. However, this 30% tax on capital gains of non-resident alien individuals who are physically present in the U.S. for more than the 182-day period only applies in exceptional cases, because any individual present in the U.S. for more than 182 days during the taxable year is generally treated as a resident for U.S. federal income tax purposes; in that case, he or she would be subject to U.S. federal income tax on his or her worldwide income at the

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

graduated rates applicable to U.S. citizens, rather than the 30% U.S. tax. In the case of a foreign shareholder who is a non-resident alien individual, the Trust may be required to withhold U.S. federal income tax at a rate of 28% of distributions of net capital gains unless the foreign shareholder certifies his or her non-U.S. status under penalties of perjury or otherwise establishes an exemption. See "Backup Withholding" above. If a foreign shareholder is a non-resident alien individual, any gain such shareholder realizes upon the sale or exchange of such shareholder's Shares of the Trust in the U.S. will ordinarily be exempt from U.S. tax unless such shareholder is physically present in the U.S. for more than 182 days during the taxable year and meets certain other requirements.

However, subject to certain limitations and the receipt of further guidance from the U.S. Treasury, dividends paid to certain foreign shareholders may be exempt from U.S. tax through 2007 to the extent such dividends are attributable to qualified interest and/or net short-term capital gains, provided that the Trust elects to follow certain procedures. The Trust does not anticipate following the procedures and as a result, the full amount of distributions of ordinary dividends, including distributions of any interest or short-term gains will be subject to withholding at a rate of 30 percent or any applicable lower treaty rate.

INCOME EFFECTIVELY CONNECTED

If the income from the Trust is "effectively connected" with a U.S. trade or business carried on by a foreign shareholder, then distributions of investment company taxable income and capital gain dividends, amounts retained by the Trust which are designated as undistributed capital gains and any gains realized upon the sale or exchange of Shares of the Trust will be subject to U.S. federal income tax at the graduated rates applicable to U.S. citizens, residents and domestic corporations. Such foreign shareholders that are corporations may also be subject to the branch profits tax imposed by the Code.

The tax consequences to a foreign shareholder entitled to claim the benefits of an applicable tax treaty may be different from those described herein. Foreign Shareholders are advised to consult their own tax advisers with respect to the particular tax consequences to them of an investment in the Trust.

OTHER TAXES

Distributions may also be subject to state, local and foreign taxes and/or the alternative minimum tax depending on each Shareholder's particular situation. Shareholders should consult their own tax advisers with respect to their particular situation.

ADMINISTRATOR, CUSTODIAN AND TRANSFER AGENT, DIVIDEND DISBURSING AGENT AND REGISTRAR

The Trust's securities and cash are held under a custodian contract with State Street Bank and Trust Company (the "Custodian"), whose principal business address is 225 Franklin Street, Boston, Massachusetts 02110. Rules adopted under the Investment Company Act permit the Trust to maintain its securities and cash in the custody of certain eligible banks and securities depositories. Pursuant to those Rules, the Trust's portfolio of securities and cash, when invested in Foreign Securities, will be held by sub-custodians who have been approved by the Board in accordance with the rules and regulations of the Securities and Exchange Commission following consideration of a number of factors, including, but not limited to, the relationship of the institution with the Custodian, the reliability and financial stability of the institution, the ability of the institution to perform capably custodial services for the Trust, the reputation of the institution in its national market, the political and

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

economic stability of the countries in which the sub-custodians will be located and the risks of potential nationalization or expropriation of Trust assets. The Custodian also performs certain accounting related functions for the Trust, including calculation of NAV and net income.

State Street Bank and Trust Company (the "Administrator") also serves as administrator to the Trust pursuant to an Administration Agreement. Under the Administration Agreement the Trust's assets are combined with assets of H&Q Healthcare Investors, another closed-end mutual fund managed by the Investment Adviser. The combined assets are charged a fee computed and payable monthly at an annual rate of (i).034% of the first \$150 million; (ii) .024% of the next \$150 million; (iii) .014% on assets in excess of \$300 million, subject to annual minimum fee of \$77,500. The Administrative Agreement covers administrative costs, including out-of-pocket expenses incurred in the ordinary course of providing services under the Administration Agreement.

Computershare Shareholder Services, Inc. serves as Dividend Disbursing Agent, and as Transfer Agent and Registrar for Shares of the Trust. Computershare Shareholder Services, Inc. has its principal business at 150 Royal Street, Canton, MA 02021.

FINANCIAL STATEMENTS

The audited financial statements of the Trust included in the Prospectus have been audited by Deloitte and Touche LLP, independent registered public accounting firm, whose report dated November 18, 2005 expresses and unqualified opinion. The financial highlights for the years ended September 30, 2003, 2002 and 2001 were audited by PricewaterhouseCoopers LLP, whose report dated November 25, 2003 expresses and unqualified opinion. Certain information appearing under the caption "Financial Highlights" for the fiscal years ended September 30, 2000, 1999, 1998, 1997 and 1996 was audited by Arthur Andersen LLP. Arthur Andersen LLP ceased operations in 2002. Deloitte & Touche LLP has been selected as the independent registered public accounting firm of the Trust for the fiscal year ending September 30, 2006. Deloitte & Touche LLP will provide financial statement audit services to the Trust. Deloitte & Touche LLP's offices are located at 200 Berkeley Street, Boston, MA 02116-5022.

Any statement contained in the Trust's annual report that is included in the Prospectus shall be deemed modified or superseded for purposes of the Prospectus and this SAI to the extent a statement contained in the Prospectus or this SAI varies from such statement. Any such statement so modified or superseded shall not, except as modified or superseded, be deemed to constitute a part of the Prospectus or this SAI.

The unaudited financial statements included in the Trust's Semi-Annual Report to Shareholders for the six months ended March 31, 2006 were mailed to Shareholders on or about May 25, 2006 and are available on the Trust's website (www.hqcm.com).

38

APPENDIX A
TRUSTEE AND INVESTMENT ADVISER
PROXY VOTING POLICIES AND PROCEDURES
FEBRUARY 2006

The following are the policies and procedures adopted and implemented

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

by Hambrecht & Quist Capital Management LLC (the "Investment Adviser") for voting proxies with respect to portfolio securities held by H&Q Healthcare Investors and H&Q Life Sciences Investors (each a "Fund" and collectively the "Funds"). The policies and procedures are reasonably designed to ensure that proxies are voted in the best interest of the Funds and the Funds' shareholders, in accordance with the Investment Adviser's fiduciary duties and Rule 206(4)-6 under the Investment Advisers Act of 1940 (the "Investment Advisers Act"). The Investment Adviser considers the "best interests" of the Funds and their shareholders to mean their best long-term economic interests.

The Investment Adviser shall vote proxies for the exclusive benefit, and in the best economic interest, of the Funds and their shareholders. Such exercise of voting rights shall be subject to the same standard of care as is generally applicable to the Investment Adviser's performance of its duties, as set forth in the advisory agreements with the Funds. The policies and procedures contained herein are designed to be guidelines, however each vote is ultimately cast on a case-by-case basis, taking into consideration the relevant facts and circumstances at the time of the vote. Any material conflicts that may arise will be resolved in the best interests of the Funds and their shareholders.

A proxy committee has been designated and is responsible for administering and overseeing the proxy voting process. The committee consists of the President of the Investment Adviser, the Investment Adviser's Chief Compliance Officer ("CCO"), and the analyst responsible for oversight of the company that is the subject of the proxy. The committee considers proxy questions and determines the vote on behalf of the Funds.

PROCEDURES

LOGISTICS

The Investment Adviser's CCO shall be responsible for maintaining the proxy log, monitoring corporate actions and confirming the timely voting of proxies. The proxy log shall contain the following information, in accordance with Form N-PX:

- o the name of the issuer;
- o the exchange ticker symbol, if available;
- o the CUSIP number, if available;
- o the shareholder meeting date;
- o a brief identification of the matter voted on;
- o whether the matter was proposed by the issuer or a security holder;
- o whether the Investment Adviser cast its vote on the matter;
- o how the Investment Adviser cast its vote on the matter (for, against, abstain; for or withhold regarding the election of directors); and
- o whether the Investment Adviser cast its vote for or against management;

The Investment Adviser's CCO shall also record whether any conflicts of interest have been identified and, if so, what action was taken to resolve the conflict with respect to each vote cast and each abstention.

SUBSTANTIVE VOTING DECISIONS

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

The Investment Adviser's substantive voting decisions turn on the particular facts and circumstances of each proxy vote. The following is a list of common proxy vote issues and the Investment Adviser's standard considerations when determining how to vote such proxies.

Routine Matters/Corporate Administrative Items. After an initial review, the Investment Adviser generally votes with management on routine matters related to the operation of the issuer that are not expected to have a significant economic impact on the issuer and/or its shareholders.

Potential for Major Economic Impact. The Investment Adviser reviews and analyzes on a case-by-case basis, non-routine proposals that are more likely to affect the structure and operation of the issuer and to have a greater impact on the value of the investment.

Corporate Governance. The Investment Adviser reviews and considers corporate governance issues related to proxy matters and generally supports proposals that foster good corporate governance practices.

Special Interest Issues. The Investment Adviser considers: (i) the long-term benefit to shareholders of promoting corporate accountability and responsibility on social issues; (ii) management's responsibility with respect to special interest issues; (iii) any economic costs and restrictions on management; and (iv) the responsibility of the Investment Adviser to vote proxies for the greatest long-term shareholder value.

Limitations on Director Tenure and Retirement. The Investment Adviser considers: (i) a reasonable retirement age for directors, E.G. 70 or 72; (ii) the introduction of new perspectives on the board; and (iii) the arbitrary nature of such limitations and the possibility of detracting from the board's stability and continuity.

Directors' Minimum Stock Ownership. The Investment Adviser considers: (i) the benefits of additional vested interest; (ii) the ability of a director to serve a company well regardless of the extent of his or her share ownership; and (iii) the impact of limiting the number of persons qualified to be directors.

D&O Indemnification and Liability Protection. The Investment Adviser considers: (i) indemnifying directors for acts conducted in the normal course of business; (ii) limiting liability for monetary damages for violating the duty of care; (iii) expanding coverage beyond legal expenses to acts that represent more serious violations of fiduciary obligation than carelessness (E.G. negligence); and (iv) providing expanded coverage in cases when a director's legal defense was unsuccessful if the director was found to have acted in good faith and in a manner that he or she reasonably believed was in the best interests of the issuer.

Director Nominations in Contested Elections. The Investment Adviser considers: (i) long-term financial performance of the issuer relative to its industry; (ii) management's track record; (iii) background to proxy contest; (iv) qualifications of both slates of nominees; (v) evaluations of what each side is offering shareholders as well as the likelihood that the proposed objectives and goals can be met; and (vi) stock ownership positions.

Cumulative Voting. The Investment Adviser considers: (i) the ability of significant stockholders to elect a director of their choosing; (ii) the ability of minority shareholders to concentrate their support in favor of a director or directors of their choosing; and (iii) the potential to limit the ability of directors to work for all shareholders.

Classified Boards. The Investment Adviser considers: (i) providing continuity; (ii) promoting long-term planning; and (iii) guarding against

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

unwanted takeovers.

Poison Pills. The Investment Adviser considers: (i) the Investment Adviser's position on supporting proposals to require a shareholder vote on other shareholder rights plans; (ii) ratifying or redeeming a poison pill in the interest of protecting the value of the issuer; and (iii) other alternatives to prevent a takeover at a price demonstrably below the true value of the issuer.

Fair Price Provisions. The Investment Adviser considers: (i) the vote required to approve the proposed acquisition; (ii) the vote required to repeal the fair price provision; (iii) the mechanism for determining fair price; and (iv) whether these provisions are bundled with other anti-takeover measures (e.g., supermajority voting requirements) that may entrench management and discourage attractive tender offers.

Equal Access. The Investment Adviser considers: (i) the opportunity for significant shareholders of the issuer to evaluate and propose voting recommendations on proxy proposals and director nominees, and to nominate candidates to the board; and (ii) the added complexity and burden.

Charitable Contributions. The Investment Adviser considers: (i) the potential benefits to shareholders; (ii) the potential to detract the issuer's resources from more direct uses of increasing shareholder value; and (iii) the responsibility of shareholders to make individual contributions.

Stock Authorizations: The Investment Adviser considers: (i) the need for the increase; (ii) the percentage increase with respect to the existing authorization; (iii) voting rights of the stock; and (iv) overall capitalization structures.

Preferred Stock. The Investment Adviser considers: (i) whether the new class of preferred stock has unspecified voting, conversion, dividend distribution, and other rights; (ii) whether the issuer expressly states that the stock will not be used as a takeover defense or carry superior voting rights; (iii) whether the issuer specifies the voting, dividend, conversion, and other rights of such stock and the terms of the preferred stock appear reasonable; and (iv) whether the stated purpose is to raise capital or make acquisitions in the normal course of business.

Director Compensation. The Investment Adviser considers: (i) whether director shares are at the same market risk as those of the shareholders; and (ii) how option programs for outside directors compare with the standards of internal programs.

Golden and Tin Parachutes. The Investment Adviser considers: (i) whether they will be submitted for shareholder approval; and (ii) the employees covered by the plan and the quality of management.

LIMITATIONS

The Investment Adviser may abstain from voting a proxy if it concludes that the effect on shareholders' economic interests or the value of the portfolio holding is indeterminable or insignificant. The Investment Adviser may abstain from voting a proxy if it concludes that the cost of voting is disproportionate to the economic impact the vote would have on the portfolio holdings.

CONFLICTS OF INTEREST

The Proxy Committee identifies any potential conflicts of interest. Each potential conflict must be addressed in a manner which will be in the best interest of the Funds and their shareholders. If any potential conflict is

Edgar Filing: H&Q LIFE SCIENCES INVESTORS - Form 497

identified the Proxy Committee consults with the Investment Adviser's CCO. Where conflicts of interest arise between clients and the Investment Adviser, the Investment Adviser may convene an ad-hoc committee to debate the conflict and to give a ruling on a preferred course of action. If the ad-hoc committee determines that the Investment Adviser has a conflict of interest in any instance, the Investment Adviser's CCO shall disclose the conflict to the Board and seek voting instructions.

The Investment Adviser may cause the proxies to be voted in accordance with the recommendations of an independent third party service provider that the Investment Adviser may use to assist in voting proxies.

DISCLOSURE

The following disclosure shall be provided in connection with these policies and procedures:

- o The Investment Adviser shall provide a description or a copy of these policies and procedures to the Boards of Trustees of the Funds annually and upon request.
- o The Investment Adviser shall make available to the Funds its proxy voting records, for inclusion on the Funds' Form N-PX.
- o The Investment Adviser shall include its proxy voting policies and procedures in its annual filing on Form N-CSR.
- o The Investment Adviser shall cause the Funds' shareholder reports to include a statement that a copy of these policies and procedures is available upon request (i) by calling a toll-free number; (ii) on the Funds' website, (if the Funds choose); and (iii) on the SEC's website.
- o The Investment Adviser shall cause the Funds' annual and semi-annual reports to include a statement that information is available regarding how the Funds voted proxies during the most recent twelve-month period (i) without charge, upon request, either by calling a toll-free number or on or through the Funds' website, or both; and (ii) on the SEC's website.

RECORDKEEPING

The Investment Adviser shall maintain records of proxies voted in accordance with Section 204-2 of the Investment Advisers Act, including proxy statements, a record of each vote cast, and a copy of any document created by the Investment Adviser that was material to making a decision of how to vote the proxy, or that memorializes the basis for the Investment Adviser's decision on how to vote the proxy. The Investment Adviser shall also maintain a copy of its policies and procedures and each written request from a client for proxy voting records and the Investment Adviser's written response to any client request, either written or oral, for such records. Proxy statements that are filed on EDGAR shall be considered maintained by the Investment Adviser. All such records shall be maintained for a period of five years in an easily accessible place, the first two year in the offices of the Investment Adviser.